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Abstract 
Cell adaptation to hypoxia requires activation of transcriptional programs that coordinate 
expression of genes involved in oxygen delivery (via- angiogenesis) and metabolic 
adaptation (via glycolisis). During migration and invasion of normal and pathological 
tissues, cells may encounter different oxygen levels, due to poor or altered vascularization, 
and recent evidence has suggested that chemotaxis is a cell function which may be affected 
by oxygen availability. 
This thesis describes how oxygen avaibility is a determinant parameter in the setting of 
chemotactic responsiveness to Stromal-Derived Factor 1 (SDF-1, CXCL12). Low oxygen 
concentration induces high expression of the CXCL12 receptor CXCR4, in different cell 
types (monocytes, monocyte-derived macrophages, tumor associated macrophages, 
endothelial cells, cancer cells and dendritic cells) as both mRNA and protein expression, 
which is paralleled by increased chemotactic responsiveness to its specific ligand. 
Furthermore, preliminary results on dendritic cells (DC) show that hypoxia may affect 
their maturation (CCR7'°'/CCR5h'gh) and functions. In particular, hypoxia-derived DC do 
not migrate in response to the CCR7 ligand CCL 19, while they do express higher levels of 
pro-inflammatory cytokines (IL-12, TNF-a), as compared to normoxia-derived DC. 
CXCR4 induction by hypoxia is dependent on both activation of hypoxia-inducible factor 
1 (HIF-la) and transcript stabilization. Our data identify the hypoxia/HIF-1/CXCR4 
pathway as a relevant molecular circuit in the functional tuning of the chemokine system 
and provide novel insights into the mechanisms controlling cell migration in hypoxic 
regions, with potential relevance in the pathogenesis of human diseases, including chronic 
inflammatory diseases and cancer. 
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Chapter 1 Introduction 
Chapter 1. Introduction 
1.1. Chemokines 
1.1.1. Introduction 
From the genesis of human life to birth and beyond cell migration is a complex, extremely 
important process that is not completely understood by researchers. During embryogenesis, 
cells move in sheets or loosely attached populations to create complex tissues. In adults, 
cell motility is crucial to maintain immunity, or repair damaged tissues. The recruitment of 
leukocytes in normal and pathological conditions is mainly regulated by chemokines and 
their receptors. However, cell migration is not only regulated by chemokines, but also by 
other factors such as the complement component C5a, lipid derivates leukotrienes and 
platelet-activating factor, and bacterial N-formylmethionyl-peptides. 
Chemokines have been recognized as a family of functionally related small-secreted 
molecules named "chemo-kine" because of leukocyte chemoattractant and cytokine-like 
activities. The capability to induce migration identifies molecules belonging to this family. 
The first chemokines to be discovered were Platelet Factor 4 (now called CXCL4) and ß- 
thromboglobulin in the late 1970s (Deuel, Keim et al. 1977; Begg, Pepper et al. 1978). 
However, chemokines were not recognized as chemotactic molecules until the 
characterization of interleukin 8 (IL-8, now called CXCL8) in 1987 (Yoshimura, 
Matsushima et al. 1987). 
The early chemokines were discovered because of their association with inflammatory 
responses, although, recently, genome sequencing has added numerous members with 
additional roles. 
In little more than a decade since the discovery of CXCL8 about 50 human chemokines 
and nearly 20 receptors have been identified and characterized. Research in this field has 
16 
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dramatically changed our understanding of leukocyte traffic in inflammation and 
immunity. 
1.1.2. Chemokine classification 
Chemokines are composed of single polypeptide chains 70-100 amino acids in length, with 
20-95% sequence identity to each other including conserved cysteine residues. The 
position of these conserved cysteines has been used for subfamilies definition and 
nomenclature (Vicari. Ait-Yahia et al. 2000) (Figure 1.1). 
CXC IL-8 Neu CXCR1,2 
IP-10, SDF1 T, NK CXCR3,4 
BCA-1 B CXCR5 
MCP, MIP, Mo, DC, CCR1-10 
6CCKs T, B, NK, 
Eo, Ba 
C Lymphotactin T, NK XCR1 
CX3C 
Fractalkine T, NK, Mo CX3CR1 
Figure I. I. Chemokine submilies 
Sub families of chemokines are classified following the disposition of the cystein residues at the N-terminal 
domain of the molecules. Example of members, producing cells and receptors are listed. (light cyan: 
chemokine domain; dark cyan: trasmembrane domain; blue: mucin-like stalk; white: citoplasmic domain). 
Two main sub-families, CXC and CC chemokines, are distinguished according to the 
position of the first two cysteines, which are separated by one amino acid (CXC) or 
adjacent to each other (CC). The cysteines form two disulfide bonds (Cysl-+Cys3 and 
Cys2-Cys4), which confer to the chemokine their characteristic three-dimensional folding 
(Lodi, Garrett et al. 1994). CXC chemokines are active on neutrophils (PMN) and 
lymphocytes while CC chemokines exert their action on multiple leukocyte subtypes, 
17 
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including monocytes, basophils, eosinophils, T lymphocytes, dendritic cells and NK cells, 
but they are generally inactive on PMN. Eotaxins represent the chemokines with the most 
restricted spectrum of action being selectively active on eosinophils, basophils and Th2 
mast cells. A third subfamily includes molecules with only two conserved cysteine 
residues (C chemokines) and comprises only one member lymphotactin (Kennedy, Keiner 
et al. 1995). Finally, the fourth family is composed only by fractalkine. This is a 
membrane-bound mucin bearing an amino-terminal chemokine-like domain with three 
amino acids between the first two cysteines (CX3C motif) (Bazan, Bacon et al. 1997); 
(Pan, Lloyd et al. 1997). These two chemokines are both actives on lymphoid cells (T 
lymphocytes and NK cells) and fractalkine is also active on monocytes and NK cells. 
Many of the genes encoding chemokines have been mapped and they cluster at specific 
loci. CC chemokine genes are grouped at 17g11.2-12 and CXC chemokine genes at 4g13 
(Rollins 1997). There are some exceptions: the Lymphotactin gene is located on 
chromosome 1 (Kennedy, Keiner et al. 1995) and CX3CL1 on chromosome 16 
(Nomiyama, Imai et al. 1998) (Figure 1.2). 
This suggests that some chemokines arose by duplication and divergence from a primordial 
chemokine gene. 
18 
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Chromosomal 
Family Structure Locus 
cxc cC 
cxc 14g12-21 
Di P2 03 
cC cc 
CC 17g11.2.12 
al ez P 
C 1g23 c 
Pi fs2 p 
cxxxc CC_ 
P2 03 
CX3C 
rr-'rr 
16 
rr- ( 
rrr t rr i rr 
40 & 46 is 46 4 40 46 
Chemokine Mucin Stalk Cytoplasmic 
Domain 
Figure 1.2. Localization of chemokine genes on chromosome 
Chemokines are divided in four sub-families and each gene cluster on different chromosome with some 
exception: in the CXC family CXCL12 maps to chromosome 10, in the CC family CCL19 maps to 
chromosome 9 and CCL20 to chromosome 2 (Rollins 1997). 
Chemokine genes were designated long ago, as SCY (for small, secreted cytokines) and 
numbered chronologically. Whilst the systematic nomenclature has been generally adopted 
for the receptors, chemokines are still mostly designated by their traditional names. A 
systematic nomenclature for chemokines and chemokine receptors became necessary as 
more and more new molecules were found. This classification (Zlotnik and Yoshie 2000) 
relies on the principle established for the receptors at the 1996 Gordon Conference on 
Chemotactic Cytokines. The receptors are defined as CXC, CC, XC, and CX3C followed 
by R and a number. The chemokines are defined by the same structure-related acronyms 
followed by L (for ligand) and the number of their genes (Table 1.1). This new 
nomenclature will be used throughout this thesis. 
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Systematic name Human chromosome Human ligand Mouse ligand 
CXC chemokines 
CXCL1 4g21.1. GROa/MGSA-a GRO1/KC/MIP-2 
CXCL2 4g21.1 GROB/MGSA-ß GRO1/KC/MIP-2 
CXCL3 4g21.1 GROy/MGSA-y GRO1/KC/MIP-2 
CXCL4 4g21.1 PF4 PF4 
CXCL5 4g21.1 ENA-78 LIX 
CXCL6 4g21.1 GCP-2 CKa-3 
CXCL7 4g21.1 NAP-2 Unknown 
CXCL8 4g21.1 IL-8 Unknown 
CXCL9 4g21.1 Mig Mig 
CXCL10 4g21.1 IP-10 IP-10 
CXCL11 4g21.1 I-TAC I-TAC 
CXCL12 IOg11.21 SDF-1a/ß SDF-1 
CXCL13 4g21.1 BCA-1 BLC 
CXCL14 5g31.1 BRAK/bolekine BRAK 
(CXCL15) Unknown Unknown Lungkine 
CXCL16 17p13 SR-PSOX SR-PSOX 
C Chemokines 
XCL1 1g24.2 Lymphotactin/SCM-la Lymphotactin 
XCL2 l g24.2 SCM-l R Unknown 
CX3C chemokines 
CX3CL1 16g13 Fractalkine Neurotactin 
CC chemokines 
CCL1 17g11.2 1-309 TCA-3 
CCL2 17g11.2 MCP-I/MCAF/TDCF JE 
CCL3 17g12 MIP-la/LD78a MIP-la 
CCL4 17g12 MIP-1p MIP-1ß 
CCL5 17g12 RANTES RANTES 
(CCL6) Unknown Unknown MRP-1, C10 
CCL7 17g11.2 MCP-3 MARC/MCP-3 
CCL8 17g11.2 MCP-2 MCP-2 
(CCL9/CCL10) Unknown MRP-2 
CCLII 17g11.2 Eotaxin Eotaxin 
(CCL12) Unknown MCP-5 
CCL13 17g11.2 MCP-4 Unknown 
CCL14 17g12 HCC-1 Unknown 
CCL15 17g12 HCC-2/MIP-16 Unknown 
CCL16 17g12 HCC-4/LEC LCC-1 
CCL17 16g13 TARC TARC 
CCL18 17g12 DC-CK1/PARC Unknown 
CCL19 9pl3.3 MIP-3ß/ELC/Exodus-3 MIP-3p/ELC 
CCL20 2q36.3 MIP-3a/LARC/Exodus-1 MIP-3a/LARC 
CCL21 9p13.3 6CKine/SLC/Exodus-2 6CKine/SLC 
CCL22 16g13 MDC ABCD-1 
CCL23 17g12 MPIF-1 Unknown 
CCL24 7g11.23 MPIF-2/Eotaxin-2 MPIF-2/CKß6/Eotaxin-2 
CCL25 19p13.3 TECK TECK 
CCL26 7g11.23 Eotaxin-3 Unknown 
CCL27 9p 13.3 CTACK CTACK 
CCL28 5p12 CCK1/MEC CCKIIMEC 
Table 1.1. The systematic nomenclature for chemokines 
The most common names for the human/mouse ligands are shown, but there may be omissions. A systematic 
name in brackets indicates that human homologue has not yet been discovered. Adapted from IUIS/WIHO 
Subcommittee (2003). 
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Chemokines were also grouped in two different subfamilies: inflammatory (also called 
inducible chemokines) or homeostatic (or constitutive) chemokines (Figure 
1.3). 
Inflammatory chemokines control the recruitment of effector leukocytes in infection, 
inflammation, tissue injury and tumours. Homeostatic chemokines, by contrast, navigate 
leukocytes during hematopoiesis in the bone marrow and thymus, and during initiation of 
adaptive immune responses in the spleen and lymph nodes (Mantovani 1999; Moser, Wolf 
et al. 2004). 
Constitutive 
CCL15 CCL14 
CX3CL1 
CCL18 
CCL16 
Normal 
trafficking 
CXCL12 CCL21 
CCL25 
CXCL13 
CCL27 
Inducible 
CCL2 CXCL3 CCL3 
CCLS CCL3Li 
CCL17 CCL4 
CXCL9 CCL7 CCL19 XCL1 CCLB 
CXCL5 Infection 
Neoplasla 
CXCL7 
Inflammation CCLI1 
Immunity 
XCL2 CCL20 CCL23 CXCL10 CCL13 
CCL22 CXCL11 CCL24 
CXCL2 CCL26 CXCL1 
CCL28 CXCL8 
Figure 1.3. Constitutive and inducible chemokines: two overlapping realms 
Constitutive chemokines are produced in a tonic fashion in lymphoid and/or nonlymphoid organs: they 
probably direct the normal traffic of leukocytes under physiological conditions. Inducible chemokines are 
produced in response to microbial, inflammatory or immune signals and account for increased recruitment of 
leukocytes under these conditions. The distinction between constitutive and inducible chemokines is useful 
but schematic because the two realms overlap in terms of pathology and molecules. In neoplasia, inducible 
chemokines such as CCL2 are made constitutively. Moreover, certain constitutive chemokines expressed in 
lymphoid organs in the absence of deliberate stimulation, such as CCL22, are also produced in an inducible 
way. Adapted from (Locati, Otero et al. 2002). 
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CXC chemokines can be further classified according to the presence of the tripeptide motif 
glutamic acid-leucine-arginine (ELR) in the NH2-terminal region. ELR+ chemokines are 
specific for myeloid cells, are angiogenic and the first angiogenic chemokine to be 
described was CXCL8/IL-8 in 1992 (Koch, Polverini et al. 1992). On the other hand ELR- 
chemokines attract a variety of leukocytes without a clear specificity and they are anti- 
angiogenic chemokines. The first member of this family to be identified was CXCL4/PF4. 
It is a weak attractant for neutrophils (Deuel, Senior et al. 1981) but it is an inhibitor of 
angiogenesis, probably by inhibiting endothelial cell proliferation (Maione, Gray et al. 
1990). 
1.2. Chemokine receptors 
1.2.1. Introduction 
Biochemical and functional analysis with CXCL8 and related chemokines demonstrated 
that neutrophils express two types of CXCL8 receptor, one with selectivity for CXCL8 and 
GCP-2/CXCL6, and another with promiscuous binding of CXCL8 and numerous other 
related CXC chemokines (Baggiolini, Dewald et al. 1994). The subsequent cloning of the 
corresponding receptor cDNAs (called CXCR1 and CXCR2) confirmed these early 
observations and, in addition, provided molecular tools for the subsequent cloning of novel 
chemokine receptor genes. Currently, 20 human chemokine receptors are known, including 
six CXCRs, ten CCRs, one XCR, and one CX3CR, and they are known to bind a total of 
more than 50 human chemokines. 
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1.2.2. Chemokine receptor nomenclature 
Chemokines act through the binding to chemokine receptors which are members of a 
distinct subfamily in the rhodopsin-like G protein-coupled receptors. (Figure 1.4) (Thelen 
2001; Murphy 2002; Moser, Wolf et al. 2004). 
I lo-and 
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Figure 1.4. G protein coupled receptors structure 
The G protein coupled receptors structure consists of a single polypeptide chain that threads back and forth 
seven times across the phospholipids bilayer that forms the membrane. Downloaded and adapted from the 
website: www. mpibp-frankfurt. mpg. de/reinhart. 
Experiments with Bordetella pertussis toxin indicated that these receptors typically require 
G proteins of the G; -type for signal transduction (Thelen, Peveri et al. 1988). 
Chemokine receptors can typically bind several different chemokines, although this rarely 
occurs between different chemokine families. Therefore they are classified based on the 
chemokine family that they bind. Chemokine receptors are single polypeptide chains that 
span the membrane 7 times, with a typically acidic N-terminal extracellular domain and a 
serine/threonine-rich intracellular C-terminal domain. Two disulfide bonds in between the 
N-terminal domain and the second extracellular loop and the first and third extracellular 
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loops are normally required for the definition of the molecular structure. As for ligands, 
20-85% amino acid identity to each other is observed, particularly in transmembrane and 
intracellular domains. The significant identity score and some structural aspects indicate 
that both ligand and receptor families arose from common ancestors by repetitive gene 
duplication. Most chemokine receptor genes have their coding information on a single 
exon. Rarely, there is alternative splicing: this is the case of the genes for CCR2a and 
CCR2b which appear to be formed by alternative splicing of two exons of the same gene 
(Charo, Myers et al. 1994). 
Other than 18 conventional chemokine receptors, 7-transmembrane-domain proteins that 
bind chemokines with high affinity and no subsequent signalling activity have been 
reported. In the absence of any definitive information on their function, these molecules 
have been designated "silent" or "non-conventional" chemokine receptors (Figure 1.5). 
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TECK CCL25 CCR9 
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PARC CCL18 Unknown 
XCR1 
Fractalkine CX3CL 1 CX3CR1 
Figure 1.5. Ligand specificity of non conventional and conventional chemokine receptors. 
Conventional receptors are listed on the right, "silent" receptors on the left. The central column list 
chemokines identified with one old acronym and with the new nomenclature in which the first part of the 
name identifies the family and L stands for "ligand" followed by a progressive number. Adapted from 
(Mantovani, Sica et al. 2004). 
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The first chemokine silent receptor identified was named DARC (Duffy antigen receptor 
for chemokines), since it corresponds to the previously known Plasmodium vivax-binding 
molecule Duffy blood group antigen, and it was originally described as an highly 
promiscuous CC and CXC chemokine binding molecule expressed on erythrocytes (Neote, 
Darbonne et al. 1993). In consideration of the high expression level in erythrocytes and 
endothelium, the wide range of ligands (Figure 1.5), and the lack of any detectable ligand- 
dependent signalling activity, DARC has been proposed to act either as a chemokine 
scavenger, involved in maintaining a tissue-to-blood chemokine gradient by clearing 
chemokines from the bloodstream, or as a chemokine-presenting molecule. DARC- 
deficient mice have been generated, and have no major development abnormalities. 
D6 was the second chemokine silent receptor reported so far, with binding properties 
restricted to CC chemokines (Figure 1.5) (Nibbs, Wylie et al. 1997). D6 expression has 
been demonstrated prominently in "filter structures", such as placenta and lymphatic 
afferent vessels. This is consistent with the recent demonstration that D6 acts as a 
chemokine scavenger receptor in vitro (Fra, Locati et al. 2003; Bonecchi, Locati et al. 
2004). It was recently demonstrated that D6"1" mice showed an anticipated and exacerbated 
inflammatory response in a model of skin inflammation (Jamieson, Cook et al. 2005; 
Martinez de la Torre, Locati et al. 2005). 
Chemokine receptors have also been identified which have no known ligand. These are 
classified as `orphan' receptors, and include CC-chemokine receptor like 1 (CCRL1) 
which is expressed predominantly in the heart (Khoja, Wang et al. 2000) and HCR which 
is expressed in lymphoid tissues such as the spleen, lymph nodes and bone marrow (Fan, 
Kyaw et al. 1998). Functional chemokine receptor genes have also been found in viruses, 
for example ECFR3 in Herpesvirus saimiri (Ahuja and Murphy 1993), which has structural 
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similarities to CXCRI and CXCR2, and US28 in human CMV (Gao and Murphy 1994) 
which can bind multiple CC chemokines with high affinity. Some viruses as HHV-8 
(Couty and Gershengorn 2004) and EBV (Uchihara, Krensky et al. 2005) might selectively 
mimic chemokines or chemokine receptors in order to subvert or inactivate the host 
defence (Nicholas 2005). Virus-encoded chemokines [e. g. vMIP-I, vMIP-II and v-MIP-III; 
(Murphy 2001)] are either antagonists that block leukocyte recruitment to sites of 
infection, or agonists that could enhance the recruitment of cells that support viral 
replication or prevent Thl anti-viral responses (Alcami and Koszinowski 2000). 
1.2.3. Chemokine receptors are expressed on a variety of cell types 
Chemokine receptors are selectively expressed on different types of leukocytes (Figure 
1.6) 
Some receptors are restricted to certain cells (e. g., CXCRI is predominantly restricted to 
neutrophils), whereas others are widely expressed (e. g., CCR2 is expressed on monocytes, 
T cells, natural killer cells, dendritic cells, and basophils). In addition, chemokine receptors 
are constitutively expressed on some cells, whereas they are inducible on others. 
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Figure 1.6. Cells types that express chemokine receptors 
A range of different cells types can express various chemokine receptors (Luster 1998). 
Along with agonist production, regulation of chemokine receptors expression is a crucial 
event for the tuning of the chemokine system (Mantovani 1999). CCRI and CCR2 are 
constitutively expressed on monocytes but are expressed on lymphocytes only after 
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stimulation by IL-2 (Loetscher, Geiser et al. 1994). In addition, some constitutive 
chemokine receptors can be down-regulated; CCR2 is down-regulated by LPS, making the 
cells unresponsive to CCL2, but remains responsive to CCL3/4 (Sica, Saccani et al. 1997). 
Chemokine receptors are also regulated by pro- and anti-inflammatory stimuli with 
divergent effects: pro-inflammatory stimuli as IFNg downregulate CCR2 receptor while 
anti-inflammatory stimuli as IL-10 upregulate CCR2 expression (Sozzani, Ghezzi et al. 
1998). 
In contrast, the expression of other chemokine receptors is restricted to a cell state of 
activation and differentiation. For example CXCR3 is expressed on activated T 
lymphocytes of the T helper type 1 (Thl) phenotype, whereas CCR3, is expressed on 
activated lymphocytes of the T helper type 2 (Th2) phenotype (Sallusto, Mackay et al. 
1997; Bonecchi, Bianchi et al. 1998). Some chemokine receptors are also expressed on 
nonhematopoietic cells, including neurons, astrocytes, epithelial cells, and endothelial 
cells. This suggests that the chemokine system has other roles in addition to leukocyte 
chemotaxis. 
1.2.4. Chemokine receptor signaling 
There are still many open questions with regard to signalling elements involved in the 
initiation of leukocyte migration as opposed to those signalling elements controlling 
migration-unrelated processes. Figure 1.7 gives an overview of signalling via chemokine 
receptors. 
The signal transduction mechanisms activated by chemokines such as CCL2 and CCL5 
have been extensively investigated (Sozzani, Molino et al. 1993; Kuang, Wu et al. 1996). 
A given chemokine may be able to activate different responses depending on the 
chemokine receptor or cell type to which it binds. CXCL8 can bind to CXCRI and 
CXCR2, both of which have the same preference for G protein family members (Wu, 
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LaRosa et al. 1993); CXCRI activates phospholipase D (PLD) and causes the formation of 
superoxide, but CXCR2 does not (Jones, Wolf et al. 1996). The mechanism for receptor- 
specific signal transduction remains to be elucidated. 
It seems that most chemokines are able to elicit an increase in intracellular calcium, 
although the functional requirement for this is unclear, since chemotaxis can occur in 
situations where calcium flux is undetectable (Turner, Ward et al. 1995). During 
chemotaxis, the essential step upon ligation of a chemokine receptor is the release of the 
G, 
y subunit 
from the Ga; subunit (Neptune, Iiri et al. 1999). Experiments in Dictyostelium 
discoideurn have shown that ßy subunits accumulate at the leading edge of migrating 
amoebae, supporting their role in chemotaxis (Jin, Zhang et al. 2000). 
Multiple intracellular second messengers are coupled to chemokine receptor-mediated G 
protein activation, including phospholipase Cß (PLC(3) isoforms, Ser/Thr-kinases, 
phosphatidylinositol-3-kinase-y (PI3Ky) and c-Src-related non-receptor tyrosine kinases 
(Thelen 2001). 
The G,, subunit can then activate PLC-ß2 and PLC-ß3; these isoenzymes are involved in 
chemokine signal transduction in immune cells (Li, Jiang et al. 2000) and lead to inositol- 
1,4,5-trisphosphate formation (IP3) and a transient rise in the intracellular free calcium 
concentration. There is no calcium flux in neutrophils from PLC-ß2 and PLC-(33 knockout 
mice, but these cells are still able to migrate normally. However, PLC can also generate 
diacylglycerol (DAG) and this can lead to the activation of protein kinase C (PKC). This 
enzyme plays a role in chemokine receptor phosphorylation and hence desensitisation 
(Richardson, DuBose et al. 1995). It can also activate the respiratory burst in neutrophils 
(Li, Jiang et al. 2000). 
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Figure 1.7. Signalling through chemokine receptors 
This diagram illustrates some of the potential downstream signalling pathways following chemokine binding 
to a chemokine receptor. The (3y subunits can activate Phospholipase C (PLC) and PI3Ky, leading to 
activation of Protein Kinase C (PKC), Phosholipase D (PLD), Protein Kinase B (PKB) and the MAPK 
cascade - with numerous downstream effects. PKC may be important for receptor desensitisation. The Gai 
subunit can activate Protein Tyrosine Kinases (PTK) such as Src, which may lead to activation of FAK and 
Pyk2 (which are involved with cytoskeletal arrangements), the MAPK cascade and also P13K p85/p110 
which may be involved in the prolonged signalling seen with CXCR4. Adapted from (Thelen 2001). 
Perhaps most importantly, chemokine stimulation leads to the activation of PI3Ky (Turner, 
Domin et al. 1998). 
Mice lacking this gene have impaired signal transduction in response to chemokines, 
demonstrating an important role for this molecule in signalling pathways downstream of 
chemokine receptors (Hirsch, Katanaev et al. 2000; Sasaki, Irie-Sasaki et al. 2000). The G111 
subunit can also activate signal transduction pathways which lead to the activation of 
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p85/p 110 P13K. Both forms of P13K can activate protein kinase B (PKB) (Burgering and 
Coffer 1995). PKB (also known as Akt) can have numerous downstream effects, including 
promotion of cell survival (Chan, Rittenhouse et al. 1999). In prostate cancer, increased 
Akt/PK13 activity has also been shown to contribute to tumour progression, by accelerating 
tumour growth (Graff, Konicek et al. 2000). PKB is also involved in chemotaxis and is 
recruited to the leading edge of cells undergoing migration (Servant, Weiner et al. 2000). 
Chemokines (including CXCL8, CXCL12, CCL2 and CCL20) have also been shown to 
activate the MAPK cascade (Sullivan, McGrath et al. 1999; Majka, Ratajczak et al. 2000; 
Ashida, Arai et al. 2001). The Gßy subunit leads to activation of PI3Ky, and this in turn 
can activate the MAPK cascade, possibly through its intrinsic protein kinase activity, rather 
than its ability to phosphorylate lipids (Lopez-Ilasaca, Crespo et al. 1997; Bondeva, Pirola 
et al. 1998). MAPK activation may or may not be required for chemotaxis. Inhibition of 
ERK activation using inhibitors such as PD98059 abrogates actin polymerisation and/or 
migration of eosinophils and T cells in response to CXCL12, CCL11 and CCL20 
(Boehme, Sullivan et al. 1999; Sotsios, Whittaker et al. 1999). Yet PD98059 does not 
block the migration of neutrophils to IL-8 (Knall, Worthen et al. 1997). 
Phospholipase D (PLD) is also activated in response to chemokines including CXCL8 and 
CCL5 (Bacon, Flores-Romo et al. 1995; Bacon, Schall et al. 1998) and may be involved in 
rearrangement of the actin cytoskeleton (Du, Altshuller et al. 2000). A variety of other 
signalling pathways may be activated in response to chemokines: stimulation of CCR2b 
and CXCR4 can lead to the activation of the Jak/Stat pathway (Mellado, Rodriguez-Frade 
et al. 1998; Vila-Coro, Rodriguez-Frade et al. 1999); ligation of CXCR4 can also activate 
Pyk2 and NFKB (Ganju, Brubaker et al. 1998) and CCL5 can activate focal adhesion 
kinase (FAK) (Bacon, Szabo et al. 1996). Transient signalling is a common characteristic 
of most chemokine receptors, but one which requires rapid inactivation. This is achieved 
through receptor phosphorylation, desensitisation and internalisation. CCR2b, CCR5, 
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CXCRI, CXCR2 and CXCR4 are all rapidly internalised after ligand-binding (Arai, 
Monteclaro et al. 1997; Guinamard, Signoret et al. 1999; Huttenrauch, Pollok-Kopp et al. 
2005; Nasser, Marjoram et al. 2005). Chemokine receptors are phosphorylated at serine or 
threonine residues in their C-termini, which may alter their three-dimensional 
conformation, impairing the interaction with G proteins. 
Desensitisation of G protein-coupled receptors may be performed by four families of 
regulatory molecule: PKC, cAMP-dependent PK, arrestins and GPCR-coupled kinases 
(GRKs) (Lefkowitz 1998). GRKs are recruited to the cell membrane by Gßy, where they 
can phosphorylate the chemokine receptor; arrestins can then bind to the receptor, 
sterically inhibit the binding of G proteins and cause internalisation (Barlic, Khandaker et 
al. 1999; Cheng, Zhao et al. 2000). 
CXCR4 may be unusual in this regard, since it has been shown to stimulate prolonged 
signalling of Akt/PKB and ERK2 in T cells, despite receptor internalisation (Tilton, Ho et 
al. 2000). The studies by Tilton et al have raised various possibilities to explain this 
phenomenon, the most likely being that CXCR4 remaining at the surface is not 
desensitised (as is usual with chemokine receptors) but can continue to transduce a signal 
in response to CXCL12. Receptor recycling could also contribute to this effect. 
Signal transduction downstream from chemokine receptors is much more complicated than 
the overview given here. Signalling pathways activated by a given receptor will be 
influenced by those from other receptor systems, and can also cross-regulate one another. 
The challenge now will be to understand how chemokine-induced signals are fine-tuned 
and integrated with other signals. 
1.3. Chemokine/chemokine receptor function 
In the last ten years it became clear that chemokines not only function as chemoattractants 
but their interaction with the receptors influences processes such as angiogenesis, 
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hematopoiesis, inflammation and T cell differentiation. This section will outline some of 
these functions. The particular role of CXCR4 and CXCL12 will also be described, since 
the results chapters concentrate on this chemokine/receptor pair. 
In the chemokine/chemokine receptor system there is an apparent redundancy: chemokines 
can often bind to more than one receptor, each receptor can often bind more than one 
chemokine, and multiple receptors can be expressed on a given cell type. The importance 
of chemokine/chemokine receptors is shown by knockout mice. Our understanding of the 
roles of chemokines in physiological and pathological processes has advanced 
significantly. It has become clear that in addition to wound healing, metastasis, 
angiogenesis/angiostasis, cell recruitment, lymphoid organ development, and lymphoid 
trafficking (Zlotnik and Yoshie 2000) chemokines are fundamental in mediating innate and 
adaptive immune responses by their ability to activate cells of the immune system (Ward, 
Bacon et al. 1998). Chemokine gene disruption studies have confirmed most of these 
biological functions. For example, the CCL3 knockout mouse was the first to be generated. 
While developmentally normal with no apparent lymphoid or myeloid defects, these mice 
were reduced in their ability to mount an inflammatory response to influenza infection 
(Cook, Beck et al. 1995). CCR7-deficient mice exhibit impaired lymphocyte migration, 
delayed antibody responses and defects in lymphoid architecture signifying an important 
role for CCR7 signalling in coordinating primary immune responses (Forster, Schubel et 
al. 1999). Lastly, mutating CCR1, CCR2 or CCR5 in mice impairs monocyte functions 
such as chemokine-dependent chemotaxis and alters the balance of Thl or Th2 cytokine 
responses upon challenge with Th class-specific antigens or pathogens (Boring, Gosling et 
al. 1997; Gao, Wynn et al. 1997; Gerard, Frossard et al. 1997; Zhou, Kurihara et al. 1998; 
Sato, Ahuja et al. 2000). 
Aspects of these different functions will be discussed briefly below. 
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1.3.1. Role in normal physiology 
1.3.1.1. Chemotaxis 
Chemotaxis can be defined as the directed migration towards a gradient of soluble 
extracellular agents. Cells showing positive chemotaxis move towards areas with higher 
concentration of these agents, whilst those showing negative chemotaxis move away from 
these areas. This behaviour is in marked contrast to the reactions elicited by some other 
compounds, known as chemokinesis, which is characterized essentially by an undirected 
movement of cells. Dose dependent migration of cells induced by gradients of substratum- 
bound substances has been called haptotaxis. Chemokines are so named because they are 
chemotactic cytokines that can stimulate the directed migration (through both chemotaxis 
and haptotaxis) of distinct subsets of leukocytes and other cell types. 
The process of migration includes cell polarization, the formation of lamellipodia and 
filipodia and the attachment of cell to the surface on which it is migrating (Balkwill 1998). 
This process is driven by actin filaments while surface integrins are thought to guide the 
cell (Parsey and Lewis 1993). 
The capability of chemokines to guide cell migration is fundamental to their role in normal 
and pathological physiology. 
1.3.1. ii. Leukocyte trafficking. 
Chemokines are thought to provide the directional cues for the movement of leukocytes in 
development, homeostasis, and inflammation. Leukocyte extravasion from the blood into 
the tissues is a regulated multistep process involving a series of coordinated interactions 
between leukocytes and endothelial cells (Figure 1.8) (Springer 1994). 
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Figure 1.8. Leukocyte extravasion from the blood into the tissues 
Leukocytes in the bloodstream become tethered to endothelial cells and roll slowly downstream. Tethering is 
greatly facilitated by leukocyte receptors, whereas subsequent rolling is not influenced by the topography of 
adhesion receptors. Rolling leukocytes respond to chemoattractants on endothelial cells and the activating 
signal induces rapid activation of (32 and a4 integrins. The "4 integrins can mediate activation-independent 
rolling interactions as well as arrest rolling leukocytes. From (von Andrian and Mackay 2000). 
Several families of molecular regulators, such as selectins, integrins, and chemokines, are 
thought to control different aspects of this process. Selectins facilitate the movement of 
leukocytes along the surface of endothelial cells (rolling). Chemokines are thought to 
provide the signals that convert the low affinity. selectin-mediated interaction into the 
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higher-affinity, integrin mediated interaction that leads to extravasion of leukocytes (Luster 
1998). Chemokines are believed to control the homeostatic circulation of leukocytes 
through tissues. The continuous recirculation of lymphocytes through the blood, tissue, and 
lymphatics in an organized manner brings naive lymphocytes into the lymph nodes, where 
they encounter antigen and are transformed in memory lymphocytes that migrate into 
inflamed tissue to ensure immunity. Macrophages, eosinophils, and mast cells also migrate 
into tissues (Ono, Nakamura et al. 2003). Although these cells are produced in the bone 
marrow, they reside primarily in other tissues. The role of chemokines in regulating the 
movement of cells into tissues has begun to be elucidated on the basis of studies in mice 
deficient in a particular chemokine. For example, CXCL12 is critical for the migration of 
myeloid precursors from the fetal liver to the bone marrow (Nagasawa, Hirota et al. 1996), 
and CCL11 is important in the recruitment of eosinophils into tissues (Rothenberg, 
MacLean et al. 1997). Therefore, chemokines and chemokine receptors play a vital role in 
the trafficking of leukocytes to and from secondary lymphoid organs, and this function is 
important particularly during an immune response. 
1.3.1. iii. Haematopoiesis 
T lymphopoiesis occurs mainly in the thymus, while B lymphopoiesis occurs 
predominantly in the bone marrow, leading to the development of mature naive 
lymphocytes. T and B lymphocytes are thought to develop from a common haematopoietic 
progenitor cell (HPC) found in the bone marrow. Stem cells and progenitor cells in the 
bone marrow are subjected to the influence of a variety of different cytokines, resulting in 
either stimulation or inhibition of proliferation (Youn, Mantel et al. 2000; Lataillade, 
Domenech et al. 2004). Members of the chemokine family, including CXC, CC and C 
chemokines, have been shown to suppress haematopoiesis (Broxmeyer and Kim 1999). 
Work by Reid et al (Reid, Ritchie et al. 1999) and Haneline et al (Haneline, L. S., 1998. 
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Blood 91: 4092-4098) implicated CCL3 and CCR2 in the induction of HPC apoptosis. In 
contrast, various chemokines promote haematopoiesis: for example, CXCL12 has been 
shown to enhance HPC survival (Youn, Mantel et al. 2000). 
HPC can express CXCR4 and CCR7 and migrate towards CXCL12, CCL19 and CCL21 
(Kim, Bae et al. 1998). Chemokine receptor expression by HPC may regulate the homing 
of these cells within the bone marrow during differentiation and maturation, and their 
mobilisation into the circulation. CXCR4 may be important for the retention of HPC in the 
bone marrow, particularly during B lymphopoiesis; retaining B cell precursors in the bone 
marrow would enable their regulated differentiation into mature B cells (D'Apuzzo, Rolink 
et al. 1997; Zou, Kottmann et al. 1998). 
1.3.1. iv. T cell differentiation 
Chemokines can differentially attract naive and activated T cells, but they may also have 
roles in regulating T cell differentiation. In many situations, it is still not clear how Thl or 
Th2 responses develop, yet this decision is critical to the outcome of the immune response. 
Chemokines, including CCL2 and CCL3, have now been shown to influence this Thl/Th2 
polarisation. CCL2 can suppress Thl responses and cause an increase in IL-4 (Th2 
cytokine) production by activated and memory T cells in vitro (Karpus, Lukacs et al. 1997; 
Sallusto, Lanzavecchia et al. 1998). CCL2 addition to macrophages in vitro can also 
decrease IL-12 (a Thl cytokine) expression (Chensue, Warmington et al. 1996). CCL2 
may therefore promote Th2 polarisation both directly and indirectly by increasing IL-4 and 
decreasing IL-12 production, respectively. In contrast, addition of CCL3 to in vitro 
cultures of activated T cells promoted the development of IFN-y-producing cells (Karpus, 
Lukacs et al. 1997) and hence Thl differentiation. Similarly, CCL3,4 and 5 production by 
monocyte-derived DC can promote the development of IFN-y-producing cells (Zou, 
Borvak et al. 2000). Experiments in mice deficient in the chemokines CCL2 and CCL3 and 
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the chemokine receptors CCR1 and CCR2 have been less conclusive, with a preference for 
either Thl or Th2 polarisation depending on the experimental protocols used (Cook, Beck 
et al. 1995; Gao, Wynn et al. 1997; Gu, Tseng et al. 2000; Traynor, Kuziel et al. 2000). For 
example, CCL2-deficient mice have increased Leishmania resistance, indicating a shift 
from Th2 to Thl (Gu, Tseng et al. 2000), while CCR2-deficient mice have diminished 
IFN-y production, increased Th2-type cytokines and higher IgE, suggesting a shift from Th 
1 to Th 2 (Blease, Mehrad et at. 2000; Traynor, Kuziel et al. 2000). More work is required 
to further elucidate the requirements for chemokines in the differentiation of T cells, and 
also the contribution of chemokines produced by T cells themselves. This may have 
implications for the use of chemokine receptor antagonists in the treatment of 
inflammatory disease. 
1.3.2. Role of chemokines in infection and inflammatory disease 
The vital role of chemokines in directing leukocyte traffic during immune responses 
necessarily involves chemokines/receptors in infection, as well as inflammation and 
various other disease states. Thus, viral infection, autoimmune diseases such as multiple 
sclerosis and rheumatoid arthritis, allergy, transplantation, atherosclerosis and cancer are 
all affected by chemokine and chemokine receptor expression and function. Some of the 
roles of chemokines and their receptors in inflammatory responses, allergy and asthma, 
HIV infection and cancer will be described here. 
1.3.2.1. Tissue recruitment of leukocytes 
The dramatic increase in the secretion of chemokines during inflammation results in the 
selective recruitment of leukocytes into inflamed tissue. Chemokines are produced during 
inflammation in most organs as for example skin, brain, joints, and lungs. Leukocyte 
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infiltration in inflammatory sites would be a special case of this general model of leukocyte 
movement (Figure 1.9). 
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Figure 1.9. Chemokine-induced leukocyte transmigration during an inflammatory response 
Circulating leukocytes loosely adhere to the endothelium through interaction with selectins and roll along the 
vessel wall. Activation by chernokines (possibly bound to glycosaminoglycans) causes upregulation of 
leukocyte integrins, leading to firm adhesion to the endothelium. This is followed by extravasation through 
the vessel wall, and migration into the tissue towards the chemokine source. From (Luster 1998). 
Production of chemokines by sentinel cells at an inflammatory focus may be responsible 
for inducing strong adhesive interactions between rolling leukocytes and the endothelium. 
Diapedesing cells are then attracted into the inflammatory site by the chemokine 
concentration gradient (Rollins 1997). 
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But to do so, tissue-derived chemokines must traverse the endothelium of blood vessels. 
Originally this was thought to be achieved by chemokine diffusion through intercellular 
gaps (Ebnet, Kaldjian et al. 1996), but work by Middleton et al (Middleton, Neil et al. 
1997) suggests that chemokines, in particular CXCL8, are transcytosed across the 
endothelium. Immunoelectron microscopy and electron microscopic autoradiography were 
used to follow the localisation of radio-labelled CXCL8 injected into rabbits. The 
timecourse of localisation of CXCL8 was consistent with transcytosis of CXCL8 from the 
abluminal endothelial cell surface, via caveolae, to the luminal surface, where it was 
presented on the surface of microvilli. Transcytosis of the chemokine CCL19 has also been 
demonstrated in high endothelial venules (Baekkevold, Yamanaka et al. 2001). 
During the multi-step process of transendothelial migration (Figure 1.9), leukocytes first 
undergo a process of `rolling' along the endothelium. This is mediated through weak 
adhesive interactions between L-, P- and E-selectins on the endothelium and selectin 
ligands on the leukocytes (Panes and Granger 1998). Then the increased avidity of 
leukocyte integrins leads to leukocyte arrest and firm adhesion (Constantin, Majeed et al. 
2000; Grabovsky, Feigelson et al. 2000). These integrins include VLA-4, which captures 
lymphocytes under shear flow conditions but only in response to immobilised chemokines, 
not soluble chemokines (Cinamon, Grabovsky et al. 2001), and ß2 integrins on monocytes 
and neutrophils (Detmers, Powell et al. 1991; Jiang, Beller et al. 1992). 
Subsequently, leukocytes undergo transendothelial migration, which may only initiate and 
progress under conditions of shear flow (Cinamon, Grabovsky et al. 2001), and chemotaxis 
through the tissue towards the site of chemokine production. Once leukocytes reach the site 
of inflammation, modulation of chemokine receptor expression by pro-inflammatory 
signals such as LPS and TNF-a may serve to retain leukocytes in the tissue (Sica, Saccani 
et al. 1997; Sica, Saccani et al. 2000). 
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1.3.2. ii. Allergic rhinitis and asthma 
Recently, chemokines have been implicated in contributing to allergic airway 
inflammation such as allergic rhinitis and asthma (Lukacs, Strieter et al. 1996; Griffiths- 
Johnson, Collins et al. 1997). This is a chronic disease of the small airways where chronic 
inflammation leads to reversible airway obstruction and bronchopulmonary hyper- 
responsiveness as well as mucous gland hyperplasia and subepithelial fibrosis. The late 
response in this disease, occurring 4 to 12 hours after allergen exposure, is characterised by 
a leukocyte infiltrate consisting of eosinophils, mononuclear cells (particularly Th2 cells), 
basophils and mast cells (Owen 2001; D'Ambrosio 2005). Various chemokine receptors 
are expressed on the leukocytes associated with asthma, including CCR1,2,3,4,7 and 8 
(Owen 2001). Of these, CCR3 may be particularly important since it is the receptor for 
CCL 11; this chemokine was first described due to its ability to attract eosinophils (Jose, 
Griffiths-Johnson et al. 1994) which are closely correlated with lung dysfunction clinically 
(Rankin, Conroy et at. 2000). Protein and mRNA expression of CCR3 are elevated in the 
bronchial mucosa and skin of patients with asthma (Ying, Robinson et at. 1997); CCR3 is 
expressed on eosinophils, basophils, mast cells and airway epithelial cells (Uguccioni, 
Mackay et al. 1997; Quackenbush, Wershil et al. 1998; Stellato, Brummet et at. 2001) and 
can bind CCL5,7,11,13,24 and 26. Airway epithelial cells are a major source of CC and 
CXC chemokines in asthma (Nickel, Beck et al. 1999), and CCR3 expression by these 
cells could modulate several aspects of epithelial function, including production of more 
chemokines, activation, proliferation and apoptosis. 
Another leukocyte population prominent in the pathogenesis of allergic diseases is the T 
cells with a Th2 phenotype (Gavett, Chen et al. 1994). Th2 cells preferentially express 
CCR4 and CCR8 (Zingoni, Soto et al. 1998). The ligands for these chemokine receptors 
(CCL17, CCL22 and CCL1) are potent chemoattractants for Th2 cells. These observations 
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suggest that both CCR4 and CCR8 play a role in the control of Th2 responses and may 
represent potential targets for the treatment of allergic diseases (Murdoch and Finn 2000). 
The functional importance of CC-chemokines in rodent asthma models has been 
demonstrated in studies using neutralising antibodies to CC chemokines, aminoterminal 
modified CC-chemokines that act as receptor antagonists and a pan-CC chemokine 
antagonist protein from pox virus (Gonzalo, Lloyd et al. 1998; Dabbagh, Xiao et al. 2000). 
Chemokine receptor antagonists may therefore be useful for blocking the inflammatory 
infiltrate seen in this disease. 
1.3.2.11!. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease eventually leading to joint 
destruction (Harris 1990). 
One of the cardinal features of rheumatoid synovitis is the recruitment and retention of 
inflammatory cells (Thl cells, neutrophils, monocytes) in the sublining region. This 
process is mediated by chemokines as well as adhesion molecules on vascular endothelium 
and counter-receptors on circulating leukocytes that draw cells to sites of inflammation. 
Synovial fluid from inflamed joints contains several chemokines, including CCL2, 
CCL3, CCL5, CXCL8 and CXCL10 (Godessart and Kunkel 2001; Patel, Zachariah et al. 
2001) that are produced by resident synovial cells as well as by infiltrating leukocytes. 
CCR5 and CXCR3 are expressed by T cells infiltrating the synovial tissue (Qin, Rottman 
et al. 1998; Ruth, Rottman et al. 2001). CXCRI on neutrophils, CCR1 and CCR2 on 
monocytes and CXCR6 on T cells have also been involved in the pathogenesis of the 
disease (Konig, Krenn et al. 2000; Hayashida, Nanki et al. 2001; Kim, Kunkel et al. 2001). 
Recently it was demonstrated that CXCL16/CXCR6 pathway has a pathogenic role in RA 
and that using CXCL16 monoclonal antibody significantly reduced infiltration of 
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inflammatory cells and bone marrow destruction in mouse model (Nanki, Shimaoka et al. 
2005). 
It is known that CXCL12 expressed in the rheumatoid synovium, is involved in the 
recruitment of CD4+ memory T cells but may also play a role in the migration of dendritic 
cells (DC) from the blood into the rheumatoid synovium (Penna, Sozzani et al. 2001). 
Local production of CCL19 and CCL21 could play a role in the trafficking of mature DC 
from the blood into the rheumatoid sinovium (Cravens and Lipsky 2002). 
The temporal expression of CXCL5, CCL2 and CCL3 was assessed during the course of 
rat AIA, a model for human RA, to understand which chemokines are involved in the early 
events and later stages of the disease (Szekanecz, Kim et al. 2003). CCL3 was associated 
with early inflammatory events, including leukocytosis and the production of acute phase 
reactants, while CCL2 seems to be involved mostly in the later phase of AIA (Kasama, 
Stricter et al. 1995). 
Chemokine production in the RA joint could be targeted indirectly, through the inhibition 
of cytokine production, or directly. Anti- TNF-a and anti-IL-1 strategies have been shown 
to downregulate chemokine synthesis (Szekanecz, Kim et al. 2003). 
In mouse models of arthritis, neutralizing antibodies to CCL2 reduced the severity of 
disease (Gong, Ratkay et al. 1997) dimishing the monocyte recruitment and disease 
development. An antagonist of CCR1 and CCR5, met-CCL5 was also effective in reducing 
inflammation in experimental mouse models of arthritis (Plater-Zyberk, Hoogewerf et al. 
1997; Bruhl, Cihak et al. 2001). These experiments are not only useful for the development 
of future therapeutic strategies, but provide insights into the pathogenic action of these 
chemokines. 
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1.3.2. iv. HIV 
Human immunodeficiency virus (HIV) is a retrovirus surrounded by a viral envelope 
which consists of virus-encoded glycoproteins embedded in a host cell-derived lipid 
bilayer (Robey, Safai et at. 1985). The primary cell surface receptor for HIV entry is CD4; 
however, in 1996, viral strain-specific co-receptors were discovered that are also required 
for HIV entry into cells (Deng, Liu et al. 1996; Doranz, Rucker et al. 1996; Dragic, Litwin 
et al. 1996; Feng, Broder et at. 1996). These co-receptors were the chemokine receptors 
CXCR4 and CCR5, which along with CD4 (present on T cells and macrophages) allow 
viral envelope fusion and entry (Berger, Murphy et al. 1999). A range of chemokine 
receptors have now been shown to have co-receptor activity in vitro, including CCR1,2,3, 
4,5,8,9, CXCR2,4,5,6 and CX3CR1 (Simmons, Reeves et al. 2000) but so far only 
CXCR4 and CCR5 have been shown to act as co-receptors in vivo [hence X4 tropic and R5 
tropic viruses (Berger, Doms et al. 1998)]. The co-receptor usage also determines the 
cellular tropism: R5 virus tends to be macrophage tropic (Collman, Hassan et al. 1989) 
while X4 virus tends to be T cell tropic, despite the fact that macrophages can express 
CXCR4 (McKnight, Wilkinson et al. 1997). Virus entry into cells involves a process 
whereby the gp120 protein in the viral envelope interacts with CD4 on the cell surface. 
This results in a conformational change in gp120 that allows a secondary interaction with 
the chemokine co-receptor. This results in further conformational changes in the viral 
envelope protein gp4l, resulting in membrane fusion and virus entry (Wu, Gerard et al. 
1996; Turner and Summers 1999). In a recent work, Tian et al. have demonstrated that 
many residues of CXCR4 and extracellular loop 2 domains are specifically involved in 
interaction with HIV-1 gp120 (Tian, Choi et al. 2005). 
Since chemokine receptors act as co-receptors for HIV entry, endogenous chemokine 
production can regulate HIV replication. In 1995, Cocchi et al published that CCL3, CCL4 
and CCL5 have CD8+ T-cell-derived HIV inhibitory activity (Cocchi, DeVico et al. 1995) 
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and individuals with high levels of these chemokines have reduced HIV 
infectability 
(Paxton, Liu et al. 1998). 
Also, individuals homozygous for the A32 allele of CCR5, who are deficient in cell surface 
CCR5 expression, can remain uninfected despite exposure to HIV (Benkirane, Jin et al. 
1997). These observations suggest that chemokines and their receptors which are 
implicated in HIV infection are potential targets for the development of new drugs to treat 
HIV. For example, small molecule antagonists of CCR5 and CXCR4, which can block 
HIV entry, are entering clinical trials (Simmons, Clapham et al. 1997; Donzella, Schols et 
al. 1998). 
1.3.3. Role in malignancy 
1.3.3.1. Leukocyte infiltrate 
In 1863, Virchow noted that neoplastic tissues contain a "lymphoreticular infiltrate", 
suggesting a connection between cancer and inflammation. Many tumours of epithelial 
origin contain a leukocyte infiltrate consisting predominantly of macrophages and T 
lymphocytes (Mantovani, Bottazzi et al. 1992). Analysis of carcinomas of the colon, lung, 
breast and stomach showed that the infiltrating mononuclear cells were predominantly in 
the stroma (Svennevig and Svaar 1979). 
In ovarian cancer, leukocytes can be found both within the supporting stroma and the 
tumour areas (Negus, Stamp et al. 1997). 
Leukocytes can infiltrate tumours in response to tumour-derived chemokines, including 
CCL2 (Negus, Stamp et al. 1995; Negus, Stamp et al. 1997). These chemokines are 
produced by tumour cells, resident and infiltrating stromal cells (Bottazzi, Ghezzi et al. 
1985; Walter, Bottazzi et al. 1991; Negus, Stamp et al. 1997). It is unclear what function is 
performed by the leukocyte infiltrate. Mantovani et al introduced the concept of a 
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`macrophage balance', where tumour-associated macrophages (TAM) may promote or 
inhibit tumour growth depending on their state of activation (Mantovani, Bottazzi et al. 
1992). In recent work by Nesbit et al, high levels of CCL2 over-expression in melanoma 
cells led to tumour destruction in nude mice, due to a massive monocyte/macrophage 
infiltrate (Nesbit, Schaider et al. 2001). However, low levels of CCL2 led to an angiogenic 
effect mediated through TAM, which resulted in increased tumour growth. In work 
by Lin 
et al, PyMT mice (which are susceptible to mammary carcinoma) that were deficient 
in 
CSF-1 developed primary mammary tumours at the same rate as wild-type mice. However 
in the CSF-1 deficient mice, the progression to malignancy and metastasis was delayed due 
to a paucity of TAM (Lin, Nguyen et al. 2001). In breast cancer, macrophage infiltration 
has been correlated with vascularity, suggesting that leukocytes may promote tumour 
angiogenesis and hence survival (Leek, Lewis et al. 1996). 
It is also possible that the infiltrate represents the host's attempt at mounting an ineffective 
immune response. Enhancing anti-tumour immune responses may lead to tumour 
regression. A number of chemokines have been over-expressed in murine tumour models: 
engineered over-expression of CCLI, 2,5,20, CXCL IO and XCL 1 have all led to an 
enhanced immune response and hence tumour rejection (Rollins and Sunday 1991; Luster 
and Leder 1993; Laning, Kawasaki et al. 1994; Dilloo, Bacon et al. 1996; Mule, Custer et 
al. 1996; Fushimi, Kojima et al. 2000; Vicari, Ait-Yahia et al. 2000). 
Vicari et al transduced a colon carcinoma cell line with CCL21; these cells showed a 
reduction in tumourigenicity in both immunocompetent and nude mice, possibly due to 
angiostatic mechanisms and anti-tumour immunity (Vicari, Ait-Yahia et al. 2000). The 
CCL21-transduced tumours had an increased infiltrate, which included immature dendritic 
cells and CD8+ T cells; the data suggested that these cells participated in anti-tumour 
immunity. In a study of oesophageal carcinoma by Schumacher et al, the intratumoural 
CD8+ T cell infiltrate showed proliferative activity and IFN-y secretion and this infiltrate 
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(rather than the peritumoural T cell infiltrate) was correlated with a good prognosis in both 
squamous cell and adenocarcinomas (Schumacher, Haensch et al. 2001). 
Tumour-derived chemokines may therefore contribute to tumour growth and spread; TAM, 
for example, can produce growth and angiogenic factors, and proteases which may favour 
invasion and metastasis (Balkwill and Mantovani 2001). In addition, reactive oxygen 
species released by TAM can damage DNA, causing mutation and hence tumour 
progression (Hagen, Huang et al. 1994). 
Conversely, tumour-derived chemokines can be manipulated to encourage massive 
leukocyte infiltration and tumour destruction. 
I. 3.3. ii. Angiogenesis 
Angiogenesis is the development of new blood vessels from pre-existing vasculature, and 
it depends on a balance between pro- and anti-angiogenic factors. These factors are 
normally precisely regulated and only allow neovascularisation when appropriate, for 
instance during wound repair (Leibovich and Wiseman 1988). Tumour growth is also 
dependent on angiogenesis (Folkman 1990); once a tumour reaches a few millimetres in 
diameter, further tumour expansion requires neovascularisation. Once this is achieved, 
tumour growth is usually rapid and allows the potential for metastasis (Weidner, Semple et 
al. 1991). 
A variety of pro-angiogenic factors, including vascular endothelial growth factor (VEGF), 
are produced by the tumour and the leukocytic infiltrate (Folkman and Klagsbrun 1987). 
TAMs in particular have been correlated with tumour vascularity and prognosis (Leek, 
Landers et al. 1999). Chemokines may also have a role in tumour angiogenesis (Arenberg, 
Polverini et al. 1997). CXC chemokines can be both pro- and anti-angiogenic, depending 
on the presence of a tripeptide motif (glutamate-leucine-arginine: the ELR motif) within 
the N-terminus of the protein (Belperio, Keane et al. 2000). ELR+ CXC chemokines are 
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potent pro-angiogenic factors, while ELR- CXC chemokines are angiostatic (Stricter, 
Polverini et al. 1995). Therefore, the balance between the expression of ELR+ and ELR- 
chemokines in tumours has important implications for the regulation of angiogenesis. 
ELR+ chemokines such as CXCL8, CXCL5 and CXCL6 directly promote chemotaxis and 
proliferation of endothelial cells in vitro and in vivo (Stricter, Polverini et al. 1995; Stricter, 
Addison et al. 1999). These effects may be mediated through CXCRI and/or CXCR2; 
CXCR1 can only bind CXCL6 and CXCL8, while CXCR2 can bind all ELR+ chemokines. 
Work by Addison et al (Addison, Daniel et al. 2000) with neutralising antibodies to 
CXCR2 and CXCR2-deficient mice suggests that this receptor is the putative receptor for 
chemokine-induced angiogenic activity. 
Many of the angiostatic ELR- CXC chemokines are inducible by IFNs, including CXCL9, 
10 and 11 (Luster and Ravetch 1987; Farber 1993; Cole, Strick et al. 1998). All three of 
these IFN-inducible chemokines bind to CXCR3, and this receptor may mediate their 
angiostatic functions by inhibiting the proliferation of endothelial cells (Romagnani, 
Annunziato et al. 2001). CXCL12 is also an ELR- CXC chemokine, but it is unclear 
whether this chemokine is pro- or anti-angiogenic; CXCL12 is chemotactic in vitro for 
endothelial cells (Gupta, Lysko et al. 1998) and can induce neovascularisation in vivo 
(Salcedo, Wasserman et al. 1999), yet it can antagonise the pro-angiogenic activity of 
ELR+ chemokines and VEGF (Arenberg, Polverini et al. 1997). 
Recently the CC chemokine, CCL2, has also been shown to have a direct role in 
angiogenesis. Endothelial cells can express CCR2, the receptor for CCL2, and can migrate 
towards CCL2. Moreover, CCL2 can promote blood vessel formation in angiogenic assays 
in vivo (Salcedo, Ponce et al. 2000). 
CXC chemokines can have important roles in angiogenesis in tumours. Transfection of 
melanocytes with the ELR+ chemokines CXCL1,2 and 3 enables them to form tumours in 
nude mice, and these tumours are highly vascularised (Luan, Shattuck-Brandt et al. 1997; 
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Owen, Strieter et al. 1997). CXCL8 contributes to angiogenesis in models of non-small cell 
lung cancer (NSCLC) in vivo (Arenberg, Kunkel et al. 1996), while CXCL5 correlates with 
the degree of vascularity in human NSCLC biopsies (Arenberg, Keane et al. 1998). Work 
by Yoneda et al (Yoneda, Kuniyasu et al. 1998) showed a role for CXCL8 in the 
angiogenesis and hence progression of human ovarian cancer xenografts in nude mice. 
Studies in various other tumours and tumour models have indicated a role for ELR+ 
chemokines in promoting angiogenesis and tumour progression, including prostate cancer 
(Engl T. et al. Life Sci. 2005 Epub ahead of print), gastric cancer (Kitadai, Haruma et al. 
1998) and pancreatic cancer (Shi, Abbruzzese et al. 1999). 
Angiostatic ELR- chemokines may have therapeutic benefit in cancer. The expression of 
CXCL9 and 10 in Burkitt's lymphoma cell lines in nude mice was higher in tumours that 
spontaneously regressed and was correlated with impaired angiogenesis (Sgadari, 
Angiolillo et al. 1996). Production of CXCL 10 from adenocarcinoma or squamous cell 
carcinoma cell lines inoculated in SCID mice was inversely correlated with tumour growth 
(Arenberg, Kunkel et al. 1996). Thus the balance between pro- and anti-angiogenic 
chemokines can regulate angiogenesis, indirectly affecting tumour cell growth. Interfering 
with this balance may have therapeutic benefits. 
1.3.3. iii. Growth-promoting effects in malignancy 
Chemokines can also have direct effects on the growth of tumour cells. In 1985, an 
autostimulatory melanoma mitogen was discovered, termed melanoma growth stimulatory 
activity (MGSA), which is now known to comprise the CXCL1/2/3 chemokines 
(Richmond, Lawson et al. 1985; Richmond, Balentien et al. 1988). MGSA can stimulate 
the proliferation of melanoma cell lines and also pancreatic cell lines (Takamori, Oades et 
al. 2000). CXCL8 can act as an autocrine growth factor for melanoma cell lines; inhibiting 
its production in vitro prevented cell proliferation and colony formation in soft agar 
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(Schadendorf, Moller et al. 1993). This chemokine can also stimulate the proliferation of 
some ovarian cancer cell lines (Xu and Fidler 2000), pancreatic cell 
lines (Takamori, 
Oades et al. 2000) and colon carcinoma cell lines (Brew, Erikson et al. 2000). In 
B-cell 
chronic lymphocytic leukaemia, CXCL8 does not stimulate the proliferation of leukaemic 
cells, instead it acts as a survival factor, protecting cells from apoptosis and causing their 
accumulation (di Celle, Carbone et al. 1994). The effects of CXCL 1 /2/3 and CXCL8 may 
be mediated through either CXCRI or CXCR2. Both of these receptors can be expressed 
by tumour cells in head and neck squamous cell carcinoma (Richards, Eisma et al. 1997). 
Therefore chemokines may be responsible for direct effects on cancer growth, as well as 
indirect effects through the stimulation of angiogenesis and promotion of a leukocyte 
infiltrate which can provide growth and survival factors. 
1.3.3.1v. Invasion and metastasis 
Tumour metastases probably develop due to interactions between selected tumour cells and 
a supportive microenvironment: the concept of `seed' and `soil' coined by Paget in 1889 
(Paget 1889). Thus, tumour cells may need enhanced adherence to the microvascular 
endothelium of the target organ and increased response to local mitogens, while the target 
site requires an appropriate microvascular endothelium, stroma and matrix, and the 
expression of mitogens (Nicolson 1993). It is also apparent that metastasis is not a random 
process and that different tumours have preferential metastatic sites (Nicolson 1993). 
Breast cancer frequently spreads to regional lymph nodes, bone marrow, lung and liver 
(Muller, Homey et al. 2001); malignant melanoma is similar, but also has frequent skin 
metastases (Moore 2001). These patterns of metastasis are reminiscent of leukocyte 
trafficking, so it seems possible that chemokines and their receptors could have a role in 
tumour metastasis. It is also possible that monocytes infiltrating a tumour may provide 
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tumour cells with a ready made path for invasion: the `countercurrent invasion theory' 
(Opdenakker and Van Damme 1992). 
A number of different tumour cells have been shown to migrate towards chemokines, or to 
express chemokine receptors. Breast cancer cells and melanoma express CXCR4 and 
CCR7, which bind to CXCL 12 and CCL 19/CCL21, respectively, which are express at 
major sites of metastasis, skin, bone marrow, lung, liver and lymph nodes (Muller, Homey 
et al. 2001). The human breast cancer cell line MCF-7 migrated towards CC chemokines, 
including CCL3,4 and 5 and to a lesser extent CCL2, CXCL1 and CXCL8 (Youngs, Ali et 
al. 1997); binding studies indicated that MCF-7 possess binding sites for these chemokines, 
indicating the presence of multiple chemokine receptors. Muller et al. have shown that this 
cell line expresses high level of CXCR4, CCR7 and CXCR2 (Muller, Homey et al. 2001). 
The prostate cancer cell line PC3 expresses CXCR2 and can migrate and invade in 
response to CXCL1 and CXCL8 (Reiland, Furcht et al. 1999). The ovarian cancer cell line 
CAOV-3 expresses CXCR4 and migrate to CXCL12 (Scotton, Wilson et al. 2002). Scotton 
et al. showed that CXCL12 was present in ascitic fluid and that CXCR4 was expressed 
more strongly by tumour cells in ascites concluding that this chemokine receptor/ligand 
interaction could be involved in peritoneal spread of this cancer (Scotton, Wilson et al. 
2002). Many pancreatic tumour cell lines express CXCR4 and it was recently shown that 
this receptor was expressed most prominently in cell lines derived from metastatic tumours 
(Marchesi, Monti et al. 2004). Functional CXCR4 expression has been demonstrated on a 
variety of leukaemic cells, including acute myelomonocytic and lymphoblastic leukaemia 
(Mohle, Schittenhelm et al. 2000), enabling these cells to migrate towards CXCL12. 
CXCR4 can also be expressed by a colonic epithelial cell line (Jordan, Kolios et al. 1999). 
Many in vivo studies have demonstrated that injection of tumour cells transfected with 
CXCR4 are more aggressive with increased migration, invasion and metastasis formation 
(Balkwill 2004). 
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These results suggest that chemokine receptors may play a role in tumour metastasis and 
that in particular the chemokine receptor CXCR4 seems to play a crucial role in this 
process. 
1.3.4. CXCR4 and CXCL12 
1.3.4. i. Introduction 
CXCR4 was originally identified by different groups as an orphan chemokine receptor 
(Federsppiel, Melhado et al. 1993; Loetscher, Geiser et al. 1994) and they called it LESTR 
or fusin. It is expressed by most leukocyte populations including the majority of T- 
lymphocyte subsets, all B cells and monocytes, but is only weakly expressed on natural 
killer cells (Hori, Sakaida et al. 1998). LESTR/fusin was then identified as HIV-1 
coreceptor (Feng, Broder et al. 1996) and the CXC chemokine SDF-1 was identified as a 
potent ligand and agonist of this receptor (Bleul, Farzan et al. 1996; Oberlin, Amara et al. 
1996). From this moment LASTR/fusin was reclassified as chemokine receptor CXCR4. 
CXCR4 and CXCL12 are now known to have important roles in leukocyte trafficking, 
haematopoiesis, organogenesis, vascularisation and embryogenesis (Murdoch 2000). 
CXCL12 is a homeostatic chemokine - it is expressed constitutively in a range of tissues 
and does not appear to be regulated by pro-inflammatory cytokines (Bleul, Fuhlbrigge et 
al. 1996). 
Shirozu et al investigated CXCL12 mRNA expression in human organs (Shirozu, Nakano 
et at. 1995). Almost all organs tested resulted positive, with abundant mRNA expression in 
pancreas, spleen, ovary and small intestine. This ubiquitous expression may be due to the 
presence of a GC-rich sequence in the 5'-flanking region of the CXCL12 gene, a feature 
which is associated with `housekeeping' genes. The human and murine CXCL12 proteins 
are 90% identical compared with other chemokines, while the CXCR4 proteins are 
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approximately 91% identical; therefore this chemokine/receptor pair is highly conserved 
between species. 
1.3.4. ii. CXCR4/CXCL12 deficient mice 
CXCR4- and CXCL12-deficient mice have been generated (Nagasawa, Hirota et al. 1996; 
Ma, Jones et al. 1998; Tachibana, Hirota et al. 1998; Zou, Kottmann et al. 1998), and they 
have almost identical phenotypes. CXCL12-deficient mice die in utero and have severely 
reduced numbers of B cell progenitors in the foetal liver and bone marrow. 
Myeloid progenitor cells were also reduced in number in the bone marrow, but not in the 
liver, suggesting that CXCL12 is responsible for B cell lymphopoiesis and bone marrow 
myelopoiesis. CXCL12-deficient mice also had severe heart defects, including defective 
cardiac ventricular septum formation (Nagasawa, Hirota et al. 1996), and a disorganised 
cerebellum (Ma, Jones et al. 1998). 
CXCR4-deficient mice also die in utero or, in the rare instances when homozygous mutant 
mice are born alive, die within a few hours. As with CXCL12-deficient mice, they have 
profound defects in their haematopoietic systems, including severely reduced B 
lymphopoiesis, reduced myelopoiesis in the foetal liver, and almost absent myelopoiesis in 
the foetal bone marrow; T lymphopoiesis is unaffected in these mice. 
CXCR4-deficient mice also displayed the same defects in cerebellum formation, with 
abnormal neuron migration (Ma, Jones et al. 1998). Recently it was demonstrated that mice 
deficient for CXCR4 exhibit impaired limb innervation and myogenesis (Odemis, Lamp et 
al. 2005). Other work has shown that CXCR4/CXCL12 are also essential for 
vascularisation of the gastrointestinal (GI) tract; mice deficient in either CXCR4 or 
CXCL12 have defective formation of the large blood vessels supplying the GI tract, 
possibly due to defective regulation of vascular branching and/or remodelling processes in 
endothelial cells (Tachibana, Hirota et al. 1998). The near identical phenotypes of the 
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CXCR4- and CXCL12-deficient mice suggest a monogamous relationship where CXCL12 
only acts through CXCR4. 
1.3.4. iii. Role of CXCR41CXCL12 in development 
Studies on CXCR4 and CXCL12 knock out mice have demonstrated their importance in 
development. The involvement in ontogeny of CXCR4 came from experiments examining 
rat embryonic development. Jazin et al. have found elevated mRNA levels of rat CXCR4 
in the thymus and brain at embryonic day 9 (E9) (Jazin, Soderstrom et al. 1997). 
As well as being involved in brain development, CXCR4 has a role in early 
embryogenesis. CXCR4 mRNA was detected in embryonic mesodermal cells by day 
seventh of embryonic development (E7.2). It was demonstrated that during organogenesis 
the CXCL 12 expression pattern is always broader than that of CXCR4. 
The CXCL12 and CXCR4 research work performed on mice confirms a key role for this 
chemokine and its receptor in multiple embryonic and developmental events. Recently 
their importance in development and germ cell migration was demonstrated using 
zebrafish model (Dumstrei, Mennecke et al. 2004; Sapede, Rossel et al. 2005). 
Taken together, these results point to CXCR4/CXCL12 as an important chemokine 
signalling system during embryogenesis and development, with broad roles in controlling 
the movement of cells in a variety of organs. This may explain why CXCL12 diverged 
from other chemokines early in evolution and remained highly conserved - due to its 
primordial role in development. 
1.3.4. iv. CXCR4/CXCL12 in haematopoiesis and leukocyte trafficking 
CXCL12 is a potent chemoattractant for T cells and monocytes, and plays a major role in 
the homing of T cells to secondary lymphoid organs and inflammatory sites. CXCR4 may 
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also be involved with the development of the thymus and positive selection of T cells: 
CXCR4 mRNA levels increase in the foetal thymus in parallel with T cell maturation, up 
to the double positive (CD4+ CD8+) stage of T cell development - at which point CXCR4 
expression is downregulated (Suzuki, Nakata et al. 1998). A central and unique role for the 
chemokine CXCL12 and its receptor CXCR4 in hematopoietic stem cell (HSCs) 
trafficking to the bone marrow has now been elucidated. CXCL12 is constitutively 
expressed by stromal cells in the bone marrow and is found on the endothelium of bone 
marrow microvessels (Peled, Grabovsky et al. 1999), and it promoted chemotaxis of HSC 
and progenitor cells in human and mice (Kim and Broxmeyer 1998; Wright, Bowman et al. 
2002; Dalakas, Newsome et al. 2005). 
CXCR4 may also help to maintain the contact between pro/pre-B cells and bone marrow 
stromal cells by supporting the retention of progenitor B cells within microenvironments 
that promote B lymphopoiesis (Ma, Jones et al. 1998). Peled et al have also shown a 
requirement for CXCR4/CXCL12 in murine bone marrow engraftment by human SCID- 
repopulating stem cells (CD34+ cells derived from cord blood). CXCR4 antibodies 
prevented engraftment in the bone marrow of SCID mice. In addition, treatment of CD34+ 
cells with IL-6 and Stem Cell Factor (SCF) upregulated CXCR4 expression and enhanced 
engraftment (Peled, Petit et al. 1999). This may have clinical implications with regard to 
therapeutic stem cell transplantation. 
In conclusion, CXCR4 and CXCL12 have the usual functions attributed to homeostatic 
chemokine/receptor pair, including effects on leukocyte trafficking and homing. But the 
unique expression of CXCR4 and CXCL12 compared with other chemokines indicates 
roles in other physiological processes including organogenesis, vascularisation, 
haematopoiesis and embryogenesis. 
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1.4. HYPOXIA 
1.4.1. Introduction 
Hypoxia is a physiological and physiopathological condition characterized by low oxygen 
tension. 
Hypoxia can be caused by a number of factors, such as: 1) low 02 partial pressure (02 
tension) in arterial blood due to, e. g., pulmonary diseases or high altitude; 2) reduced 
ability of blood to carry 02 as a result of anemia, methemoglobin formation, or carbon 
monoxide poisoning; 3) reduced tissue perfusion, generalized or local; 4) deterioration of 
the diffusion geometry; or 5) inability of cells to use 02 because of intoxication, as cyanide 
poisoning (cytotoxic hypoxia) (Hockel and Vaupel 2001). 
Hypoxia is characteristic of infected tissues, wounds, rheumatic joints, and parts of 
tumours but also of normal spleen and joints. All these are infiltrated by leukocytes, major 
cell types of the innate immune system. As local tissue hypoxia might not result from 
tissue damage but might reflect the normal tissue microenvironment and vasculature. 
Immune cells, during their life, are exposed to different oxygen concentrations ranging 
from 16% (-159 mm Hg) in the pulmonary alveoli to less than 6% (4-34 mm Hg) in most 
other organs of the body and to less than 1% (-0.8-6 mm Hg) in pathological sites, such as 
tumours (Semenza 2000; Sitkovsky and Lukashev 2005). 
The ability to maintain oxygen homeostasis is essential to the survival of all vertebrate 
species. Physiological systems have evolved to ensure the optimal oxygenation of all cells 
in each organism and this happens for the evolution of a complex physiological 
infrastructure for 02 delivery that includes an entry (lungs), transport vehicle 
(erythrocytes), a highway and secondary road system (vasculature), and a propulsion 
device (heart) (Michiels 2004). Specialized chemoreceptor cells that regulate 
cardiovascular and ventilatory rates regulate changes in 02 supply. In response to reduced 
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02 availability cells rapidly activate specific transcription mechanism to induce 
transcription of hypoxia responsive genes involved in oxygen homeostasis. 
During their life span, cells of the innate immune system may encounter environments 
characterized by different oxygen levels, ranging from normoxia (e. g. blood stream) to 
hypoxia (e. g. poorly vascularized tissues). Moreover, pathological sites are often 
characterized by poor oxygen tension, particularly evident in tumours, wounds lesions and 
joints inflammation (e. g. reumathoid arthritis). Cells localizing in hypoxic sites undergo to 
a metabolic adaptation program leading to the expression of specific genes, products of 
which are involved in the mainteinance of 02 homeostasis. 
Homeostatic responses to hypoxia can be classified as systemic, local, or cellular in nature. 
Systemic changes include increased erythropoiesis, ventilation and cardiac output. Local 
responses include changes in vascular tone and neovascularization. Cellular responses 
include the transition from oxidative phosphorylation to glycolysis pathway for ATP 
generation. 
1.4.2. Generation of cellular energy 
Oxygen plays a major role in the energy metabolism of aerobic living organism. Under 
aerobic conditions, the source of cellular energy is glycolysis coupled to oxidative 
phophorylation (also known as respiration) (Figure 1.10). 
In this process glucose is converted to pyruvate, with ATP being concomitantly produced 
as a result of substrate-level phosphorylation of ADP using high-energy phosphate groups 
from intermediates of glucose conversion. After this, pyruvate enters the tricarboxylic acid 
(TCA) cycle in mitochondria. In the TCA cycle we have the production of electrons that 
are transfered to oxygen that represents the terminal electron acceptor (Sitkovsky and 
Lukashev 2005). At this step acts the ATP synthase that transforms the electrochemical 
gradient created by the electron-transport pathway into energy-carrying ATP. 
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When there is insufficient oxygen supply, anaerobic glycolysis takes place, and this results 
in the accumulation of a large amount of pyruvate, which cannot be used by the TCA 
cycle. In this case we have the production and subsequently the release of lactate. 
Several definitions of hypoxia exist, and depend on the experimental endpoint or detection 
methods. Although no sharp threshold exists between normoxia and hypoxia, the literature 
shows that median PO2 levels below 10 mm Hg generally result in intracellular acidosis, 
ATP depletion, and a drop in energy supply. Oxidative phosphorylation for ATP 
production measured in vitro continues to 0.5-10 mm Hg depending on the cell line and the 
experimental setup (Hockel and Vaupel 2001). Cell cycle progression is affected 
(prolonged) at 0.2-1 mmHg, and hypoxia may induce transcriptional or posttranslational 
changes resulting either in cell death or malignant progression in the range 1-15 mm Hg 
(Hockel and Vaupel 2001). 
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Figure 1.10. Simplified schema ofglycolysis and oxidative phosphorylation. 
Glucose is converted to pyruvate during glycolysis, with concomitant production of ATP. Pyruvate enters the 
tricarboxylic acid (TCA) cycle in mitochondria. where electrons are released in a series of TCA-cycle 
reactions. These electrons enter the electron-transport chain. which creates an electrical gradient at the 
mitochondrial membrane. To equalize charge on both sides of the membrane, protons move across the 
membrane, and this is coupled to the generation of ATP as a result of oxidative phosphorylation. In the 
absence of oxygen (O, ). anaerobic glycolysis results in the reduction of pyruvate to lactate, which is then 
released from the cell. CO-', carbon dioxide, H2O, water. From (Sitkovsky and Lukashev 2005). 
1.4.3. Hypoxic microenvironments in tissues 
Usually local-tissue hypoxia is not due to tissue damage but might reflect the normal tissue 
microenvironment, vasculature and geometry. Each tissue compartment is different in 
vascularization and therefore in the level of oxygenation. In normal situations. the oxygen 
tension in tissues is proportional to the distance from the end of the nearest capillary. Many 
groups measured the oxygen level in different tissue and they have found that is different 
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from air: the pO2 of inspired air is 21 % (159 mmHg), however it was shown that the p02 
is 1.3 % (10 mmHg) in the thymus and 2.1 % (16 mmHg) in the spleen (Vaupel. 
Braunbeck et al. 1973: Braun. Lanzen et al. 2001). The pO-, was found to be highest near 
the artery and to gradually decrease with distance from the artery (Figure 1.11) (Sitkovsky 
and Lukashev 2005). 
Inspired air I Po9 = 21 kPa (159 mm Hg) 
Lungs 
Poe = 20 kPa (150 mm Hg) 
Immune cell Circulation 
Po = 5-13 kPa t40-100 mm Hg) 
Tissues ý Po> = 0.5-2.5 kPa (4-20 mm Hg) 
(hypoxia) 
Figure 1.11. Low oxygen concentration in tissue environments 
Oxygen is inspired from the air; the oxygen tension (pO, ) in air is 21 kPa (159 mm Hg), which is a 
concentration of 21%. When warmed air arrives in the lungs, it loses some pressure: pO, = 20 % (150 mm 
Hg). The oxygen pressure continues to decrease in the circulation: pO2= 13 % (100 mm Hg) in alveoli and 5 
% (40 mm Hg) in veins that reach the heart. The oxygen pressure in the tissues then decreases with 
increasing distance from the blood vessels: pO, =0.5-2.5 % (4-20 nom Hg). From (Sitkovsky and Lukashev 
2005). 
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1.4.4. HIF-1 
HIF-1 is the master regulator of oxygen homeostasis. HIF-1 was identified as a hypoxia- 
inducible HRE (hypoxia responsive element)-binding activity (Semenza and Wang 1992). 
The Semenza group used the HIF-1 binding site in the erythropoietin (EPO) HRE and they 
purified HIF-la and HIF-1(3 subunits by DNA affinity chromatography (Wang and 
Semenza 1995). cDNA cloning revealed that both subunits were basic helix-loop-helix 
(bHLH)-PAS proteins: HIF-la was a novel protein, whereas HIF-1(3 was identical to the 
aryl hydrocarbon nuclear translocator (ARNT) protein (Wang, Jiang et al. 1995) (Figure 
1.12) 
HIF-1 (f 
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Figure 1.12. Domain structure of the human HIF-la and HIF-10. 
Proteins show a high degree of homology with similar structural features including basic helix loop helix 
(bHLH), PAS, and NH, - and COOH-terminal transactivation domains (TAD-N and TAD-C). Adapted from 
(Brahimi-Horn and Pouyssegur 2005). 
HIF-la is encoded by the HIFIA gene, HIF-1ß is encoded by the ARNT gene. Hifla and 
HHF IA mapped to mouse chromosome 12 and human chromosome 14, respectively 
(Semenza, Rue et al. 1996). 
Mouse and rat HIF-lu amino acid sequences share 95% identity with the human sequence, 
and in particular it was found that this protein is highly conserved from Caenorhahditis 
elegans via Drosophila melanogaster to Homo sapiens providing evolutionary evidence 
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for the functional importance of HIF-la (Li, Ko et al. 1996; Wenger, Rolfs et al. 1996; 
Luo, Gu et al. 1997; Kietzmann and Gorlach 2005). 
HIF-la and HIF-lß mRNAs are expressed ubiquitously in human and rodent tissues 
(Wenger, Rolfs et al. 1996; Wiener, Booth et al. 1996; Wenger, Rolfs et al. 1998). 
The basic domain and the COOH-terminal half of PAS are specifically required for DNA 
binding of HIF-1, whereas the HLH domain and the NH2-terminal half of the PAS 
domains are responsible for the formation of the HIF-la/HIF-lß heterodimer capable of 
DNA binding (Jiang, Rue et al. 1996). 
HIF-la also contains two transactivation domains (TADs). The main function of the TADs 
is to recruit and interact with coactivators, which are crucial for the transcriptional 
activation of target genes (Hopfl, Ogunshola et al. 2004). These domains are also important 
because HIF-la undergoes posttranslational regulation mediated through hydroxylation, 
phosphorylation, acetylation, and/or redox modifications of these two TAD domains 
(Richard, Berra et al. 1999; Bruick and McKnight 2001; Jeong, Bae et al. 2002). It was 
demonstrated by different groups that cells cultured under hypoxic conditions (1% 02) 
show an increase of HIF-la protein levels without concomitant elevation in mRNA 
expression (Hopfl, Ogunshola et al. 2004) suggesting that the main regulation pathways 
rely on oxygen-dependent protein stabilization (Gradin, McGuire et al. 1996; Huang, 
Arany et al. 1996). HIF-lu also comprises a sequence termed oxygen-dependent 
degradation domain (ODD domain) that allows regulation of protein stability as a function 
of the 02 concentration (Huang, Gu et al. 1998). 
Hypoxic HIF-1a translocation and nuclear accumulation still occur in HIF-1(3/ARNT- 
deficient hypoxic cells, demonstrating that these events are ARNT independent (Ilopfl, 
Ogunshola et al. 2004). HIF-1I is a nuclear protein (Chilov, Camenisch et at. 1999) and it 
is constitutively expressed. 
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Gassmann's group have shown that HIF-lu protein is present in the nucleus after <2 min 
of exposure to hypoxia or anoxia and that the reoxygenation reduced HIF-I DNA binding 
and nuclear HIF-lu protein levels within 4-8 min. suggesting a protein half life of -5 min 
(Wang, Jiang et al. 1995; Jewell, Kvietikova et al. 2001). 
1.4.5. Other members of the HIF family 
To date, another two member of the HIF family have been cloned: HIF-2a and HIF- 
3a (Figure 1.13). 
HIF-1 a 
1 
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Figure 1.13. Domain structure of the human HIF family. 
The HIF-la and HIF-2a subunits contain two transactivation domains, the N- and C- terminal activation 
domain (N-TAD and C-TAD) while the b subunit contains only one TAD. Of note is the lack of TAD-C in 
HIF-3u. Adapted from (Brahimi-Horn and Pouyssegur 2005). 
These proteins share several characteristics with HIF-Ia, such as hypoxic protein 
stabilization, heterodimerization with ARNT(s), DNA-recognition/binding, and reporter 
gene transactivation (Hopfl, Ogunshola et al. 2004). Eckardt's group has demonstrated that 
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HIF-2a is expressed in a complementary but not overlapping pattern to HIF-1a in specific 
cells of most organs after systemic hypoxic exposure (Wiesener, Jurgensen et al. 2003). 
HIF-2a is expressed in a variety of tumours at different levels, but mostly its expression is 
associated with stromal cells, especially with tumour-associated macrophages (Talks, 
Turley et al. 2000; Leek, Talks et al. 2002). HIF-2a levels have been correlated with 
tumour grade in non-Hodgkin lymphoma (Stewart, Talks et al. 2002) and bladder cancers 
(Onita, Ji et al. 2002). MacDonald's group has demonstrated that there are different levels 
of expression of HIF-la and HIF-2a in the astrocytomas: we can find similar levels of 
HIF-la in high- and low grade astrocytomas but HIF-2a is overexpressed in high grade 
astrocytomas (Khatua, Peterson et al. 2003). They have also shown that the HIF- 
2a overexpression is related to a dysregulation of the epidermal growth factor/PI3K 
pathway. 
HIF-2a may also upregulate a different set of target genes involved in neoangiogenesis 
than HIF-la: VEGF receptor 2 and angiopoietin receptor tie-2 (Tian, McKnight et al. 
1997; Kappel, Ronicke et al. 1999). 
HIF-la and HIF-2a bind to the same HREs; but for example the VEGF promoter sequence 
is more inducible by HIF-2a than by HIF-la (Camenisch, Stroka et al. 2001; Hopfl, 
Ogunshola et al. 2004). 
A third protein called HIF-3ct was cloned. It is characterized by the loss of a TAD-C 
(Figure 1.13) but presents a considerable sequence homology with HIF-1a and HIF-2a. 
(Gu, Moran et al. 1998; Hopfl, Ogunshola et al. 2004). At the moment HIF-3a was found 
to be expressed in the distal tubules of the kidney (Hara, Hamada et al. 2001) but its role 
has not been well defined. This third member produces multiple splice variants (Makino, 
Kanopka et al. 2002; Maynard, Qi et al. 2003) that contain extra DNA binding elements 
and protein-protein interaction motifs not found in HIF-la and HIF-2a. In particular 
Maynard MA et al. have found that the HIF-3a variant HIF-3a4 attenuates the ability of 
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HIF-1 to bind HRE of HIF target genes. They also demonstrated that his expression is 
down-regulated in renal cell carcinoma (Maynard, Evans et al. 2005). 
All these observations suggest that members of HIF family are involved in many processes 
and in particular that they play a crucial role in the tumour pathology becoming a good 
target for new therapeutic strategies. 
1.4.6. HIF-la degradation and oxygen sensing 
For many years the oxygen sensor mechanism remained unknown but more recently two 
different groups identified an oxygen-dependent enzymatic modification of the ODD 
domain of HIF-la (Ivan, Kondo et al. 2001; Jaakkola, Mole et al. 2001). 
They have found that there are three new prolyl-4-hydroxylases that are able to 
hydroxylate two HIF-Ict prolin residues (Pro 402 and Pro 64) in the presence of oxygen, 
inducing its degradation by the proteasome (Figure 1.14). 
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Figure 1.14. O_-dependent regulation of HIT-la activity. 
O, regulates the rate at which HIF-la protein is degraded. In nonnoxic conditions. O2-dependent 
hydroxylation of proline (P) residues 402 and 564 in HIF-la by the enzymes PHD (prolyl hydroxylase- 
domain protein) 1-3 is required for the binding of the von Hippel-Lindau (VHL) tumour-suppressor protein, 
which is the recognition component of an E3 ubiquitin-protein ligase. VHL binding is also promoted by 
acetylation of lysine (K) residue 532 by the ARDI acetyltransferase. Ubiquitylation of HIF-la targets the 
protein for degradation by the 26S proteasome. Oz also regulates the interaction of HIF-Ict with 
transcriptional co-activators. 02-dependent hydroxylation of asparagine (N) residue 803 in HIF-Ia by the 
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enzyme FIH-1 (factor inhibiting HIF-1) blocks the binding of p300 and CBP to HIF-la and therefore inhibits 
HIF-1-mediated gene transcription. Under hypoxic conditions, the rate of asparagine and proline 
hydroxylation decreases. VHL cannot bind to HIF-1 a that is not prolyl-hydroxylated, resulting in a decreased 
rate of HIF-la degradation. By contrast, p300 and CBP can bind to HIF-la that is not asparaginyl- 
hydroxylated, allowing transcriptional activation of HIF-1 target genes. (Semenza 2003) 
PHDs hydroxylate specific prolines recognizing a strongly conserved LXXLAP motif 
(where X indicates any amino acid and P indicates the hydroxyacceptor proline), requiring 
oxygen and 2-oxoglutarate as co-substrates as well as iron and ascorbate (Hopfl, 
Ogunshola et al. 2004). 
HIF-la can be stabilized also by hypoxia-mimicking elements such as iron chelators or 
transition metals such as cobalt because they suppress the hydroxylation of the proline 
residues (Jaakkola, Mole et al. 2001; Hopfl, Ogunshola et al. 2004). 
It was recently demonstrated that PHD2 has the highest specific activity toward HIF-1 a's 
main hydroxylation site (Huang, Zhao et al. 2002). Recent studies have shown the cellular 
localization and hypoxia dependency of these PHDs (Huang, Zhao et al. 2002; Metzen, 
Berchner-Pfannschmidt et al. 2003). PHDI is localized only in the nucleus, PHD2 in the 
cytoplasm, and PHD3 is found in both the cytoplasm and the nucleus, with cytoplasmic 
predominance (Hopfl, Ogunshola et al. 2004). HIF-la ubiquitination has been reported to 
be strictly nuclear (Groulx and Lee 2002). 
The most important part of its degradation is the prolyl hydroxylation; HIF-la is 
constitutively expressed, but it is difficult to detect it under normoxic conditions (Jewell, 
Kvietikova et al. 2001; Hopfl, Ogunshola et al. 2004). 
The degradation pathway starts with the binding of the von Hippel-Lindau tumour 
suppressor protein (pVHL) to the hydroxylated ODD domain of HIF-la (Ivan, Kondo et 
al. 2001; Jaakkola, Mole et al. 2001). pVHL is part of the E3 ubiquitin-ligase complex 
67 
Chapter 1 Introduction 
(elongin B. elongin C. cullin 2 and RBX1) that targets key regulatory proteins 
for 
ubiquitin-mediated proteolysis in the proteasorne (Krek 2000) (Figure 1.15). 
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Figure 1.15. HIF-1 pathway. 
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In the presence of oxygen (O, ), prolyl hydroxylase post-translationally modifies hypoxia-inducible 
transcription factor (HIF)-lcz, allowing it to interact with the von Hippel-Lindau (VHL) complex. V1-IL is a 
part of a larger complex that includes elongin-B, elongin-C, CUL2, RBXI and a ubiquitin-conjugating 
enzyme (E2). This complex, together with an ubiquitin-activating enzyme (El), mediates the ubiquitylation 
of HIF-la. In the absence of oxygen, prolyl hydroxylase cannot modify HIF-Ict, and the protein remains 
stable. Stabilized HIF-la is translocated to the nucleus, where it interacts with cofactors such as aryl 
hydrocarbon receptor nuclear translocator (ARNT), CBP/p300 and the DNA polymerase 11 (Pol II) complex 
to bind to hypoxia-responsive element (HREs) and activate transcription of target genes. (Harris 2002) 
The loss or mutation of pVHL in vivo stabilizes the HIF-lcc protein under normoxic 
conditions and may lead to the VHL hereditary cancer syndrome (Cockman, Masson et al. 
2000; Krieg. Haas et al. 2000; Ohh, Park et al. 2000; Yu, White et al. 2001) characterized 
by the development of vascular tumors of the central nervous system and retina, clear cell 
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renal carcinoma, pheochromocytomas, pancreatic islet cell tumors, cnciolymhhatic sac 
tumors and benign cyst aflccting a variety of organs. 
Recently a new enzyme was identilied: the acetyltranslerase ARDI (Figure 1.14) that 
inhibits Ill{ -lu transcriptional activation and protein stability and stimulates its 
degradation acetylating the Lysi 32 within the ODL) domain of IllF Iu (Jeong, Rae et al. 
2002). 
Iwo other groups have identified a third hydroxylation site, the asparagyl-residue Asn8"3 in 
I IIF- Iu and Asn851 in I IIlý-2u (Lando, Pect et al. 2002). The hydroxylation oC the Asnx°3 
residue leads to a steric inhibition of' he interaction between IIIF- I« and its coactivator 
C'BP/p300. intertcring with its recruitment (Figure 1.14). This asparagyl hydroxylase was 
first described as factor inhibiting IllF-I (Fill-1) (Mahon, Ilirota et al. 2001: Hewitson, 
McNeill et at. 2002). Recently Semenza's group have identified a common partner Im 
III F- I cu and the Pl I Ds. They used a C-terminal fragment oC III F-] cc (residues 576-826) in a 
yeast two-hybrid screen led to the identification of OS-9 as a IIIF-Icy binding protein 
(Back. Mahon ei al. 2005). 
N Hlf lv 
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Figure 1.16. Proposed role for OS-9 in the hypoxic response. 
The figure shows IIIF-I(x and IIIF hydroxylases (PIiU and FIH) with a possible role for OS-9 in binding to 
both I III- Ia and the PI II) enzymes. (Flashman, McDonough ct al. 2005) 
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By immunoprecipitation analyses they demonstrated that OS-9-HIF-la interaction occurs 
in both hypoxic and normoxic cells and that OS-9 also binds to PHD2 and PHD3. 
Interestingly, OS-9 and PHD2 were shown to bind to separate regions of HIF-la (Figure 
1.16). Baek et al. therefore suggest that OS-9 is a critical factor in the oxygen-mediated 
regulation of HIF-la. OS-9 is ubiquitous in human tissue and is overexpressed in tumour 
cells (Baek, Mahon et al. 2005). 
Cytoskeletal proteins also regulate HIF-la levels: small GTPases such as Racl, Rho and 
Cdc42 are upregulated by hypoxia and are important for HIF-la activation (Hirota and 
Semenza 2001; Turcotte, Desrosiers et al. 2003). 
1.4.7. HIF-1 DNA binding 
After the stabilization of the a subunit, nuclear translocation, and dimerization, HIF-la 
binds to its consensus binding site (HBS, HIF-1 binding site) within the hypoxia response 
element (HRE). The core sequence of HBS is (A/G)CGTG. HRE may be located within 
either promoter or enhancer regions of target genes (Table 1.2). 
HBS is the minimal sequence necessary for HIF-1 binding. In the majority of hypoxia- 
induced genes HRE contains HIF-1 ancillary sequence (HAS), which is located 8-9 nt 
down- or upstream of HBS and is necessary for HIF-1-mediated transcription activation 
(Kimura, Weisz et al. 2001). An HBS is necessary but not sufficient for efficient hypoxic 
gene activation. Usually the HRE contains neighboring DNA binding sites for additional 
transcription factors that are not hypoxia inducible but they can amplify the hypoxic 
response (Wenger 2002). 
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Core 11RE sequence Location Hypoxia-inducible gene Species 
DB TA References 
Oxygen supply 
(Wang and Semenza 
gccctACGTGctgtctca 3'FS +3065/+3082 Erythropoietin (erythropoiesis) Human + + 1993) 
gccctACGTGctgcctcg 3'FS +359/+376 Erythropoietin (erythropoiesis) 
Mouse + + (Firth, Ebert et at. 1994) 
gaaatACGTGcgctttgt 5'FS -201/-184 Transferyin (iron transport) 
Human + + 
(Rolfs, Kvietikova et al. 
1997) 
agcgtACGTGcctcagga STS -93/-76 Transferyin receptor (iron transport) 
Human + + 
(Tacchini, Bianchi et at. 
1999) 
tctgtACGTGaccacact 5'FS -3639/-3544 Ceruloplasmin (iron oxidase) 
Human 
+ + 
(Mukhopadhyay, 
Mazmnder et al. 2000) 
tgcatACGTGggctccaa 5'FS -978/-961 VEGF (angiogenesis) 
Human + + 
(Forsythe, Jiang el at. 
1996) 
tgcatACGTGggcttcca 5'FS +61/+78 VEGF (angiogenesis) Rat + + 
(Levy, Levy et al. 
1995) 
gaacaACGTGgaattagt 5'FS +1408/+1425 Flt-INEGF-RI (angiogenesis) MI(H) - + 
(Gerber, Condorelli et 
al. 1997) 
agtggGCGTGggaaaccg STS -124/-107 Flk-1/VEGF-R2 (angiogenesis; HIF- Mouse + + 
(Elvert, Kappel et al. 
2) 2003) 
ngcggACGTGctggcgtg 5'FS +322/+339 Heme oxygenase I (vessel diameter) Mouse + + 
(Lee, Jiang et at. 1997) 
Cellular metabolism 
ctcggACGTGactcggac 5'FS -184/-201 Aldolase A (glycolysis) Human + + 
(Semenza, Jiang et al. 
1996) 
gccggACGTGacaaacgg S'FS -206/-189 Phosphoglycerate kinase 1 Human + - 
(Semenza, Jiang et al. 
(glycolysis) 1996) 
gtgagACGTGctacttcc 5'FS -184/-201 Phosphoglycerate kinase I Mouse + - 
(Okino, Chichester et 
(glycolysis) al. 1998) 
gccggACGTGgggcccca 5'FS -413/-396 Enolase 1(glycolysis) Human + - 
(Semenza, Jiang et al. 
1996) 
cetacACGTGggttcccg STS -89/-72 Lactate dehydrogenase A (glycolysis) Mouse + + 
(Firth, Ebert et at. 
1995) 
ctgatGCGTGtcagacgg S'FS +300/+283 Glucose transporter I (glucose Mouse + + 
(Okino, Chichester et 
uptake) al 1998) 
Cell growth and apoptosis 
aggacACGTGgagaggct 5'FS -6280/ 6263 
TGF-ß3 (placenta development) Mouse + + 
(Schaffer, Scheid et al. 
2003) 
ct te ctGCGTGc a 5'FS -89/-72 
TGF-03 (placenta development) Human + + 
(Nishi, Nakada et al. 
gg g gg 20(4) 
tgtccACGTGggggcctg S'UT +348/+331 
Endoglin (TGF-p coreceptor) Human + + 
(Sanchez-Elsner, 
Botella et al. 2002) 
cagggACGTGtccccagg 5'FS -1243/-1226 SDF-1 (CXCL12 chemokine) Human - + 
(Ceradini, Kulkami et 
at. 2004) 
gaggcGCGTGcgtcgcga 5'FS -1292/-1309 CXCR4 (chemokine receptor) Human + + 
(Staller, Sulitkova et al. 
2003) 
agcgcGCGTGtgggaagg STS +142/+159 niet (prolooncogene) Human + 
(Pennacchietti, Michieli 
et at. 2003) 
agagcACGTGgcgggcca 5'FS -222/-205 Wil (Wilms' tumor suppressor) Mouse + + 
(Wagner, Wagner et at. 
2003) 
ttcccACGTGgcggaggg STS -169/-152 TERT (telomerase) Human + + 
(Yatabe, Kyo et at. 
2004) 
Others 
tgtgcGCGTGgtgccata 5'FS -1197/-1184 
Cited2/p35srj (transcriptional Human + + (Bhattacharya, 
Michels 
cofactor) et al. 1999) 
cgaatGCGTGcgtgggtg S'FS -729/-712 ID2 (transcriptional repressor) Human + + 
(Lofstedt, Jogi et al. 
2004) 
gccagACGTGcctggagt 5'FS -461/-444 DECI (transcription factor) Human + + 
(Miyazaki, Kawamoto 
et al. 2002) 
agctcACGTGcggaacgt 5'FS -297/-314 DEC2 (transcription factor) Human + + 
(Miyazaki, Kawamoto 
et al. 2002) 
tggagACGTGcgcgtcct 5'FS -235/-218 Human Herpesvirus 8 ORF34 Viral + + 
(Haque, Davis et al. 
2003) 
tctagACGTGacccaggg S'UT -5/+13 CD18 (leukocyte adhesion) Human - + 
(Kong, Eltzschig et al. 
2004) 
tcgctACGTGcgctcagt STS -75/-92 Collagen prolyl 4-hydroxylase (I) Rat + 
(Takahashi, Takahashi 
+ 
et al. 2000) 
ggtgtACGTGcagagcgc 5'FS -417/-400 PHD2 ((:, sensing) 
Human 
+ + 
(Metzen, Stiehl et at. 
2005) 
gggctACGTGcgctgcgt IVS1 +12583/+12600 P11D3 (O= sensing) Human (Pescador, Cuevas et al. + + 2005) 
Table 1.2. Compilation of some known IIIF target genes 
Examples of only those genes were included in which binding of IIIF to target DNA sequence is a DNA 
binding (DB) assay or functional transactivation (TA) of reporter gene expression, or both, have been shown. 
FS, flacking sequence; IVS, intervering sequence; UT, untranslated region. For abbreviation of gene name, 
refer to references. Adapted from (Wenger, Stiehl et al. 2005) 1 
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1.4.8. HIF-1 activation in normoxic conditions 
Recently it was demonstrated that HIF-la protein can be stabilized already under 
normoxic conditions in vivo (Stroka, Burkhardt et al. 2001). It appears that 
posttranslational modifications especially phosphorylation play a major role in HIF-la 
activation. Many oncogenes and tumour suppressor genes can modulate phosphorylation 
cascades and so they affect HIF-la expression levels independent of oxygen levels. HIF- 
la expression and activity are regulated by major signal transduction pathways including 
those involving phosphatidylinositol 3-kinase (P13K) and ERK/MAPK. 
Different pathways involved in the HIM activation in normoxic conditions will be 
discussed briefly below. 
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Figure 1.17. Phosphorylation of ILIF-la. 
The two main pathways leading to phosphorylation of HIF-1 a. Adapted from (Hopfl, Ogunshola et al. 2004) 
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Signaling of the PI3K-AKT-FRAP pathway to HIF-1 a 
Stimulation of cells with a variety of growth factors and cytokines (EGF, 
FGF-2, heregulin, IL-1ß) induces the expression of HIF-la protein, HIM 
DNA-binding activity, and HIF-1 target gene expression under non hypoxic 
conditions (Feldser, Agani et al. 1999; Hellwig-Burgel, Rutkowski et al. 
1999; Laughner, Taghavi et al. 2001). Binding of these factors to their 
tyrosine receptor induces many pathways including P13K. The downstream 
serine-threonine protein kinases AKT has several targets involved in 
apoptosis, cell cycle, and growth as well as translation (Vivanco and 
Sawyers 2002). One of these target is FRAP (FKBP12/rapamycin- 
associated protein). The only known targets of FRAP are p70 s6 Kinase and 
eIF-4E binding protein, both of which function as regulators of translation 
(Semenza 2002). P70s6k is a kinase that enhances the translation of mRNAs 
that have 5'-polypyrimidine tracts as can be found in HIF-la mRNA (Iyer, 
Leung et al. 1998). This pathway is also negatively regulated by the tumour 
suppressor gene PTEN [phosphatase and tensin homologue deleted on 
chromosome 10; (Vivanco and Sawyers 2002)] PTEN loss of function is 
associated with angiogenesis and tumour progression in gliomas and 
prostate cancers. Forced overexpression of recombinant PTEN in glioma 
cells results in a dramatic reduction in HIF-lu expression (Zundel, 
Schindler et al. 2000) suggesting that the presence or not of PTEN activity 
influences the stabilization of HIF-lu. 
Signaling of the MAP kinase pat/sway to HIF-1 
Receptor tyrosine kinase activity also leads to signaling via ERK (p42 and 
p44) and p38 MAP kinase pathways. (Richard, Berra et al. 1999; Alfranca, 
Gutierrez et al. 2002; Gao, Jiang et al. 2002; Shemirani and Crowe 2002). 
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One of the best studied MAPK pathways involved in HIF-la regulation 
leads to the activation of ERK1-2 (p44/p42) after activation of the upstream 
molecules Ras/Raf-1/MEK-l/ERK1-2 (Hopfl, Ogunshola et al. 2004). It 
was demonstrated that the MAP kinase inhibitor PD-98059 attenuated HIF- 
la protein modifications and trans-activation ability but not protein 
stabilization and DNA-binding activity, demonstrating the importance of 
the MAPK pathway for the functionality of HIF-la (Hofer, Desbaillets et 
at. 2001). Recently it was also suggested that MAPK signalling affects the 
transactivation activity of p300, possibly by regulating the interaction 
between p300 and TAD-C (Sang, Stiehl et al. 2003). 
Oncogenic Ras path way 
Ras is a multifunctional oncogene that can stimulate both the MAPK- and 
the PI3K-pathways (Rodriguez-Viciana, Warne et al. 1994; Pouyssegur, 
Volmat et al. 2002). H-Ras transformation has been shown to increase HIF- 
la protein levels and target gene activation independent of oxygen through 
the PI3K pathway (Chen, Pore et at. 2001). Giaccia's group have 
demonstrated that increased VEGF gene transcription in H-RAS- 
transformed cells is dependent upon the presence of an intact HIF-1 binding 
site in the VEGF promoter (Mazure, Chen et al. 1997) and it was also 
demonstrated that loss of HIF-la negatively affects tumour growth in these 
cells (Ryan, Poloni et al. 2000). Thus many essential signal transduction 
pathways modulate HIF-1 activity. 
ROS 
When 02 is not completely reduced to water, the electron transfer results in 
the production of oxygen-containing free radicals and subsequently also of 
other reactive compounds, which are referred to as reactive oxygen species 
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(ROS). High amounts of ROS are known to cause damage to proteins, DNA 
and lipids (Kietzmann and Gorlach 2005). ROS appear to play an important 
role in both the hypoxic and non-hypoxic signalling processes which control 
the activity of HIFs. Under normoxia, enhanced ROS levels in response to 
many agonists appear to serve as signalling molecules to upregulate HIF-la 
in a variety of cell types, possibly by modulating upstream signalling 
pathways such as hydroxylases or kinases and phosphatases. In contrast, the 
role of ROS in the regulation of HIF-la under hypoxia is less well 
understood. 
Another reactive molecule that seems to have a role in the HIF-la 
stabilization is nitric oxide (NO). There are contradictory reports: one group 
has found that NO stabilizes HIF-la (Sandau, Fandrey et al. 2001); but 
there is also evidence that treatment with NO abrogates HIF-1 activity 
(Huang, Willmore et al. 1999; Yin, Yang et al. 2000). These different 
results may be because treatment of cells for short time with NO induces 
activation, but for long time an abrogation. In particular these results were 
obtained by in vitro experiment and they could not reflect the physiological 
situation in vivo (Wenger 2002). 
Pro-inflammatory stimuli 
Inflammatory cytokines, including TNF-a have been described previously 
to induce HIF-1 DNA-binding concomitant with increase in either HIF-la 
mRNA or protein, although the published results are somewhat 
contradictory. Thus Thornton et at. (Thornton, Lane et al. 2000) have 
reported that brief exposure of gingival and synovial fibroblasts to TNF-a 
resulted in elevated HIF-la mRNA level and DNA-binding activity, 
whereas Hellwig-Burgel et al (Hellwig-Burgel, Rutkowski et al. 1999) 
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reported no change in HIF-la mRNA or protein level after treatment of 
HepG2 cells by TNF. Nevertheless, these investigators confirmed that TNF- 
a induced HIF DNA binding. Zhou J et al. have shown that TNF-a favored 
accumulation of a ubiquitinated form of HIF-Ia and that NF-KB is involved 
in this TNF-a response (Zhou, Schmid et al. 2003). 
Another cytokine that induce the expression of HIF-la in normoxic 
condition is IL-1p. Ferrara et al. have demonstrated that IL-lß increase 
mRNA levels of HIF-la in several cell lines (Ferrara and Davis-Smyth 
1997). Hellwig-Burgel et al. showed that IL-1ß, as TNF-a, caused a 
moderate activation of HIM DNA binding but only IL-1ß increased HIF- 
la protein levels (Hellwig-Burgel, Rutkowski et al. 1999). 
Interestingly, treatment of macrophages with lipopolysaccharide (LPS) can 
increase the expression of a number of hypoxic genes (Camhi, Alam et al. 
1995; Xiong, Elson et al. 1998). Blouin CC et al. have shown that LPS 
increases HIF-1a expression inducing an active form of HIF-1, which binds 
specific HIF-1 DNA target sequences (Blouin, Page et al. 2004). 
The ability of proinflammatory stimuli in inducing HIF-1 activation 
suggests a central role of this transcriptional factor during inflammatory 
processes, as recently demonstrated in HIF-1 conditional KO mice (Cramer, 
Yamanishi et al. 2003). 
However other studies are needed to understand the molecular mechanism 
regulating these pathways. 
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Stimulus References 
Proteins 
Insulin (Treins, Giorgetti-Peraldi et al. 2002) 
IGF-1 (Fukuda, Hirota et al. 2002) 
IGF-2 (Feldser, Agani et al. 1999) 
bFGF (Shi, Wang et al. 2005) 
EGF (Jiang, Jiang et al. 2001) 
HGF (Tacchini, Dansi et al. 2001) 
PDGF (Richard, Berra et al. 2000) 
TGF-ß (Shih and Claffey 2001) 
II-10 (Stiehl, Jelkmann et al. 2002) 
TNF-u (Haddad and Land 2001) 
Angiotensin II (Page, Robitaille et al. 2002) 
Endothelin-1 (Spinella, Rosario et al. 2002) 
Thrombin (Richard, Berra et al. 2000) 
Heregulin (Laughner, Taghavi et al. 2001) 
Nur77 (Yoo, Yeo et al. 2004) 
Antigens (T cell receptor) (Nakamura, Makino et al. 2005) 
Small molecules 
Androgens (Mabjeesh, Willard et at. 2003) 
Thyroid hormone (Ma, Freitag et al. 2004) 
Acetylcholine (Kakinuma, Ando et al. 2005) 
FSH (Alain, Maizels et at. 2004) 
Serotonin (Richard, Berra et at. 2000) 
NO (Sandau, Fandrey et at. 2001) 
ROS (junD-/- cells) (Gerald, Berra et al. 2004) 
LPS (Blouin, Page et at. 2004) 
Viral infection 
Epstein-Barr virus (Wakisaka, Kondo et at. 2004) 
Hepatitis B virus (Yoo, Oh et at. 2003) 
Herpes virus 8 (Sodhi, Montaner et at. 2000) 
Physical stimuli 
Heat (Katschinski, Le et at. 2002) 
Mechanical stress (Chang, Shyu et at. 2003) 
Ions 
Fe3+ chelation (Wang and Semenza 1993) 
Co2+ (Wang and Semenza 1993) 
Ni2+ (Salnikow, Donald et at. 2004) 
Ca2+ (Mottet, Michel et at. 2003) 
Cu2+ (Martin, Linden et at. 2005) 
Zn2+ (Chun, Choi et at. 2000) 
As+III (Duyndam, Ilulscher et at. 2001) 
V+V '(Gao, Ding et at. 2002) 
Cr+VI (Gao, Jiang et at. 2002) 
11+ (PI 1) (Mekhail, Gunaratnam et at. 2004) 
Table 1.3. Stimuli that induce IIIF-la protein abundance, IIIF transactivation activity, or both 
independently of hypoxia. 
Many proteins, peptides, and small molecules are known to induce HIF-la under normoxic conditions. 
Growth factors usually increase cell growth, and small-molecule ligands, viruses, and various environmental 
stimuli often elicit specific cell responses, all of which are associated with increased metabolism and oxygen 
consumption, finally leading to hypoxia. On the other hand, some stimuli, such as NO, ROS, and certain 
cations, might directly interact with the PHD oxygen sensors, leading to HIF-la stabilization. From (Wenger, 
Stiehl et al. 2005) 
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1.4.9. Involvement of HIF-1 in embryogenesis 
The essential role of HIM in embrionic development has been demonstrated by the 
analysis of mice that lack expression of HIF-1a (lyer, Kotch et al. 1998) or ARNT/HIF-I 
(Kozak, Abbott et al. 1997; Maltepe, Schmidt et al. 1997). 
ARNT' mice manifested developmental delay, neural tube defects, abnormal 
vascularization of the yolk sac, embryo, and placenta, and died by embryonic day (E) 10.5 
(Kozak, Abbott et al. 1997; Maltepe, Schmidt et al. 1997). ARNT could dimerize with 
other bHLH-PAS transcription factors in addition to HIF-la and the loss of activity of one 
or more of these factors could therefore contribute to the observed phenotype (Semenza 
1998). In fact it was not surprising that HIF-la and ARNT (HIF-1 ß) deficiency resulted in 
overlapping but distinct embryonic phenotypes. HIF-la embryos suffered 
developmental arrest at E8.5-8.75 and died at E10.5 (Iyer, Kotch et al. 1998). Analisis of 
viable embryos at E9.75-E10.0 showed a failure of neural tube closure with massive death 
of cephalic mesenchymal cells and the appearance of markedly enlarged/dilated vascular 
structures. Vascularization and development at E8.5-8.75 appeared normal, whereas one 
day later the entire vascular system of the branchial/cephalic region was disrupted. In 
contrast to this, the presumptive myocardium of HIF-la '/" embryos was strikingly 
hyperplastic, resulting in obliteration of the heart lumen. Neither the cephalic nor 
myocardial defects were observed in ARNT"'' embryos (Semenza 1998). There was no 
differences at the level of the yolk sac between HIF-la "/' and HIF-la +1+ demonstrated that 
HIF-1 is required for the establishment of the embryonic cardiovascular system. 
1.4.10. Tumour hypoxia 
Tumour hypoxia is the net result of an imbalance between the 02 supply and (metabolic) 
demand in stroma, endothelial cells, and the tumour cells. Tumour progression is 
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associated with both increased microvascular density and intratumoural hypoxia (Hockel 
and Vaupel 2001). Tissue hypoxia due to inadequate blood supply is supposed to occur 
very early during tumour development beginning at a tumour diameter of a few millimeters 
(Folkman 1990; Folkman and Shing 1992; Helmlinger, Yuan et al. 1997). 
In response to this low level of oxygen, tumour cells adapt their metabolism by increasing 
glucose transport and glycolysis in order to maintain ATP production and this switch is 
mediated by HIF-I. Tumours influence the function and positioning of immune cells and in 
particular it is known that tumour-associated macrophages (TAM) localize preferentially in 
hypoxic areas. Such environment promotes TAM adaptation to hypoxia, which is achieved 
by the increased expression of hypoxia inducible and pro-angiogenic genes, such as VEGF, 
bFGF and CXCL8, as well as glycolytic enzymes, whose transcription is controlled by the 
transcription factors HIF-1 and HIF-2 (Talks, Turley et al. 2000). The in vivo relevance of 
this metabolic adaptation to hypoxia by macrophages was recently demonstrated by 
Cramer et al (Cramer, Yamanishi et al. 2003). Ablation of the HIM cc resulted in impaired 
macrophage motility and cytotoxicity, in low oxygen conditions. 
In chapter 3 of this thesis we analized the effects of hypoxia on different immune cells and 
tumour cells in order to understand how it might influence their functions and expression 
of chemokine receptors as they are the principal regulator of cell migration. 
Immunohistochemical analysis of human tumour biopsies revealed dramatic 
overexpression of HIF-la in common cancers (Zhong, De Marzo et al. 1999; Talks, Turley 
et al. 2000). HIF-la overexpression is also a marker of highly aggressive disease in several 
different tumour types (Table 1.4) but the correlation between HIF-1a overexpression and 
adverse clinical outcome is not always demonstrated (Semenza 2002). 
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Tumor type Association 
Breast cancer, lymph-node negative Bad progression 
Cervical cancer, early-stage Bad progression 
Oligodendroglioma Bad progression 
Oropharyngeal squamous cell carcinoma Treatment failure, Bad progression 
Esophageal cancer, early-stage, BCL2-positive Treatment failure 
Ovarian cancer, p53 mutant Bad progression 
Table 1.4. Association of HIF-la overexpression with adverse clinical outcome. 
Adapted from (Semenza 2002). 
Tumour hypoxia selects for gene mutations in tumour cells, in particular in genes involved 
in the process of apoptosis (Kunz and Ibrahim 2003). 
In malignant tumours the rate of apoptosis is high in undervascularized areas but the 
mechanisms by which hypoxia induces it are poorly understood (Barnhill, Piepkorn et al. 
1998; Saikumar, Dong et al. 1998). 
It was demonstrated in ovarian cancer that the overexpression of HIF-1a is correlated with 
apoptosis in tumour expressing wild type p53, whereas it is not correlated with apoptosis in 
tumours expressing mutant p53, and the combination of mutant p53 and HIF-la 
overexpression is associated with a highly increased risk of patient mortality (Semenza 
2002). 
It's well known that low oxygen tension confers resistance of tumours to irradiation 
therapy and may thereby contribute to tumour aggressiveness (Harris 2002). Hypoxia is a 
stress factor for rapidly growing tumour cells and in fact it was demonstrated that hypoxia 
activates the JNK/SAPK and p38 stress kinases in human squamous carcinoma cells in 
vitro (Laderoute, Mendonca et at. 1999) and in low aggressive melanoma cells (Kunz, 
Bloss et at. 2002). 
The HIF-1 complex is also involved in tumourigenesis. Mouse hepatoma cell lines that 
express mutated forms of ARNT form much smaller tumours that express only low levels 
of VEGF and do not become highly vascularized (Maxwell, Dachs et al. 1997). 
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Different groups have demonstrated that HIF-la is overexpressed in various solid tumours: 
colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate and renal carcinomas, and 
that is associated with cell proliferation (Zhong, De Marzo et al. 1999; Talks, Turley et al. 
2000). 
All these evidences highlight the relevance that the hypoxia-HIF-1 pathway may play in 
the recruitment and activation of TAM in solid tumours and may represent a target for 
therapeutic strategies against tumours. 
1.4.11. HIF-1 target genes 
Over 60 HIF-1 target genes have been identified thus far; these encode proteins that play 
key roles in critical developmental and physiological processes including 
angiogenesis/vascular remodelling, erythropoiesis, glucose transport, glycolysis, iron 
transport, and cell proliferation/survival (Figure 1.18). 
Role of some of these proteins in different processes will be discussed briefly below. 
Angiogenesis. 
Vascular endothelial cell growth factor (VEGF) is one of the major HIM 
target genes; it specifically recruits endothelial cells into hypoxic and 
avascular areas and stimulates their proliferation. VEGF is the most potent 
endothelial-specific mitogen and is known to directly participate in 
angiogenesis (Harris 2000; Josko, Gwozdz et al. 2000; Conway, Collen et 
al. 2001). It was also shown that hypoxia induces the expression of VEGF 
mRNA and protein, suggesting that hypoxia is a stimulus of angiogenesis 
through the up-regulation of the VEGF expression (Harris 2000; Josko, 
Gwozdz et al. 2000). The induction of angiogenesis leads to an increase in 
vascular density and hence a decrease in the oxygen diffusion distances 
(Lee, Bae et al. 2004). However, local blood flow under pathophysiological 
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conditions is controlled by modulation of the vascular tone through 
production of inducible nitric oxide synthase (NO), heure oxygenase 1 
(CO), endothelin 1, adrenomedulin, or activation of the aIB-adrenergic 
receptor, all of which are HIM target genes (Eckhart, Yang et al. 1997; 
Lee, Jiang et al. 1997; Hu, Discher et al. 1998; Palmer, Semenza et al. 1998; 
Nguyen and Claycomb 1999). 
Cell proliferation/survival 
Hypoxia-induced growth factors are known to promote cell proliferation 
and survival. Several growth factors, most notably insulin-like growth 
factor-2 (IGF-2) and transforming growth factor-a (TGF-a) are also HIF-1 
target genes (Feldser, Agani et al. 1999; Krishnamachary, Berg-Dixon et al. 
2003). Binding of these factors to their cognate receptors, the insulin-like 
growth factor 1 receptor (IGFIR) and epidermal growth factor receptor 
(EGFR), respectively activates signal transduction pathways that lead both 
to HIF-la expression and to cell proliferation/survival (Semenza 2003). 
Glucose metabolism 
Under hypoxic conditions, cells switch to the oxygen-independent 
metabolic pathway, and they use anaerobic glycolysis as a primary 
mechanism of ATP production (Sitkovsky and Lukashev 2005). Many 
genes involved in glucose' uptake and glycolysis were identified as HIF-1 
target genes (Wenger 2000). HIF-1 regulates expression of all enzymes in 
the glycolytic pathway, as well as expression of the glucose transporters 
GLUT! and GLUT3, which mediate cellular glucose uptake (Chen, Pore et 
al. 2001). 
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Upregulation of certain glycolytic enzymes is instrumental to the 
pyrimidine/purine pathway during glycolysis, and to cell proliferation by 
enhancing the supply of DNA precursors (Griffiths, McSheehy et al. 2002). 
The end product of anaerobic glycolysis is lactate. The enhanced production 
of this metabolite, possibly in association with the HIF-1-mediated 
upregulation of carbonic anhydrases (CA) could be a major cause for the 
acidic pH usually found in tumours (Stubbs, McSheehy et al. 2000) and 
these two factors are related to tumour invasiveness and they can be used as 
marker of tumour hypoxia (Hopfl, Ogunshola et al. 2004). 
Iron metabolism 
Hypoxia has found to increase the expression of transferrin, probably to 
enhance iron transport to erythroid tissues (Rolfs, Kvietikova et al. 1997). 
The transferrin receptor is a hypoxia-inducible HIM target gene, enabling 
cellular transferrin uptake (Tacchini, Bianchi et al. 1999). Ceruloplasmin, 
also known as a ferroxidase, was reported to be a HIF-1 target gene 
(Mukhopadhyay, Mazumder et al. 2000) and is required to oxidize ferrous 
to ferric iron (Lee, Bae et al. 2004). 
Wenger's group have demonstrated that hypoxia increases the expression of 
transferrin, probably to enhance the iron transport to erythroid tissues 
(Rolfs, Kvietikova et al. 1997; Wenger 2002). 
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Figure 1.18. Genes that are transcriptionally activated by HIF-1. 
Genes that are involved in many processes are transcriptionally activated by HIF-1. ADM, adrenomedullin; 
ALDA, aldolase A; ALDC, aldolase C; AMF, autocrine motility factor; CATHD, cathepsin D; EG-VEGF, 
endocrinegland-derived VEGF; ENG, endoglin, Ell. endothelin-1; ENOI, enolase 1; EPO, erythropoietin; 
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FN1, fibronectin 1; GLUT!, glucose transporter 1; GLUT3, glucose transporter 3; GAPDH, glyceraldehyde- 
3-P-dehydrogenase; HKI, hexokinase 1; HK2, hexokinase 2; IGF2, insulin-like growth-factor 2; IGF-BP1, 
IGF-factor-binding-protein 1; IGF-BP2, IGF-factor-binding-protein 2; 
IGF-BP3, IGF-factor-binding-protein 3; KRT14, keratin 14; KRT18, keratin 18; KRT19, keratin 19; LDHA, 
lactate dehydrogenase A; LEP, leptin; LRP1, LDL-receptor-related protein 1; MDR1, multidrug resistance 1; 
MMP2, matrix metalloproteinase 2; NOS2, nitric oxide synthase 2; PFKBF3,6-phosphofructo-2- 
kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L; PGK 1, phosphoglycerate kinase 1; 
PAI1, plasminogen-activator inhibitor 1; PKM, pyruvate kinase M; TGF-a, transforming growth factor-a; 
TGF-03, transforming growth factor-ß3; TPI, triosephosphate isomerase; VEGF, vascular endothelial growth 
factor; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, vimentin. 
(Semenza 2003) 
1.5. DENDRITIC CELLS 
1.5.1. Introduction 
In the presence of infections or pathological conditions the body activates two different but 
connected defence immune systems: the innate and the adaptive immune system. They are 
coordinated by different leukocytes populations and soluble factors. 
Key features of the innate immune system include the ability to rapidly recognize 
pathogens and/or tissue injury and the ability to signal the presence of danger to cells of the 
adaptive immune system. 
On the other hand adaptive immunity has the ability to rearrange genes of the 
immunoglobulin family, permitting creation of a large diversity of Antigen-specific clones 
and immunological memory. 
In this system, dendritic cells (DCs) play a fundamental role, being unique antigen 
presenting cells (APC) able to efficiently activate a specific immune response and to 
establish immunological memory (Banchereau, Briere et al. 2000). 
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Moreover, different DC subsets and activation states, may play different and opposite roles 
in the balance between immune responsiveness and immune tolerance. 
Immature DC precursors, generated in the bone marrow, home to peripheral sites where 
they reside. Here, these immature DC have a high phagocytic ability and express moderate 
levels of surface MHC Class II. However, upon encountering antigen or inflammatory 
stimuli, immature DC undergo a number of changes: downregulation and upregulation of 
some chemokine receptors enabling them to home to secondary lymphoid organs, 
upregulation of antigen-loaded MHC II and costimulatory molecules on the cell surface 
and increased ability to present the antigen to naive T cells in lymph organs. 
1.5.2. Different dendritic cell subsets 
Dendritic cells are heterogeneous populations of antigen presenting cells highly specialized 
in priming T-cell-dependent immune responses. 
In the past there has been much confusion over the classification of DC into subclasses; 
however, recent evidence suggests that in both mice and men there exist at least two major 
subsets of DC: myeloid-related (including Langerhans' cells, interstitial DC, interdigitating 
DC, blood myeloid DC, monocyte-derived DC and CD34+-derived DC) and plasmacytoid 
DC (Figure 1.19). 
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Figure 1.19. Development of human DC subsets. 
Precursors in blood and bone marrow (left section) can give rise to four types of DCs under cytokine driven 
conditions ex vivo. Resident populations of immature, nonactivated DCs (middle section) are normally found 
in the steady state in the periphery and/or the circulation. Semimature DCs continuously present self-Ags, 
and probably harmless non-self-Ags, in secondary lymphoid organs to maintain peripheral tolerance and 
anergy. Counterparts for these various DC types develop in vitro in the presence of the indicated cytokines. 
Harmful pathogens or other dangerous insults to the steady state can lead to inflammation with full 
maturation and activation of each DC subset (right section). From (Rossi and Young 2005) 
Myeloid related DCs are the classical T cell priming subset; plamacytoid DC (pDC) play 
an important role in the body defence against pathogens and it was shown that they are 
able to produce large quantities of type I interferons (Vicari, Treilleux et al. 2004). The 
level of heterogeneity reflected by anatomical localization includes skin epidermal 
Langherans cells (LCs), dermal (interstitial) DCs (intDCs), splenic marginal DCs, T zone 
interdigitating cells, germinal-center DCs, thymic DCs, liver DCs, and blood DCs 
(Banchereau, Briere et al. 2000). Plasmacytoid DCs are found most abundantly in the 
blood, but also in the liver and bone marrow. 
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1.5.3. The maturation process 
An important attribute of DCs at various differentiation stages is their mobility (Austyn, 
Kupiec-Weglinski et al. 1988). DCs migrate from bone marrow to peripheral tissue. where 
their encounter with Antigens (Ags) triggers their migration to the secondary lymphoid 
organs. There Ag-bearing DCs select the Ag-specific lymphocytes from the pool of 
recirculating T cells (Figure 1.20). 
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Figure 1.20. The life cycle of dendritic cells (DC). 
(1) DCs originate from CD34' bone marrow precursors. (2) DC progenitors reach peripheral tissues via blood 
vessels. (3) Immature DC reside in peripheral tissue in a resting state, but upon the encounter with Ag, they 
efficiently capture and process it and initiate a process of maturation (4) and migration to regional lymph 
nodes. (5) In the T cell areas of lymph nodes, DCs present the Ag to T lymphocytes. (6) Activated T cell 
effectors will leave the lymph node to reach the peripheral site and fight the invading pathogens. 
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1.5.4. Recruitment of DC precursors 
When new dendritic cells are generated they migrate from the bone marrow to non- 
lymphoid tissues, where they eventually become resident cells and they are considered 
immature DC with high phagocytic capacity. DCs accumulate rapidly at the sites of Ag 
deposition and this accumulation is presumably due to the production of chemokines upon 
local inflammation. Different DC subsets display unique sensitivity to certain chemokines. 
For example the CD34+ HPC-derived immature DCs express CCR6 and his ligand 
(CCL20) appears to be the most powerful chemokine guiding their migration (Dieu, 
Vanbervliet et al. 1998). However, CCL20 has no effect on monocyte-derived immature 
DCs and this it could be due of a putative inhibitory effect of IL-4 on CCR6 expression. 
The accumulation of immature DCs, mostly LCs, in the breast carcinoma bed is also 
associated with the production of CCL20 by tumour cells (Bell, Chomarat et al. 1999). 
Immature DCs also express chemokine receptors (CCR2, CCR5, CCR6, CXCR1 and 
CXCR2) that bind chemokine ligands that are considered to be pro-inflammatory. 
Immature DCs express low levels of MHC class I and II molecules and costimulatory and 
adhesion molecules that are important for interaction with T cells. They can interact 
directly with microbial stimuli through pattern recognition receptors such as the Toll-like 
receptors (TLR) (Cravens and Lipsky 2002). 
In this phase dendritic cells are present as sentinels ready to capture Ag, a key event in the 
induction of immunity, with the following maturation and mobilization of DC. 
1.5.5. Antigen capture 
Immature DCs are very efficient at Ag capture and can use several pathways, such as 
macropinocytosis, receptor-mediated endocytosis via C-type lectin receptors or Fcy 
receptors and phagocytosis. 
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1.5.6. Dendritic cell activation and maturation 
The antigen/pathogen induces the immature DC to undergo phenotypic and functional 
changes that culminate in the complete transition from Ag-capturing cell to APC. DC 
maturation is intimately linked with their migration from the peripheral tissue to the 
draining lymphoid organs (Banchereau, Briere et al. 2000). 
Numerous factors induce and/or regulate DC maturation including pathogen-related 
molecules such as LPS (Rescigno, Granucci et al. 1999), bacterial DNA (Hartmann, 
Weiner et al. 1999) and dsRNA (Cella, Salio et al. 1999); the balance between 
proinflammatory and anti inflammatory signals in the local microenvironment, including 
TNF-a, IL-1, IL-6, IL-10, TGF-ß and prostaglandin; T cell-derived signals. The 
maturation process is also associated with several coordinated events such as loss of 
endocytic/phagocytic receptors; upregulation of costimulatory molecules CD40, CD58, 
CD80, and CD86; synthesis and translocation of the MHC II-peptide complexes to the cell 
surface. 
DC maturation induces also morphological changes, as loss of adhesive structures, 
cytoskeleton reorganization, and acquisition of high cellular motility (Winzler, Rovere et 
al. 1997) that is the most important characteristic of these cells. 
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Figure 1.21. Maturation of Dendritic cells (DCs). 
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The left side of the scheme shows the factors inducing progression from one stage to another (GM-CSF, 
granulocyte/macrophage colony-stimulating factor; 1L, interleukin; LPS, lipopolysaccaride; TNF, tumor 
necrosis factor; dsRNA, double-stranded RNA); the right side shows the main properties of each 
differentiation/maturation stage (IFN, interferon; MIUCII, major histocompatibility complex 11; MIIC, 
MHCII-rich compartment; LAMP, lysosome-associated membrane protein). From (Banchereau, Briere et al. 
2000) 
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1.5.7. Migration of Antigen-Bearing Dendritic Cells 
It is well demonstrated that DCs leave the non lymphoid organs through the afferent lymph 
(Kripke, Munn et al. 1990; Larsen, Steinman et al. 1990). 
The migration of maturing DCs involves a coordinated action of several chemokines. Upon 
maturation DCs upregulate chemokine receptor, CCR7 and subsequently acquire 
responsiveness to CCL19 and CCL21. Consequently, maturing DCs will leave the 
inflamed tissues and enter the lymph stream, potentially directed by CCL21 that is 
expressed on lymphatic vessels (Gunn, Tangemann et al. 1998; Saeki, Moore et al. 1999). 
Mature DC arrived near the T cell zone become themselves a source of CCL 19 and CCL20 
(Dieu, Vanbervliet et al. 1998; Ngo, Tang et al. 1998; Sallusto, Schaerli et al. 1998), 
allowing an amplification and or a persistence of the chemotactic signal. 
1.5.8. Tumour and dendritic cells 
The immune system has the potential to eliminate neoplastic cells, as evidenced by 
occasional spontaneous remission in renal-cell carcinomas and melanomas (Bell, Young et 
al. 1999; Timmerman and Levy 1999). 
The induction of tumour immunity can be initiated by the effectors of innate immunity and 
further developed by cells of adaptive immunity where DCs play a central regulatory role 
(Figure 1.22). 
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Figure 1.22. Dendritic cells in tumour immunology. 
Dendritic cells as a link between innate immunity and adaptive immunity in antitumor immune responses (a 
hypothesis). Precursor DCs recognize tumor pathogen associated molecular patterns (PAMP) through their 
pattern recognition receptors (PRR). Consequently, DCs release interferon (IFN) a, which activates 
macrophages (MF), natural killer (NK) T cells, and NK cells that kill tumors leading to the release of tumor 
cell bodies. The cell bodies are captured by immature DCs (which may be the progeny of the initial 
precursor), which will mature and display tumor antigens for selection of tumor specific lymphocytes. CD8 T 
cells will further directly kill the tumor while selected CD4 T cells will activate macrophages, NK cells, and 
eosinophils. The tumor may affect this process at various stages, by either preventing DC maturation or 
skewing the T cell responses towards the type 2. From (Banchereau, Briere et al. 2000) 
Tumour immunity can be viewed as a three-step process that includes (i) presentation of 
tumour-associated Ags (TAAs); (ii) selection and activation of TAA-specific T cells as 
well as non-Ag-specific effectors, and (iii) homing of TAA-specific T cells to the tumour 
site and elimination of tumour cells (Bell, Chomarat et al. 1999). Tumours may escape 
immune surveillance owing to alterations at each of these steps. Tumour can prevent DC 
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differentiation and/or APC function producing cytokines such as IL-6, IL-10, M-CSF, 
VEGF. Recent pubblications demonstrated that hypoxia, which is characteristic of solid 
tumours, may affect functions and maturation process of DC (Qu, Yang et al. 2005; Zhao, 
Darmanin et al. 2005). This may be an example of how tumours may subvert immune cells 
functions. 
Analysis of DCs distribution in breast carcinoma revealed two levels of heterogeneity: a) 
immature CD1a+DCs, mostly of the LC type are retained within the tumour bed, b) mature 
DCs are confined to peritumoural areas (Banchereau, Briere et al. 2000). Scarpino S. et al. 
have found that in papillary carcinoma in thyroid most dendritic cells present an immature 
phenotype and are located at the invasion edge of the tumour while macrophages are 
evenly distributed throughout the tumour (Scarpino, Stoppacciaro et al. 2000). 
It was recently demonstrated that also pDCs are present in tumours [reviewed in (Vicari, 
Treilleux et al. 2004)] and their infiltration in ovarian tumours is paralleled by the 
expression of CXCL12, to which they respond (Zou, Machelon et al. 2001). 
Many chemokines active on immature DC (CCL2, CCL3, CCL4, CCL7) are secreted 
under inflammatory conditions and by tumours [as reported by histological analysis 
(Negus, Stamp et al. 1997; Scarpino, Stoppacciaro et al. 2000; Tang, Tan et al. 2001)] and 
their activity appears to be restricted to specific DC subsets. 
The significance of the recruitment of DC in tumours is an important issue not properly 
investigated yet. 
New studies are requested to clarify the mechanisms by which microenviromental signals 
affect DC functions. 
1.6. Aims 
J 
The aim of this thesis is to investigate the effects of tumour hypoxia on cell migration. It is 
known that solid tumours are generally characterized by regions of necrosis, associated 
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with low oxygen tension and the consequent activation of metabolic adaptation pathways 
by resident (cancer cells) and infiltrating cells (stroma cells). Based on these observations 
the first aim was to describe the functional chemokine receptor profile acquired by cancer 
and stroma cells in hypoxia and to identify the molecular mechanisms promoting this 
event. The results of this study provide novel insights into the mechanisms governing 
recruitment and activation of macrophages associated with tumours and identify possible 
therapeutic targets to prevent their accumulation, as well as their protumoral functions. 
The second aim was to investigate the influence of hypoxia on dendritic cells maturation 
and function. The rational of this study stems from the observation that DC play an 
essential role in the activation of specific antitumour immunity and represent an important 
component of the inflammatory infiltrate of inflammatory deiseases characterized by low 
oxygen tension (e. g. tumours, arthritis rheumatoid). Identification of mechanisms 
governing DC maturation and functions in hypoxia represents an unexplored field which 
may eventually lead to the discovery of specific pathways governing activation of immune 
programmes associated with several pathological conditions. 
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Chapter 2. Materials and Methods 
2.1. Cells and Culture Conditions 
2.1.1. Isolation of human monocytes 
Human monocytes were separated from the peripheral blood of human healthy donors by 
Percoll gradient centrifugation (Sica, Saccani et al. 1997). Briefly, blood was diluted 1: 5 
with PBS and centrifuged for 10 min at 1000 rpm. The supernatant was eliminated, cells 
pellet were re-diluted 1: 4 in PBS, the Ficoll (Amersham Biosciences) stratificated at the 
bottom and centrifuged for 25 min at 1650 rpm at room temperature. The mononuclear cell 
layer was collected and washed thoroughly by resuspension in PBS. After washing, the 
mononuclear cell layer was diluted in osmolorized medium (285 mOSM) and an equal 
volume of Percoll (46% in osmolorized medium) was stratificated at the bottom. Following 
centrifugation for 30 min at 2000 rpm at room temperature, monocytes were collected at 
the interface between medium and Percoll, while lymphocytes were at the bottom of the 
tube. Monocytes were >90% pure as assessed by morphology criteria (Giemsa-stained 
cytospin preparations, looking at the morphology of the nucleus and FACS analysis using 
CD14 antibody). The cells were washed thoroughly by resuspension in PBS and finally 
resuspend at 107/ml in RPMI 1640 (Biochrom, Berlin, Germany) supplemented with 10% 
FBS (HyClone, Logan, UT), 2 mM glutamine, and antibiotics. All reagents contained 
<0.125 EU/ml of endotoxin as checked by limulus amebocyte lysate assay 
(Microbiological Associates, Walkersville, MD). 
2.1.2. Generation of monocytes-derived macrophages and dendritic cells 
Monocyte-derived macrophages (MDMs) were derived from freshly isolated monocytes 
(3-5x106 cells/ml) after incubation for 5 days in RPMI 1640 medium supplemented with 
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10% FBS, 2 mM glutamine, antibiotics, and 40% autologous serum on hydrophobic 
petriperm plates (Sigma-Aldrich), as described previously (Mantovani, Caprioli et al. 
1977). The resulting macrophages were washed and resuspended in RPMI 1640 
supplemented with 10 % foetal bovine serum (FBS; Gibco BRL) prior to use. The viability 
of the cell population was assessed by Trypan Blue staining. Macrophage differentiation 
was assessed by FACS analysis using specific marker CD68. 
Human dendritic cells were derived from freshly isolated monocytes, followed by plastic 
adherence, after incubation for 6 days at 1x106/ml in medium RPMI 1640 with 50 ng/ml 
GM-CSF and 20 ng/ml IL-13. After 6 days of culture, the outcoming population consisted 
of typical immature dendritic cells which usually expressed CDIa (>90% positive cells), 
low levels of CD80 and CD86 and was negative for CD83 (<10%) and CD14 (<10%) 
(Piemonti, Bernasconi et al. 1995; Sozzani, Sallusto et al. 1995; D'Amico, Bianchi et al. 
1998). 
To induce maturation, LPS (Rescigno, Martino et al. 1998) at different concentration 
ranging from 0.1 ng/ml to 100 ng/ml was added at day 6 for 24 h in normoxia (20% 02) 
5% C02, and 75% N2) or hypoxia conditions (94% N2,5% C02, and 1% 02). 
2.1.3. Isolation of tumour associated macrophages 
TAMs were obtained from ascitic fluids collected from untreated patients with 
histologically confirmed epithelial ovarian carcinoma admitted to the Department of 
Obstetric and Gynecology, S. Gerardo Hospital, Monza, Italy (Sica, Saccani et at. 2000). 
All patients had cancer classified as stage II, III, or IV. Ascitic fluid was collected and 
centrifuged for 10 min at 1500 rpm. Cells pellet was resuspended in RPMI 1640 medium 
without serum and layered on top of a Ficoll-Hypaque cushion to prepare mononuclear 
cells. Purification of peritoneal macrophages was further conducted by two subsequent 
adherence steps for 45 min each in RPMI 1640 medium without serum. After adherence 
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procedures, cells were repeatedly washed with saline to remove all non adherent cells. 
TAMs were >85% pure as assessed by morphology criteria (Giemsa-stained slide 
preparation treated as all the other samples). The adherent cells were rested with complete 
medium overnight at 37°C and subsequently stimulated as indicated in the result chapters 
of this thesis. 
2.1.4. Isolation of human endothelial cells 
Human endothelial cells were obtained from umbilical veins (from normal placenta 
without hepatitis or HIV contamination). The umbilical vein was cannulated with sterile 
blunt needles and perfused with PBS to wash out the blood. Then, the vein was filled with 
collagenase at 1 mg/ml (Boehringer) and allowed digestion to proceed for 20 minutes at 
37°C. After this period the vein was washed with Hanks buffer (Sigma, Milan) and the 
supernatant was collected. Cells were pelleted by centrifugation (5 min at 1500 rpm), 
respuspended in M199+20% FCS without growth factor and put in a flask without 
gelatine. When cells formed a monolayer, they were trypsinased, resuspended in medium 
supplemented with growth factor (50µg/ml of endothelial cell growth supplement and 100 
µg/ml heparin) and transfered in flasks coated with gelatine at 0.5% (Sigma) (Romano, 
Sironi et al. 1997). We used routinely confluent cells at second to sixth passages. Cells at 
the concentration of 1.5x104/0.2 ml were cultured for 24 h in flat-bottomed 96-well plates 
(Falcon) in M199 medium with 20% FCS, supplemented with 50µg/ml of endothelial cell 
growth supplement (Collaborative Research Inc. ) and 100 µg/ml heparin. Cells were 
maintained at 37°C in a humidified incubator containing 20%02,5% C02, and 75% N2. 
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2.1.5. Isolation of plasmacytoid dendritic cells 
PBMCs were isolated from buffy coats by Ficoll gradient and plasmacytoid dendritic cells 
(P-DC) were magnetically sorted with blood DC Ag BDCA-4 cell isolation kits (Miltenyi 
Biotec, Milan), to a purity of 90-98 % (Penna, Sozzani et al. 2001). Blood P-DC (106 
cells/ml). Cells were then cultured in medium containing 1,000 U/ml recombinant human 
GM-CSF (Mielogen; Schering-Plough) and 20 ng/ml IL-3 (ProSpec). Cells were matured by 
24-h incubation with 100 ng/ml LPS (Escherichia coli 055: B5; Sigma-Aldrich), or 20 ng of 
hemagglutinin/ml inactivated influenza virus strain A/Moscow/10/99 (a gift from T. De 
Magistris, Istituto Superiore di Santa, Rome, Italy). 
2.1.6. Isolation of murine dendritic cells 
Mice were sacrified using C02. The skin mid-back was clipped and the skin from the 
lower part of the body was removed. All the tissue from legs was removed with scissors 
and dissected away from body. The remaining tissue was cleaned from the pelvic and 
femoral bones and separated at knee joint (it is important to remove all the tissue from the 
bones since cells associated with this can contaminate the marrow preparation). Each end 
of bone was cut off and using a 25g needle and a 12cc syringe filled with PBS. The bone 
marrow from both ends of the bone was expelled with a jet of PBS into a 50 ml Falcon 
tube. 
CD34+ bone marrow cells from femurs and tibias of C57BL/6 mice were prepared by 
positive immunoselection using MACS microbeads coated with goat anti-rat IgG (Miltenyi 
Biotec Inc. Auburn, CA), using the rat mAb MEC14.7 (Garlanda, Berthier et al. 1997) to 
mouse CD34 as selecting agent. Cells were separated following the manufacturer's 
instructions. CD34+ positive cells (23105 /mL) were cultured in RPMI 1640 medium with 
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10% fetal calf serum, 2x10"5 2-ME, GM-CSF (40 ng/mL), and Flt3 ligand (100 ng/mL). 
Cells were diluted 1: 2-1: 3 every 2 or 3 days. 
Cultured cells were collected after 9 days and used in the different assays. DC were 
characterized in terms of membrane phenotype (expression of DEC205, MHC class II, 
CD 11 c, CD86), pinocytosis, and antigen presentation in allogeneic MLR. 
Where specified, DCs were cultured with 20 ng/mL TNF-a or 10-100 ng/mL LPS for the 
last 24 h of culture in normoxia, hypoxia or desferrioxamine (DFX, 400µM) condition. 
2.1.7. Cells lines and culture 
Mouse embryonic fibroblasts (MEFs), wild type, and HIF-1a4 were a gift from G. 
Semenza (The Johns Hopkins University School of Medicine, Baltimore, MD) and were 
routinely maintained in DMEM (Invitrogen and Life Technologies, Milan) supplemented 
with 10% heat-inactivated FBS (Whittaker Bioproducts), 50 IU/ml penicillin, 50 µg/ml 
streptomycin, and 2 mM glutamine (all purchased from Invitrogen and Life Technologies, 
Milan). 
MCF-7 (human breast cancer cells), CAOV3 (human ovarian cancer cell line), 786.0 
(Lieubeau-Teillet, Rak et al. 1998), and WT2 human renal cancer cells (Ivanov, Kuzmin et 
al. 1998) were routinely maintained in RPMI 1640 medium (Whittaker Bioproducts, USA) 
supplemented with 5% heat-inactivated FBS, 50 IU/ml penicillin, 50µg/ml streptomycin, 
and 2 mM glutamine. Cells were maintained at 37°C in a humidified incubator containing 
20% 02,5% CO2 in air (referred to as normoxic conditions). 
2.1.8. Post-trypsinisation recovery of ovarian cancer cell lines 
Prior to their use in chemotaxis or flow cytometry, the adherent ovarian and breast cancer 
cell lines were trypsinised. However, to allow recovery of cell surface receptors (including 
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chemokine receptors) on these cells after trypsinisation, cells were cultured as single cell 
suspensions in teflon-coated pots (SIGMA, Milan) at 0.5-1 x 106 cells/ml for a minimum of 
5 hours. 
2.1.9. Normoxia and hypoxia treatment 
In this thesis we considered as normoxia the normal cell culture condition where the 
percentage of 02 is 21% and it is important to specify that this condition is of supra 
normoxia as it isn't a physiological normoxia corresponding to 13% of 02 in the blood 
vessels (even if used by all the scientist). 
Hypoxia treatment was performed by placing cells in a modular incubator chamber 
(Billups-Rothemberg Inc., Del Mar, California) and flushing them with a mixture of 1% 
02,5% C02, and 94% N2 for 20 min. The chamber was placed at 37°C. 
To induce pharmacological hypoxia we use desferrioxamine (Sigma Aldrich, Milan) as 
hypoxia mimicking compound at the concentration of 400 [M. 
2.2. Cytokines and Reagents 
Human recombinant CXCL12 and CCL5 were from PeproTech (London, UK). 
Desferrioxamine (DFX) and actinomycin D (used at 1 µg/ml) were purchased from Sigma- 
Aldrich (Milan). LPS (Escherichia coli 005: B5; Difco, MI) was used from 0.1 ng/ml to 100 
ng/ml. Actinomycin D were from Sigma (Milan). 
2.3. Migration Assay 
Monocyte migration was evaluated using a chemotaxis microchamber technique as 
described previously (Sica, Saccani et al. 1997). 27 µl of chemoattractant solution or 
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control medium (RPMI 1640 with 1% FCS) was added to the lower wells of a chemotaxis 
chamber (Neuroprobe). A polycarbonate filter (5µm pore size; Neuroprobe) was layered 
onto the wells and covered with a silicon gasket and the top plate. 50 µ1 of cell suspension 
(1.5x106/ml fresh human monocytes), preincubated for 16 h in the presence of 4001AM 
DFX, were seeded in the upper chamber. The chamber was incubated at 37°C for 90 min. 
At the end of this period, filters were removed and stained with Diff-Quik (Baxter), and 10 
high-power oil immersion fields were counted. 
Cancer cell migration was assayed as described previously (Scotton, Wilson et al. 2001) by 
using Falcon transwells (24-well format, 8-µM pore; BD Biosciences). 0.5 ml of media 
(DMEM plus 1% BSA) containing 5x105 cells was added to the upper chamber, and 0.5 
ml of medium alone or media supplemented with CXCL12 (PeproTech) was added to the 
lower chamber. After overnight incubation in normoxic (5% C02) or hypoxic conditions 
(1%02), cells on the upper surface of the filter were removed using a cotton wool swab. 
Migrated cells on the lower surface were stained using DiffQuick (Dade Behring, 
Düdingen, Switzerland). For each transwell, the number of migrated cells in 10 medium- 
power fields (20X) was counted. Three transwells chambers were used per condition. 
For human umbilical vein endothelial cell (HUVEC) migration, polycarbonate filters (5µm 
pore size, polyvinylpyrrolidine free) were soaked in 0.5 M acetic acid, washed with PBS, 
incubated for 24 h in 0.01% gelatin (Sigma-Aldrich), and air dried (Colotta, Bussolino et 
al. 1993). CXCL12 and fibrinogen (Sigma-Aldrich) in M199, containing 1% FCS, were 
seeded in the lower compartment, and 50µl of HUVECs (2x106/ml) was added to the upper 
compartment. After 6h of incubation at 37°C, the upper surface of the filter was scraped 
with a rubber policeman. The filters were fixed and stained, and five oil immersion fields 
(lower surface) were counted after coding samples. 
Dendritic cells migration was evaluated using a 48-well microchemotaxis chamber 
technique. Briefly 27 tI of chemokine or control medium (RPMI 1640+1%FCS) was 
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added to the lower wells of the chemotaxis chamber (Neuropore, Pleasanton, CA) 
(Sozzani, Sallusto et al. 1995) and 50 µl of cell suspension (1.5x106/ml) were seaded in the 
upper chamber. The two compartments were separated by 5 µm pore size 
polyvinylpyrrolidone polycarbonate filter (Neuroprobe). The chamber was incubated for 
90 min at 37°C in a humified atmosphere in the presence of 5% C02. 
2.4. Methods for analysing RNA expression 
2.4.1. Preparation of RNA from tissue samples and cell lines 
Total RNA was prepared from monocytes, TAM, M-DM, endothelial cells and cancer cell 
line (MCF7 and CAOV3) using Trizoi ReagentTM (Invitrogen) according to the 
manufacturer's instructions. 
2.4.2. Northern Blot Analysis 
2.4.2.1. Northern blotting 
10 µg of total RNA was mixed with cold water to a final volume of 10 µl and added 30 µl 
of solution I for RNA (50 % deionised formamide [Merck/BDH, Lutterworth, UK], 6% 
formaldehyde [Merck/BDH, Lutterworth, UK], 400 mM MOPS [3-N- 
morpholinopropanesulphonic acid], 100 mM sodium acetate and 10 mM EDTA p118.0 [all 
from Sigma, Poole, UK] made up in DEPC-treated water). Each RNA sample was heated 
to 65 °C for 10 minutes, then placed on ice prior to loading. The RNA was subjected to 
electrophoresis through a1% agarose-formaldehyde gel (1 % agarose [Gibco BRL, 
Paisley, UK], 6% formaldehyde, 400 mM MOPS, 100 mM sodium acetate, 10 mM EDTA 
pH 8.0,0.5 µg/ml ethidium bromide) and subsequently blotted by capillary transfer onto 
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Gene screen Plus membranes (New England Nuclear Boston, MA). After transfer, the 
membrane was dried in an oven at 801 C for 2h. 
2.4.2. ii. Probe labelling and hybridisation 
The membrane was placed in a suitable hybridisation tube and pre-hybridised for 1-2 hours 
at 42 °C with 20 ml of hybridisation buffer (50 % deionised formamide, 10% destran 
sulphate, 1% SDS, 1M NaCl, 100 mg/ml Salmon Sperm DNA made up in distilled water). 
cDNA probes were labelled by random priming using a commercial kit (Boehringer) 
according to the manufacturer's instructions and a-[32P]dCTP (3,000 Ci/mmol; Amersham 
Biosciences). 
Unincorporated [32P]CTP nucleotide was removed by passing the radiolabelled probe 
through a Sephadex G50 column. Prior to use, the radiolabelled probe was heated to 100 °C 
for 5 minutes, then quenched on ice for up to 30 min. Probe was then added to 20 ml of 
hybridisation buffer (approximately 1x 106 cpm/ml of buffer), which was poured on to the 
membrane in place of the pre-hybridisation buffer. Hybridisation was performed overnight at 
42 °C. 
Following hybridisation, membranes were washed three times at room temperature for 10 
min in 0.2X SSC (1X SSC = 0.15 M NaCl, 0.015 M of sodium citrate, p'17.0), 0.1% SDS, 
and twice at 60° C for 20 min in 0.2X SSC, 0.1% SDS before being autoradiographed 
using films and intensifier screens at -80° C (XAR-5; Kodak). Densitometric analysis was 
performed with a scanning densitometer (model GS300; Hoefer Scientific Instruments). 
2.4.2. iii. cDNA probes 
CCRI and CCR5 cDNAs were obtained in our laboratory (Sica A. et al. 2000 J. Immunol. 
164: 733-738). CXCR4 cDNA was provided by T. N. C. Wells (Serono Pharmaceutical 
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Research Institute, Geneva, Switzerland). ß-Actin was provided by Dott. Chiesa R. (Mario 
Negri Institute) (Hanukoglu, Tanese et al. 1983). 
Appropriate restriction enzymes were used to cut out each cDNA insert; each digested 
reaction was added to 5 µl of loading buffer (0.25 % w/v bromophenol blue; 0.25 % xylene 
cyanol [all from Sigma] and 25% Ficoll 400, made up in distilled water) and 
electrophoresed through a1% agarose gel containing 0.5 pg/ml ethidium bromide. 
Insert cDNA bands were visualised by UV transillumination and gel extracted (QiaQuick 
Gel Extraction kit, Qiagen). The purified cDNA insert was subsequently used for probe 
labelling. 
2.4.3. Real-time PCR 
Total RNA from MEFs, 786.0, and WT2 cells was obtained using an RNA mini kit 
(QIAGEN). REAL TIME RT-PCR was performed using a REAL TIME RT-PCR kit (PE 
Biosystems) as described previously (Wang and Semenza 1993). To measure the human 
vascular endothelial growth factor (VEGF), human CXCR4 and mouse CXCR4 expression 
real-time PCR was performed using a sequence detector (ABI-Prism, model 7700; Applied 
Biosystems). The following primers were used: 
Species Target Forward Primer 
Reverse Primer 
Human CXCR4 GCATGACGGACAAGTACAGGCT 
AAAGTACCAGTTTGCCACGGC 
Mouse CXCR4 TTGTCCACGCCACCAACAGTCA 
TGAAACACCACCATCCACAGGC 
Detection of 18S rRNA, used as internal control, was performed using premixed reagents 
from Applied Biosystems. Detection of VEGF and 18S rRNA was performed using a PCR 
master mix (TaqMan Universal; Applied Biosystems) and CXCR4 detection was also 
performed using a PCR master mix (SyBr Green; Applied Biosystems). Detection of 
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CXCL12 expression by the MCF7 and CAOV3 cell lines was performed by using a PCR 
master mix (SyBr Green; Applied Biosystem), and the following primers were used: 
Species Target Forward Primer 
Reverse Primer 
Human CXCL12 ACACTCCAAACTGTGCCCTTCA 
CCACGTCTTTGCCCMCATC 
2.5. Transient Transfection 
DNA plasmids were prepared using a commercially available kit (Endofree Maxi-Prep; 
QIAGEN). 
Transfections were performed using effectene transfection reagents (QIAGEN) according 
to the manufacturer's instructions and the transfection efficiency in all the experiments was 
> 90%. 
Cells were seeded at a concentration of 5x104 per well in 48-well plates the day before 
transfection. 24 h after transfection, reagents were removed, and cells were allowed to 
recover for 8h before being treated for 16-24 h. Cotransfection experiments were 
performed using a 1: 1 ratio between the reporter plasmid and HIF-la expression vector. 
Luciferase reporter assays were performed in 96-well optiplates (Packard Instrument Co. ) 
using a luciferase assay system (Promega) according to the manufacturer's instructions. 
Results were normalized for the protein content using the protein assay (Bio-Rad 
Laboratories). Reporter gene assay pGL-Hyp responsive element (TIRE) plasmid contains 
three copies of the canonical HRE (5'-GTGACTACGTGCTGCCTAG-3') from the 
inducible nitric oxide synthase promoter (Melillo, Musso et al. 1995). pCXCR4 plasmid, 
containing a 2.6-kb fragment from the human CXCR4 promoter upstream of the luciferase 
reporter gene, was obtained from A. J. Caruz [Universidad de Jaen, Madrid, Spain; 
reference (Caruz, Samsom et al. 1998)]. HIF-la (ODD) expression vector was obtained 
from E. Huang [Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 
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reference (Huang, Gu et al. 1998)]. The pCMV(HA)-HIF-la expression vector was 
obtained from D. Livingston (Dana Farber Cancer Institute, Boston, MA). 
2.6. Chromatin Immunoprecipitation Assay (ChIP) 
ChIP assays was performed in CAOV3 cells, transiently transfected with the p(HA)HIF-la 
expression vector, and performed as described previously (Saccani, Pantano et al. 2002). In 
brief, 4x106 cells were fixed by adding directly to the medium formaldehyde 
(formaldehyde from a 37% formaldehyde/10% methanol stock; Calbiochem) to a final 
concentration of 1%. After 10 min, ice-cold PBS was immediately added, plates were 
transferred on ice and washed three times with PBS, and cells were collected by scraping. 
After centrifugation at 4°C (1200-1500 rpm for 5 min), cells were lysed for 5 min in L1 
buffer (50 mM Tris, pH 8.0,2 mM EDTA, 0.1% NP-40, and 10% Glycerol) supplemented 
with protease inhibitors maintaining cells in ice (nuclear membrane remains intact). Nuclei 
were pelleted at 3,000 rpm in microfuge at 4°C and resuspended in L2 buffer (50 mM Tris, 
pH 8.0,1% SDS, and 5 mM EDTA plus inhibitors). Chromatin was sheared by sonication 
(5x10 s at one fifth of the maximum potency in a Sonics vibracell VC13 equipped with a 
3-mm tip), centrifuged to pellet debris (13000 rpm at 8°C), and diluted ten times in dilution 
buffer (50 mM Tris, pH 8.0,0.5% NP-40,0.2 M NaCl, and 0.5 mM EDTA). Extracts were 
precleared for 2h (with rotation at 4°C) with 80µl of a 50% suspension of salmon sperm 
DNA-saturated protein A. Immunoprecipitations were performed at 4° C overnight with 
2µg of polyclonal anti-human hemagglutin antibody (Santa Cruz Biotechnology, Inc. ). 
Immune complexes were collected with salmon sperm DNA-saturated protein A, and 
washed three times (5 min each) with high salt buffer (washing buffer: 20 mM Tris, p11 
8.0,0.1% SDS, 1% NP-40,2 mM EDTA, and 500 mM NaCI), two times with a 0.5 M LiC1 
buffer, and three times with low salt buffer (1X TE). Immune complexes were extracted in 
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1X TE containing 2% SDS and protein; DNA cross-links were reverted by heating at 65° C 
for 6 h. After proteinase K digestion (100µg, 1-2 h at 50° C), DNA was extracted by 
phenol, chloroform, and ethanol precipitated (O/N at-20°C). The DNA was centrifuged; air 
dried, resuspended it in 30 µl of TE and I RI of RNAase was added and incubated at 37°C 
for 20 min. Approximately 1/20 of the immunoprecipitated DNA was used in each PCR. 
Sequences of promoter-specific primers included the CXCR4 promoter region 1860 to 
1578 as follows: 
Species Target Sense 
Antisense 
Human CXCR4 TCGTGCCAAAGCTTGTCCCTG 
GCGGTAACCAATTCGCGAATAGTGC 
2.7. Immunohistochemistry 
2.7.1. Tissues 
Neoplastic breast tissues from patients with a diagnosis of invasive ductal carcinoma were 
revised. Tissue had been previusly fixed in buffered formalin for 24 hours at room 
temperature and embedded in paraffin. 3-µm sections were obtained from blocks and 
stained with Haematoxylin and Eosin for routine histological examination. 
2.7.2. Antibodies 
The following antibodies were used: mouse monoclonal antiserum to HIF-1 alpha (clone 
Hlalpha67, Novus Biologicals) and mouse fluorescein-conjugated monoclonal antiserum 
to CXCR4 (clone 12G5, R&D System). 
2.7.3. Immunohistochemical method 
2-µm paraffin sections were cut from blocks and dried at 37°C for 10 minutes. 
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The following steps were then carried out at room temperature: 
1) Sections were deparaffinised in xylene (3x10 min) and hydrated immerging the 
slides in 100% ethanol (2x1 min), 90% ethanol (1 min), 90% ethanol with 0.3% 
H202 (to block endogenous peroxidase), 70% ethanol (1 min) and distill water 
(1 mm). 
2) Sections were laid out in a humid chamber 
3) Sections were washed twice in PBS (5 minutes each) 
4) Microwave pretreatment (780W, 5 min. twice, in 0.01M citrate buffer, pH 6.0) was 
performed in order to retrieve antigen only for anti HIF-Ict antiserum 
5) Sections were washed in PBS for 5 minutes 
6) 5% normal human serum (DAKO) was added to each section for 10 min, then 
drained off. 
7) To each section, primary antibody (monoclonal antiserum to HIF-la at the dilution 
of 1: 50 and mouse fluorescein-conjugated monoclonal antiserum to CXCR4 at the 
dilution of 1: 20) was added. The slides were incubated for 2 hour in a humid 
chamber at room temperature. 
8) Sections were washed twice in PBS (5 minutes each) 
9) For anti HIT-la antiserum a double indirect immunoperoxidase staining was used 
to reveal the immunohistochemical reaction: first, a rabbit anti mouse peroxidase- 
conjugated secondary antibody (at the dilution of 1: 50, Dako, I hour incubation) 
followed by a swine anti-rabbit peroxidased secondary antibody (at the dilution of 
1: 50, Dako, 1 hour incubation). 
10) For anti CXCR4 antiserum a double indirect staining was used to reveal the 
immunoistochemical reaction: a first reaction with monoclonal anti-fluorescein 
antiserum (1: 20, Dako, 1 hour incubation) followed by a double indirect 
immunoperoxidase technique (a rabbit anti mouse peroxidased secondary antibody, 
109 
Chapter 2 Materials and Methods 
at the dilution of 1: 50, Dako, 1 hour incubation, Dako, and a swine anti rabbit 
peroxidased secondary antibody, at the dilution of 1: 50, Dako, 1 hour incubation) 
11) Sections were washed twice in PBS for 5 min 
12) The chromogen was prepared as indicated: 250 µl 3,3'-diaminobenzidine free base, 
10 ml PBS, 10 µl H202 
13) DAB solution was added to each section and incubated for less than 5 min; the 
positivity was identified as a brown staining 
14) Sections were washed in distilled water 
15) Sections were counterstained for 2 minutes in Haematoxylin 
16) Sections were dehydrated in taken dow through 70% ethanol (1 min), 90% ethanol 
(1 min), 100% ethanol (2x1 min) and xylene (3x1 min). 
17) Sections were mounted with Eukitt (Sigma) 
2.8. Methods for analysing protein expression 
2.8.1. Flow cytometry 
2.8.1.1. Monoclonal antibodies 
Cell staining was performed using mouse monoclonal anti-human CXCR4 antibody (clone 
12G5; BD Biosciences) and an irrelevant isotype-specific control mouse, IgG2a, (UPCIO; 
Sigma-Aldrich) followed by FITC-conjugated, isotype-matched affinity-purified, goat 
anti-mouse antibody (Southern Biotechnology Associates, Inc. ). 
Monocytes were stained with mouse monoclonal anti-human CCRI (clone 53504) and 
CCR5 (clone 45531) antibodies (all from R&D). 
Human dendritic cells were stained for mouse monoclonal anti-human CCR7 (clone 2H4), 
R-phycoerythrin (R-PE)-conjugated mouse anti-human monoclonal CD80 (clone L307.4), 
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mouse anti-human CD83 (clone HB15e) (all from BD Biosciences) and MHCII (L243 
clone hybridoma from ATCC). 
2.8.1. ii. Immunofluorescent staining protocol 
For staining, cells were washed in PBS supplemented with 1% of inactivated human serum 
or FCS respectively for human or murine cells (FACS buffer). Approximately 5x 105 cells 
were resuspended in 100 µ1 of FACS buffer in a microfuge tube then 10 µg of human IgG 
(Sigma) was added to block Fc receptors. After 15 min incubation at room temperature, 
primary antibody was added to a final concentration ranging between 2-20 µg/m1. Cells 
were incubated with the primary antibody for 30 min on ice. The cells were then washed 
twice by addition of 1 ml of cold FACS buffer, centrifugation at 13,000 rpm for 10 seconds 
in a microfuge at 4°C, and resuspension in cold FACS buffer. Cells stained with PE- 
conjugated antibodies were then ready for flow cytometric analysis. For unconjugated 
antibodies, cells were resuspended in 100 µl of FACS buffer and FITC-conjugated 
secondary antibody was added (at an appropriate dilution). Following further 30 minutes of 
incubation in ice, the cells were washed twice as before, then analysed by flow cytometry 
(FacsCalibur, Becton-Dickinson, Milan). 
2.8.2. Laser Confocal Microscopic Analysis of CXCR4 Expression 
Cells growing on sterile coverslips were washed with PBS after 16-h incubation in hypoxic 
or normoxic conditions, as indicated in the text. Non-specific sites were blocked by 10-min 
incubation at room temperature with wash buffer containing 0.9% wt/vol sodium chloride, 
1% vol/vol human serum, and 0.02% wt/vol sodium azide. Thereafter, the cells were 
stained with mouse anti-human CXCR4 antibodies (BD Biosciences) at a dilution of 1: 20 
for 30 min at room temperature. The cells were washed twice with 2 ml of wash buffer and 
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incubated with goat F(ab') 2 anti-mouse Ig-FITC (human adsorbed) at a dilution of 1: 20 
for another 30 min at room temperature. After two changes in wash buffer, the cells were 
fixed in 4% wt/vol paraformaldehyde for 15 min, and the coverslips were mounted on 
glass slides for microscopy. Images were visualized using a system with differential 
interference contrast (FV500; Olympus, UK). 
2.8.3. Enzyme-linked immunosorbent assay (ELISA) 
The concentration of hTNF-a, hIL-12, mIL-12, mTNF-a, mIL-10 and mIL-6 levels was 
measured using ELISA Sandwich purchased by R&D in according to manufacter's 
instructions. 
2.8.4. Statistical method 
All measurement are shown as average ± SD. Statistical analysis of data was performed 
using a two-tailed unpaired t-test. All p values were calculated vs untreated samples unless 
indicated otherwise. P values of <0.05 were considered as statistically significant. 
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Chapter 3. Expression of chemokine receptors in 
different cells types after hypoxia treatment 
3.1. Introduction 
Regulation of chemokine receptor expression is a crucial level of control for the tuning of 
the chemokine system. In particular, pro- and anti-inflammatory stimuli have divergent 
effects on chemokines and chemokine receptors. Original observations by our group 
demonstrated that pro-inflammatory stimuli, such as LPS and IFN-y, downregulate the 
expression of CCR2, while upregulate CCL2 expression (Sica, Saccani et al. 1997). In 
contrast, anti-inflammatory stimuli (e. g. IL-10) upregulate CCR2 and downregulate CCL2 
expression (Sozzani, Ghezzi et al. 1998). 
The downregulation of certain inflammatory chemokine receptors may serve as stop signal 
to focus their actions at sites of infection and inflammation. In particular our lab has 
demonstrated that tumour derived TNF-a, in human ovarian cancer, inhibits CCR2 
expression by TAMs (Sica, Saccani et al. 2000). In addition to pro and anti-inflammatory 
stimuli other microenvironmental stimuli can regulate the chemokine receptors expression. 
For instance, stress stimuli could induce changes in the expression level of several 
chemokine and chemokine receptors and reactive oxygen intermediates (ROI) upregulate 
the expression of CCR5 and CXCR4 (Saccani, Saccani et al. 2000). 
3.2. Aim of this chapter 
Hypoxia is a feature of several inflammatory diseases as rheumatoid arthritis, 
atherosclerosis, acute respiratory distress syndrome, psoriasis, etc. hlypoxia also has a 
fundamental role in tumours and tumour-associated macrophages were reported to localize 
preferentially in necrotic zones of the tumour. Based on these observations, the initial aim 
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of this chapter was to examine the effects of microenviromental hypoxia on the chemokine 
receptor expression and functions. 
3.3. Results 
3.3.1. Hypoxia-increased CXCR4 Expression in Mononuclear Phagocytes 
As the inspired air has a concentration of 21% of 02, we considered normoxia (Norm) the 
standard cell cultured condition, characterized by 20% of 02 tension, and hypoxia (Hyp) 
culture conditions with 1% of 02, in line with previous works and with the observation that 
in hypoxic tissues the 02 concentration ranges between 0.5 and 2.5%. 
Monocytes were cultured in normoxia (20% oxygen) and hypoxia (1% oxygen) and the 
total RNA was next collected at different time points, mRNA expression of CXCR4, 
CCR1 and CCR5 was analyzed by Northern blot. As shown in Figure 3.1, human 
monocytes cultured in hypoxia, for 4 and 6 h, showed a strong increase in the expression of 
CXCR4 mRNA, as compared with normoxia-cultured monocytes. 
Hyp-mediated up-regulation of CXCR4 mRNA was still present at 16 h. In Hyp, a slight 
increase was also observed for CCR1 mRNA expression, whereas CCR5 mRNA level was 
unaffected. Interestingly, it was reported that Hyp down-regulates the responsiveness of 
monocytes to the CCR2 agonists CCL2 (Turner, Scotton et al. 1999; Grimshaw and 
Balkwill 2001). Based on these results, we focused our attention on CXCR4. 
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Figure 3. I. Analysis of chemokine receptors by Northern III of. 
Fresh hUlllall monocytes obtained from peripheral blood of' healthy I onors \\cre cultured for different tunes 
in normoxia (Norm) or hypoxic (I Iyp) conditions, as indicated. "Total RNA was analyzed b Northern blot for 
CXCR4, CC'RI, and CCR5 mRNA expression. Results are representative of five diiffcrent esherinicnts. 28S 
and 18S are shown to demonstrate the equal amount of RNA. 
3.3.2. The hypoxia mimicking compound desferioxammine induces CXCR4 
expression 
Dcs[crioxamtrninc (DIA) is an iron chelator rccognizcd as all hypoxia niimicLiºng 
conmpound (W'r'ang and Scmcnza 1993). Fresh human momocytcs were incubated fo1- 4h iº1 
the presence cat' diflcrcnt concentration of DIA and total RNA was analyzed by Northern 
blot. C'XCR4 mRNA levels increased in a dose-depenclcnt manner in response to I )FX 
(Figure 3.2). 'logcther. these results show that ('X('R4 mRNA expression is controlled by 
changes in oxygen levels. 
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Figure 3.2. Ilypoxia-mimicking compound induces CXC'R4 expression. 
Total RNA from fresh human monocytes cultured for 4h in the presence of increasing concentration of DFX 
was analyzed by Northern blot. Results are representative of three experiments and the effect was consistent 
in the different donors analyzed (different donors can have different basal levels of ('X('R4). 
3.3.3. Analysis of chemokine receptor surface expression 
Modulation cif CXCR4 by I lyp was confirmed at the protein level by flow cytOmctry. '10 
evaluate the functional effects of' I lyp on this chemokine receptor, nionocytes wcrc 
incubated in hypoxic conditions and surface expression of' dii terent chemokinc receptors 
was determined. l; xposure of monocytes lcr 16 h to I lyp resulted in a strong increase of' 
CXCR4 surface expression (Figure 3.3). Similarly, cells incubated) in the presence of' 4U0 
ItM I)IA for the same duration showed a significant increase of' ('X('R4 surface 
expression. In contrast, neither I lyp nor DIA treatment all'cctcd ('('R I and ('C'R5 surface 
expression (Figure 3.3), confirming the data obtained by Northern Not. 
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Figure 3.3.11yp- an (I DIA-in duced ('X(R4 surface expression in fresh Iinnian monocytes. 
Cells were cultured for 16 Ii in the indicated conditions and analyzed lür ('r('It i surface expression. Surface 
expression was determined by flow cytometry using a mouse monoclonal antibody anti human ('WR I. The 
results are representative of three independent experiments. In the right corner percentage of' positive cells for 
CXCR4 and mean of fluorescence are shown for normoxia condition (white box) and hypoxia conditions 
(grey box). (dotted line) Irrelevant antibody. (continuous line) Norm. (sha(Ied region) Ityp or DIA. Results 
are representative of five different experiments. 
3.3.4. Migration assay 
The observed DIA-dependent increase of ('X('R4 surface expression was paralleled by a 
rise in the number of monocytes migrating in response to ('`C(. 'I, I2 (I igurc 3.4). 'I the 
increascd cheniotactic reslxmtiivcºlcss toward ('X(1I2 was spcciflc, as both ('(15 and 
IN1I P-induced migration were not Signilicaintly aIThCle(l. 
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Figure 3.4. Effects of DFX on the chemotactic response of monocytes. 
Cells were en lured for 16 h in the presence of 400 1tM1 DIA. Migration of monocytes was assayed by 
chemotaxis microchamber technique (100 ng/mI ('XCL12,100 ng/ml ('CL5, and I0-" M I'MI, I'). Results are 
mean -LSD of five experiments. *, P<0.05 versus cells cultured in normoxic conditions (haired Student's I 
test) 
Thus, in human monocytcs, low oxygen conditions result in a specific up-regulation of the 
CXCR4 expression and function. 
3.3.5. Reoxygenation 
I Iypoxia and reoxygenation are important pathophysiological Conditions that Occur during 
injury. ischcmia, repot-usion and stroke. It is known that the response to hypoXia and 
reoxygenation is mediated by different transcriptional (actor (AI'-l, NI, k13) inducing the 
expression of' several genes (Rupee and Bacuerlc 1995). As decreased oxygen availability 
modifies the expression of CXC'R4 it was important to assess the reversihility of this effect 
following reoxygenation. As shown in Figure 3.5, flesh human mmnocytrti cultured in 
hypoxic conditions for 16 h and then reoxygenated, retained high levels cat' ('X( R4 for a8 
h. Higher levels than control cells were still present at 16 Ii (Figure 3.5), while tllev 
returned to baseline by 24 h (data not shown). 
119 
Chapter 3 Expression ofchemokine receptors in different cells types after hypoxi In the itn of 
. ý"ý. 
I-) 
N 
.ý 
J 
ý.  v ýp 
+ 
litii.. I wY H; ri v 
o 
- 
L . 
1J 
-r s 
U 
X 
U 
c 
ti c 
1 
7S 12 
i 
- - T v 
r- 
r. "r" r C 
C .L 7 
C 
M 
vý 
h 
7 
y 
'L 
E 
L. 
n 
ool V) V) 
.a 
c C13 
ü co 
w n v 
T 
C 
= 
v 
ý 
n 
ä 
ý Oq L 
W. C 
O 
I 
L 
IZ 
Or E. 
cd 
_L L ýy c aL, 
1 19 
Chapter 3 Expression of chemokine receptors in cblletent cells types after hypoxia treatment 
3.3.6. Hyp-increased CXCR4 Expression in Monocytes-Derived Macrophages 
(M-DM) and Tumour Associated Macrophages (TAM) 
When monocytcs infiltrate tissues they dlitTcrcntiatc into macrophages. As tissues are 
characterized by lower oxygen concentrations in comparison with peripheral circulation 
(Scmcnza 2001). it was important to determine whether CX('R4 up-regulation in response 
to low oxygen conditions could be also applied to macrophages. C'X('R4 cxpressiOn in 
I lyp was determined in fresh human monocytcs. in iii vilru dif ercntiated macro})hagcs 
(MOM) and in TAM obtained Tram the ascitic fluid of human ovarian carcinoma. Cells 
were cultured for 4h in Norm or Ilyp, and total RNA was analyzed liar ('X('R4 mRNA 
expression by Northern blot. In all these cell populations the ('XCR4 niRNA expression 
was strongly up-regulated alter hypoxia treatment (Figure 3.6). 
E 
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Figure 3.6. Effect of IIýp on ('\('R4 inItNA expression by different celI types. 
Human nionocytes (mono), monocyte-derived macrophages (MI)M1s), and tumor associated macrophages 
(fAMs) were cultured for 4h in I lyp, and total RNA was analyzed by Northern Not fier ('X('1(4 uRNA 
expression. Results are representative of four experiments. 
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These results were confirmed by laser confocal microscopy Figure 3.7 (A and I3). \\herein 
Hvp induced a strong up-regulation of CXCR4 surface expression. in both Ml)'M1s and 
TAM s. 
M-DM 
A 
CXCR4-FITC 
B 
Norm 
CXCR4-FITC 
Norm: DFX 
  
TAM 
Hyp Pry 
PHASE ý, 
CONTRAST 
MERGE ioox 
Figure 3.7. Effect of Ilyp or 1)1A on the ('X('1(4 surface expression. 
M9-DM (A) and I'AMs from ascitic fluid of human o%:, riaii cancLr (13) were cultured for 16 h in Norm, 11 1), 
or in the presence of 400 uN1 I) X. as indicated. ('XCR4 surtäce staining was performed and detected by 
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laser confocal microscopy (-70% of CXCR4 positive cells). Staining with both isotype matched control 
antibodies was done for all samples (not depicted). Results are representative of three experiments. 
Thus hypoxia controls CXCR4 expression in mononuclear phagocytes at different stages 
of differentiation. 
3.3.7. Hyp-increased CXCR4 Expression in HUVECs 
CXCL12 is a potent chemoattractant for endothelial cells of different origin and 
participates in angiogenesis (Nagasawa, Hirota et al. 1996; Salcedo, Wasserman et al. 
1999). As hypoxia induces angiogenesis, we investigated the effect of Hyp on CXCR4 
expression by endothelial cells. Human umbelical vein endothelial cells (HUVEC) were 
cultured in normoxia and hypoxia conditions or in presence of 400 µM DFX for 4,8 and 
16 h. Total RNA was analyzed by Northern blot for CXCR4 and VEGF mRNAs 
expression. VEGF mRNA expression is induced by Hyp (Semenza 2001) and served as an 
internal control. The results showed an increased CXCR4 mRNA expression after either 
hypoxia or DFX treatment, as compared with normoxic conditions. As expected, VEGF 
mRNA levels were up-regulated either by Hyp or DFX (Figure 3.8). 
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Figure 3.8. Effect of IIyp on ('\('R4 expression by Iiuman endothelial vell tiles (I It N, FA' S). 
Cells were cultured for 4.8, and 16 h under Norm, Iiyp. or in the presence of 400 itNI DIA, respectively. 
"Thereafter, total RNA was analyzed by Northern blot for CX('R4 and VI A& mRNAs expression. The 
different bands present in the northern Blot for VEG1 correspond to different splicing forms of VI? (il:. 
Results are representative of threce experiements. 
These data were then confirmed analyzing the ('XCR4 sm-Lice expression by laser 
confocal microscopy. Cells were treated for 16 h in Norm, I lyp and DIA conditions and, 
as shown in Figure 3.9, CXCR4 surface expression in endothelial cells was strongly 
increased. 
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Figure 3.9. Effect of Hyp or DFX on the CXCR4 surface expression. 
HUVECs were cultured for 16 h in Norm, Hyp, and in the presence of 400 µM DFX. as indicated. CXCR4 
surface staining was performed and detected by laser confocal microscopy. Results are representative of three 
experiments. 
3.3.8. Endothelial cell migration 
Endothelial cell recruitment represents an initial step of the angiogenetic process and it was 
therefore important to evaluate if hypoxia could influence this event. HUVECs cultured in 
Norm or Hyp were tested for their capability to migrate in response to CXCL12. Cells 
were cultured for 16 h in hypoxia conditions and then tested for their capability to migrate 
in response to chemotatic signals. As shown in Figure 3.10, the number of migrated 
HUVECs in response to CXCL 12 was significantly higher in hypoxic conditions, at 
concentrations ranging from I to 100 ng/ml. CXCL12 was -100-fold more effective at 
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eliciting IIUVF. C migration under llyh than under normoxic conditions. 
Migration Of 
I IUV1 C toward fibrinogen. used as control. was not alTectcd by hypoxia. 
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Figure 3.10. Effect of {lyp on the chemotactic response of IIUVE('s to ('X('1.12. 
Cells were cultured for 16 Ii in hypoxic conditions. Fibrinogen was used as a reference attractant. Results are 
mean SD of three experiments. *, P<0. O5versus cells cultured in normoxic conditions (paired Student's I 
test). 
3.3.9. Hyp increases CXCR4 Expression in Cancer Cells 
Chcmokinc receptors may act as molecular tools exploited by cancer cells which 
metastasize to target organs (Muller, Ilomey et al. 200 l; Kang, Watkins ct al. 2005; Saun. 
Seidler et al. 2005). In particLiltu', C'XCR4 was shown to play a major role in the migration 
of breast cancer cells from the primary tumor to secondary metastatic sites, such as lung, 
liver and bone. As solid tumors are often characterized by the presence of' necrotic areas 
with low oxygen tension, hypoxia may he a potential mechanism that uh-regulates 
expression of' chemokine receptors in cancer cells localized in poorly vasculariied and 
oxygenated areas. To test this hypothesis, we investigated the level of' CX('R4 mRNA 
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expression in response to I Iyp in the ovarian cancer cell line ('AOV 3 by Northern blot 
analysis. As shown in Figure 3.1 IA. C'AOV3 cells shovved up-regulation of 
('X('R4 
mRNA after 4h olculture under hypoxic conditions, which was paralleled 
by a signilicant 
increase in the surface expression of this receptor. as 
demonstrated by cytofluorimetric 
analysis (Figure 3.11 13). 
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Figure 3.1 I. Effects of Ilyp on ('X('1113 expression by ('AOV-3 
The ovarian cancer cell line ('ßAOV3 was cultured in normoxic or hypoxic conditions and analyzed 
respectively for both CXCR4 mRNA expression (A) and ('X('R, 1 surface expression (13). (A) ('ells were 
cultured for 4 Ii in normoxia (Norm) or hypoxic (I lyp) conditions, as indicated. fohl RNA was analyzed by 
Northern blot for CXCR4. (13) Cells were cultured for 16 h in Norm or hypoxic (I lyp) conditions. Aller this 
period, CXCR4 surface expression was determined by flow cytometry. In the right corner percentage of 
positive cells for CXCR4 and mean of fluorescence are shown for normoxia condition (white box) and 
hypoxia conditions (grey box). (dotted line) Irrelevant antibody. (continuous line) Norm. (shaded region) 
I lyp. Results are representative of' five experiments. 
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Similar results were obtained with the breast cancer cell line M('F-7 (Figure 3.12). 
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Figure 3.12. Fffects of Ilyp on CX('R4 expression by MCF-7. 
the breast cancer cell line MCF-7 was cultured in normoxic or hypoxic conditions and analyzed respectively 
for both CXCR4 mRNA expression (A) and CXCR4 surface expression (B). (A) Cells were cultured for 4h 
in normoxia (Norm) or hypoxic (I lyp) conditions, as indicated. "Total RNA was analyzed by Northern blot for 
CXCR4. (B) Cells were cultured for 16 Ii in Norm or hypoxic (I lyp) conditions. After this period, ('X('R4 
surface expression was determined by flow cytometry. In the right corner percentage of positive cells for 
CXCR4 and mean of fluorescence are shown for normoxia condition (white box) and hypoxia conditions 
(grey box). (dotted line) Irrelevant antibody. (continuous line) Norm. (shaded region) I typ. Results are 
representative ofthree experiments. 
3.3.10. Migration of cancer cells 
Hic I lyp-induced expression of CXCR4 in the (AOV3 cclls correlated with an increased 
migration 0fthese cells toward CXCI , 12 in the chemotaxis assay (Figure 3.13). 
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Figure 3.13. Effects of Ilyp on the chemotactic response of C'AM3 ovarian cancer cells to ('X('1 12. 
Cells were incubated 16 Ii in Hyp condition and migration to ('X('L12 (100 ng/ml) was assayed by 
Transwells. Results are mean +SD of three experiments. *, P<0.05 versus cells cultured in nornioxic 
conditions (Paired Student's I test). 
Similar results were obtained with the MCI -7 breast cancer cell line (I figure 3.14). 
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Figure 3.1 3. Effects of Ilyp on the chemotactic response of M('F-7 breast cancer cells to ('X('I, I2. 
Cells were incubated 16 It in I lyp condition and migration to ('N('I1I2 (100 nu, /ml) was assayed by 
Transwells. Results are mean i Sl) of' three experiments. *. 1' - 0.05 versus cells cultured in normoxic 
conditions (Paired Student's t test). 
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3.3.11. Effects on CXCR4 expression on cancer cells after reoxygenation 
CXCR4 expression by cancer cells may play an important role in the metastatic process 
(Muller, Homey et al. 2001). The process of metastasis formation includes the exit of 
cancer cells from the primary tumor site and their entrance into the circulation, where the 
oxygen levels will markedly increase, relatively to those present in the tumour 
microenvironment. To assess the impact of cancer cells reoxygenation on the surface 
expression of CXCR4, CAOV3 cells were cultured in hypoxic conditions for 16 h and 
subsequently exposed to Norm up to 14 h. As shown in Figure 3.13, hypoxia (16 hrs) 
increased CXCR4 surface expression in CAOV3 cells and high levels of CXCR4 were 
retained after reoxygenation for 14 h, while they returned to baseline by 24 h (not shown). 
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3.3.12. Effects of Hyp on CXCL12 mRNA expression by MCF-7 and CAOV3 
cells 
CXCL12 is highly expressed in some solid tumours, as shown in ovarian cancer (Zou, 
Machelon et al. 2001). Based on this, we wanted to understand whether hypoxia could 
enhance CXCL12 expression. Ovarian (CAOV3) and breast (MCF7) cancer cells were 
incubated for 4h in Norm or Hyp (>90% of cells viability). Subsequently total RNA was 
collected and CXCL12 gene expression was determined by real-time RT-PCR (Figure 
3.16). No significant differences were observed between normoxic and hypoxic cells in 
terms of CXCL12 mRNA expression. 
1,2 
0 Norm 0 Hyp 
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Ü 0.4 
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Figure 3.16. Effects of Ilyp on CXCL12 mRNA expression by MCF-7 and CAOV3. 
Cells were incubated for 4h in Norm and Hyp as indicated, and CXCR4 gene expression was next 
determined by real-time PCR. Results are representative of two independent experiments. Values are 
expressed as fold increases relative to the reference sample (Norm). 
3.4. Discussion 
Regulation of cell migration by changes in oxygen availability is a central event during the 
organization of host response in inflammatory and neoplastic diseases as it may influence 
131 
Chapter 3 Expression of chemokine receptors in different cells types after hypoxia treatment 
leukocyte recruitment and activation, angiogenesis, and metastasis formation (Semenza 
2002). In this chapter we have demonstrated that Hyp mediates selective up-regulation of 
CXCR4 in different cell types, including mononuclear phagocytes (monocytes, MDMs, 
and TAMs), endothelial cells, and cancer cells, and shown that oxygen levels act as an 
important regulator of CXCR4 receptor expression. 
In contrast to standard cell culture conditions, characterized by 20% oxygen concentration, 
cells in the human body are exposed to much lower oxygen concentrations, ranging from 
16% in the pulmonary alveoli to -6% in most other organs of the body. Moreover, oxygen 
concentration may even drop to extremely low concentrations, close to anoxia, in the 
presence of altered vascularization as observed at pathological sites such as tumours 
(Semenza 2001). As selective accumulation of leukocyte subpopulations is the hallmark in 
allergy, inflammation, and tumours (Mantovani, Sozzani et al. 2002), it was important to 
investigate how leukocyte recruitment is affected by changes in oxygen tension. We first 
observed that in response to Hyp monocytes and MDM increase CXCR4 expression and 
function, as assessed by surface expression and chemotactic responsiveness to its specific 
ligand CXCL12. Thus, dynamic regulation of the chemotactic responsiveness of 
monocytes/macrophages may represent a feature of the pathophysiology of inflammatory 
diseases associated with Hyp. Interestingly, Hyp is present in the joint microenvironment, 
because articular cartilage is an avascular tissue that functions at lower oxygen tension 
than do most tissues. Moreover, in the setting of diseases such as rheumatoid arthritis and 
osteoarthritis, in which macrophages promote perpetuation of chronic inflammation (Liew 
and McInnes 2002), a further decrease in synovial fluid oxygen tension may occur (Blake, 
Winyard et al. 1994; Cernanec, Guilak et al. 2002). 
In solid tumours, TAMs represent a prominent component of the mononuclear leukocyte 
population, which displays an ambivalent relationship with tumours [the "macrophage 
balance hypothesis"; (Mantovani, Bottazzi et al. 1992)]. Interestingly, TAMs preferentially 
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localize at the tumour-host tissue interface, in regions often associated with low oxygen 
tensions. Increasing evidences show that TAMs mainly accumulate in avascular, 
necrotic/hypoxic areas of tumors where they presumably act to clear necrotic cell debris 
from this sites (Murdoch, Giannoudis et al. 2004). 
Several lines of evidence also indicate that chemokines play a pivotal role in the 
recruitment of monocytes to neoplastic tissues (Mantovani, Bottazzi et al. 1992; Gerard 
and Rollins 2001; Mantovani, Sozzani et at. 2002) and a variety of chemokines have been 
detected as products of cancer cells or tumour stromal elements (Azenshtein, Luboshits et 
al. 2002; Milliken, Scotton et al. 2002). In particular, CCL2 was proposed as tumor- 
derived chemotactic factor which plays a major role in the recruitment of macrophages at 
the tumour site (Mantovani, Sozzani et al. 2002). Receptor expression is a crucial 
determinant of the spectrum of action of chemokines (Mantovani, Sozzani et al. 2002). It 
was reported that the capacity of monocytes/macrophages to migrate in response to CCL2 
is decreased in low oxygen conditions (Turner, Scotton et al. 1999; Grimshaw and 
Balkwill 2001). Thus, our observation of Hyp-mediated up-regulation of CXCR4 
expression in TAMs may indicate that in regions associated with oxygen decrease, a 
dynamic change of their receptor profile occurs, with up-regulation of functional CXCR4. 
A relay of distinct chemokine-chemokine receptor interactions may regulate initial 
recruitment, tissue infiltration in hypoxic areas, and in neoplastic and non-neoplastic 
inflammatory sites in a multistep navigation process (Foxman, Campbell et al. 1997). 
Angiogenesis is a prerequisite for the expansion of solid tumors and is often activated 
during the early, preneoplastic stages of tumor development (Folkman 1995; Hanahan and 
Folkman 1996). Tumour angiogenesis is controlled by a number of positive and negative 
regulators produced by cancer cells and tumour-associated leukocytes. 
A number of molecules with possible impact on angiogenesis have been shown to be 
expressed by macrophages in low oxygen conditions, such as VEGF, TNF-a, bFGF, and 
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CXCL8 (Crowther, Brown et al. 2001). The contribution of chemokines toward 
angiogenesis is currently a focus of intensive investigation (Hirani, Antonicelli et al. 2001). 
It was recently demonstrated that in CCL3-deficient mice the tumour angiogenesis 
diminished, demonstrating its fundamental role (Yang, Lu et at. 2005). 
Strikingly, it was recently reported that CXCL12 acts as a potent chemoattractant for 
endothelial cells of different origins bearing CXCR4 and is a participant in angiogenesis 
that is regulated at the receptor level by VEGF and bFGF (Strieter, Polverini et al. 1995; 
Salcedo, Wasserman et at. 1999; Nagasawa 2001; Payne and Cornelius 2002). In 
agreement with these observations, we observed an increased chemotactic responsiveness 
of HUVECs toward CXCL12, which may well be part of the angiogenic program induced 
by hypoxia. Hyp is a well-recognized pathophysiological condition for the induction of 
angiogenic factors, including but not limited to VEGF (Semenza 2002). In agreement with 
these observations, our data suggest that the angiogenic program established by hypoxia 
may rely also on the increased expression of CXCR4 by different cellular components in 
the tumour microenvironment, including endothelial cells, tumour cells, and TAMs. 
The involvement of CXCR4 in cancer metastasis has been proposed by Muller and 
colleagues, who showed that this receptor and its ligand (CXCL12) together govern the 
pattern of breast cancer metastasis in a mouse model (Liotta 2001; Muller, Homey et al. 
2001). This observation is in support of the "chemoattraction" theory of metastasis, which 
holds that organ-specific attractant molecules stimulate the migrating tumour cells to 
invade the walls in blood vessels and enter the organs. 
However, this remarkable observation does not clarify the mechanisms of selection by 
which cancer cells became CXCR4 positive. Our observation that the levels of CXCR4 
surface expression induced by Hyp are sustained for several hours after reoxygenation is 
consistent with the idea that this pathway may confer metastatic potential to cancer cells. 
Indeed, it was described in in vivo models of metastasis that after entering the circulation, 
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the majority of cancer cells home to target organs in a time-frame ranging from 1 to 24 h 
(Aoudjit, Potworowski et al. 1998). 
The next chapter investigates the possible involvement of the Hypoxia-Inducible Factor 
(HIF-1) in Hyp-induced expression of CXCR4. 
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Chapter 4. Role of HIF-1a in the regulation of CXCR4 
gene expression 
4.1. Introduction 
Hypoxia occurs when oxygen availability/delivery is below the level required to maintain 
physiological 02 tensions. Tumour hypoxia is a result of an abnormal vascular formation, 
which often characterizes neoplastic tissue, and results in poor oxygen and nutrient supply. 
This supply is mainly achieved through neoangiogenesis, a process by which new blood 
vessels are formed from pre-existing ones and hypoxia induces the expression of the most 
important molecule mediating neoangiogenesis: the vascular endothelial growth factor 
(VEGF). This is only one example of response to hypoxia: hypoxic conditions elicit 
cellular responses designed to improve cell oxygenation through several mechanisms such 
as neoangiogenesis, enhanced glycolytic pathway for energy requirement, and upregulation 
of molecules related to cell survival/apoptosis (Semenza 2002). 
The master regulator of the adoptive response to hypoxia is the transcriptional factor 
Hypoxia Inducible Factor-1 (HIF-1). HIF-1 is a heterodimer that consists of a 
constitutively expressed HIF-11 subunit and a HIF-la subunit, the expression of which is 
highly regulated. HIF-1 activates the transcription of many genes that encode for proteins 
involved in angiogenesis, glucose metabolism, cell proliferation/survival and 
invasion/metastasis. 
It was recently demonstrated that in hypoxia several chemokine gene products (e. g. 
CXCL12 and CXCL8) are induced by HIF-1 activation (Ceradini, Kulkarni et al. 2004; 
Phillips, Mestas et al. 2005). 
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4.2. Aim of this chapter 
The aim cif' this chapter was to understand the molecular mechanism promoting ('XC'R4 
uprcgulation in hypoxic conditions. 
This part of the work was done in collaboration with the Laboratory of I'umouu" hypoxia, 
lead by I)r. Melillo (National Cancer Institute, Frederick), with the help of Simona Saecani 
for the Chip analysis and Manuela Nebuloni lot" the immunohistochcmical analysis. 
4.3. Results 
4.3.1. Expression of CXCR4 in HIF-1a KO mouse embryo fibroblast 
IIIF-I is a key regulator of the transcriptional response to hypoxia. To conlirm our 
hypothesis we decided to use marine embryonal fibroblasts (MI'T's) deficient Im the 1IIF- 
lcx subunit but not for IIIF-2a as well as the corresponding parental cell lines. Mouse 
embryonic fibroblasts were incubated under normoxic or hypoxic conditions for 6 Ii, and 
total RNA was tested Im- VI? GF and CXCR4 mRNA levels by Real-Time RT-PC'R. 
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Figure 4.1. Expression of ('X('1(4 in IIII -Ia KO mouse embryo fibroblast. 
(A) Mouse embryo Fibroblast from wild type (MI? f. ') or knockout for the u subunit of IIIF-I (NI1? I'') were 
incubated under normoxic or hypoxic conditions for 6 Ii. and total RNA was tested for Vl1(iI' and ('X('R4 
mRNA levels by real-time NCR. (U) DFX was used as I lypoxia inducing agent. Results are the average of 
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three independent experiments. *, P<0.05 versus cells cultured in normoxic conditions (Paird Student's t 
test) 
As shown in Figure 4.1 A, MEFs from WT animals, but not from HIF-la KO mice, 
expressed 3.5-fold-higher levels of VEGF mRNA when incubated under hypoxic 
conditions relative to the levels expressed in normoxic conditions. Likewise, MEFs from 
WT mice expressed 2.5-fold-higher levels of CXCR4 mRNA when cultured under hypoxic 
conditions relative to normoxic conditions. In contrast, in MEFs from HIF-la -/" mice, the 
hypoxic induction of CXCR4 mRNA was no longer apparent. Furthermore, DFX also 
induced VEGF and CXCR4 mRNA in HIF-1 WT cells (6.5- and 7.2-fold, respectively) but 
not in HIF-1u /" cells (Figure 4.1 B). These data suggest a role for HIF-1 in the induction of 
CXCR4 mRNA expression by hypoxia. 
4.3.2. Expression of CXCR4 in VHL WT and mutated renal carcinoma cells 
The von Hippel-Lindau tumor suppressor protein (VHL) is involved in the degradation of 
HIF-1a by the proteasome inducing its ubiquitination in presence of oxygen. Mutations in 
VHL are associated with high levels of HIF-la protein and transcriptional activity (Hon, 
Wilson et al. 2002; Min, Yang et al. 2002). 
To better evaluate the role of HIF-1a in the induction of CXCR4 in hypoxic conditions, we 
tested by Real Time RT-PCR the expression of CXCR4 mRNA in the renal cancer cell line 
786.0 [in which VHL gene is mutated; reference (Lieubeau-Teillet, Rak et al. 1998)] and 
the WT2 cell line (in which the WT VHL gene has been reintroduced). 
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Figure 4.2.1? xpression of CXCR4 in VI[L WI' and mutated renal carcinoma cells. 
Expression of CXCR4 and VEGF mRNAs was tested by real-time 1'CR in the renal cancer cell line 786.0 
(VI IL mutated) and WT2 (in which a WT VI IL has been reintroduced). Results are the average of* three 
independent experiments. 
These cells have been extensively used in several laboratories as a prototype in which lack 
of VI IL is associated with high levels o1' expression o1' I111 -1-inducible genes (Ivanov, 
Kumiin et at. 1998). As reported previously (Stratmann, Krieg et al. 1997), 786.0 cells 
expressed high constitutive Ievels of VI"I(i mRNA that were significantly Iower (-60%) in 
W1'2 cells (Figure 4.2). Accordingly, 786.0 cells expressed higher levels of C'X('R4 
mRNA relative to WT2 cells. "These data are ILIAy consistent With the IIIvolvellmelit oI' 1III - 
1 in the hypoxic regulation of ('XCR4 gene expression. 
4.3.3. HIF-1 -dependent transcriptional activation 
l'o investigate the role oI' II IF-I on the transcriptional activation oI' ('XC'R4 promoter we 
used the MCI -7 breast carcinoma cell line, ill which hypoxia augmented the expression oI 
CXCR4 mRNA (see sections 3.3.9). Cells were transiently transfccted with a plasmid 
containing a 2.6-kb fragment of the CXCR4 promoter linked to the Iucilcrase reporter gene 
and incubated under normoxic or hyl)uxic conditions For 24 It. 
139 
VEGF 
Chapter 4 Role of HIF-1 « in the regulation of CXCR4 gene expression 
[_. ' Not m* 
(Iul 15 HYp 
5-4 
cr: 
+1 HF-1 
2 
,6 
kb F-IRE 
Figure 4.3. IIIF-I dependent transcriptional activation of ('X(: R4 promoter. 
MCF-7 breast carcinoma cells were transiently transfected with a plasm id containing a 2.6 kb fragment of the 
CXCR4 promoter linked to the luciterase reporter gene, with or without a IIII -I(t expression vector. ('ells 
were incubated under normoxic or hypoxic conditions for 24 h and evaluated for the lucifcrase activity. 
Results are the average of' three independent experiments. *, P-=0.05 versus cells cultured in normoxic 
conditions (Paird Student's t test). 
As shown in Figure 4.3,1 lyp induced tour told induction of the Iucitcrasc activity relative 
to the cells cultured under normoxic conditions. Interestingly, cotransfcction of a III F- I cc 
expression vector significantly increased Iucilerase expression driven by the 2.6-kb 
C'XC'R4 promoter (four fold relative to control). I lypoxia further increased lucifcrase 
expression induced by IIIF-Iu cotranslcctiom uh to nine fold, compared to untreated 
normoxic cells. Experiments conducted in parallel using a hlasmicl containing thrcc copies 
of a canonical hypoxia responsive element (I IRI-. ) upstream of the IuciFerasc reporter gcnc 
showed a similar trend of lucilcrase expression, although levels 01' induction were 
substantially higher. 
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4.3.4. Hyp-induced HIF-1a recruitment to the CXCR4 promoter 
To obtain direct evidence of the in vivo interaction between III F- Iu and the C'XLR4 
promoter. WC used the chromatin immuno-precipitation (ChIP) assay. The ovarian cancer 
cell Iine CAOV3 transfected with the p(IIA)IIIF-] u plasmid, was either cultured in Norm 
or I lyp for 4 hrs, were fixed in formaldehyde. and subsequently analyzed by C'hIP. 
qmý IP anti-HA (HIF-1, i. ) 
"0 =ý- ---ý 0 Input 
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Figure 4.4. Ilyp-induced 111F-Ia recruitment to the CX('R4 promoter. 
CAOV3 cells transfected with the p(IIA)IIIF'-tu plasmid were cultured for 4h in normoxic or hypoxic 
conditions. ChIP was performed to investigate the recruitment of 1111 -Ict on the ('X('I(4 promoter. (lane 1) 
Untransfected. (lane 2) Norm. (lane 3) 1 lyp. 
Although no interaction between I III -1(L and the C'X('R4 promoter was observed in Norm, 
recruitment of l IIF- Iu to the CXC'R4 promoter was clearly detected at 4h alter I lyh, in the 
promoter region -1860 to -1578 (Figure 4.4, lane 3). This result is consistent with the 
functional clata obtained in transient translection experiments (Figure 4.3). Overall these 
data demonstrate that I III -lu is the molecular effect promoting ('XCIZ4 gene transcription 
in hypoxia. 
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4.3.5. Immunohistochemistry for CXCR4 and HIF-la in ductal mammary 
carcinoma 
To confirm the existence of the HIF-CXCR4 pathway in human tumours we have 
performed histological analysis of serial sections of ductal mammary carcinoma (n=3). 
Immunohistochemistry for CXCR4 and HIF-la (Figure 4.5: brown colour indicated by a 
little arrow) displayed colocalization of HIF-la and CXCR4 in ductal carcinoma cells 
from breast tissue, located in areas of intratumoral necrosis (indicated in figure by a head 
arrow). 
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Figure 4.5. Co-localization of CXCR4 and HIF-la in ductal mammary carcinoma 
Immunoistochemistry for CXCR4 and HIF-fcc on a sequential section of ductal mammary carcinoma (n=3) 
marked by arrows (necrotic areas are marked by arrowheads) 200X (A) 400X (B). 
4.3.6. Effect of Hyp and DFX on CXCR4 mRNA Stability 
To further investigate the mechanisms of hypoxia induced CXCR4 mRNA expression, we 
estimated its effects on CXCR4 mRNA stability (Figure 4.6). 
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Figure 4.6. Stabilization of ('XCR4 mRNA by hypoxia. 
(A) Fresh human inonocytes were cultured for 4h under Norm or I lyp, and in the presence or absence of I 
µglml actinomycin D (ActD). Thereafter, total RNA was extracted at different times as indicated and 
analyzed by Northern blot for CXCR4 mRNA expression. (B) Densitometric analysis: CX('R4 mRNA levels 
are expressed as arbitrary units. In this experiment, the basal CXC'R, l mRNA level appears higher compared 
with other experiments, as the film was exposed for a longer period for better visualization of the blot. 
Fresh human monocytes were cultured either in Norm or I lyp in the presence or absence of 
1 ILg/ml actinomycin I) (binds to DNA duplexcs and intcr(cres with action of' cnvymcs 
engaged in replication and transcription) tör Ih, 2h and 4h. Total RNA was extracted at 
ditTerent times and analyzed by Northern blot fier CXCR4 mRNA expression. The mRNA 
decay observed in Ilyp conditions was compared with the rate of mRNA degradation 
observed in normoxic conditions. The results indicate that I lyp increased C'X('R4 mRNA 
stability, suggesting that Ilyp-induced ('X('It4 º»RNA expression relies on both 
transcriptional and posttranscriptional mechanisms. 
Densitometric analysis shows that the mRNA level of C'X('R4 is higher in hypoxia 
conditions also after 4h (Figure 4.6 t; ). 
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4.4. Discussion 
Hypoxia is a common feature of solid tumours that has been associated with decreased 
therapeutic response, malignant progression, local invasion and distant metastasis. The 
transcription factor hypoxia-inducible factor-1 (HIF-1) is a major regulator of cell 
adaptation to hypoxic stress (Vaupel 2004) and therefore a potential target for anticancer 
therapies (Semenza 2003). 
It is known that in solid tumours genetic alterations such as mutation of VHL, PTEN, or 
p53 genes that are associated with increased levels of HIF-1 transcriptional activity. 
HIF-1 activation in tumor cells activates several mechanisms leading to angiogenesis, 
glycolysis, inhibition of apoptosis, upregulation of growth factors (eg. PDGF, TGF-(3, IGF- 
2, EGF, VEGF) and protein involved in tumor invasion (e. g. urokinase-type plasminogen 
activator). Moreover, hypoxia downregulates adhesion molecules thus contributing to 
cancer cell detachment (Koong, Denko et al. 2000; Czekay, Aertgeerts et al. 2003). 
Results obtained in this thesis propose that microenvironmental hypoxia may also increase 
CXCR4 expression and the metastatic potential of cancer cells. In line with this hypothesis, 
recent evidence has been provided that invasive cancer phenotype is associated with 
hypoxia and/or HIF-la overexpression (Krishnamachary, Berg-Dixon et at. 2003). 
HIF-1 activates transcription of genes that mediate adaptive responses to reduced oxygen 
availability and a number of HIF-1-regulated genes have been identified, whose products 
play key roles in angiogenesis, vascular reactivity and remodelling, and glucose and energy 
metabolism (Semenza 2004). 
HIF-1 is a heterodimer composed of a HIF-1 ß subunit that is constitutively expressed and a 
HIF-la subunit that is rapidly degraded by ubiquitination via the proteasomal pathway, a 
process that is inhibited under hypoxic conditions. 
Oxygen-regulated destruction of HIF-la requires the von Hippel-Lindau tumor suppressor 
protein (pVHL) (Hon, Wilson et at. 2002; Min, Yang et al. 2002). pVHL acts as the 
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recognition component of a ubiquitin E3 ligase complex, which binds HIF-1a, and loss of 
pVHL function results in constitutive activation of the hypoxic response (Min, Yang et al. 
2002; Pugh and Ratcliffe 2003). Taken together the results of this chapter suggest a role for 
HIF-1 in the regulation of CXCR4 mRNA expression: 
(a) mouse embryonal fibroblast lacking the a subunit of HIF-1 had impaired hypoxic 
induction of CXCR4 mRNA; 
(b) CXCR4 mRNA was differentially expressed in the renal cancer cell lines 786.0 and 
WT2 bearing a VHL-mutated and WT phenotype, respectively; 
(c) Hyp or cotransfection of a HIF-la expression vector induced transcriptional activation 
of a 2.6-kb CXCR4 promoter luciferase reporter construct; 
(d) ChIP analysis demonstrated that after Hyp, HIF-la is specifically recruited to the 
CXCR4 promoter, in the nucleotide region -1860 to -1578; 
(e) the HIF-1 inhibitor Topotecan inhibited the Hyp-induced expression of CXCR4 in 
CAOV3 cells. 
A sequence homology search of the region -1860 to -1578 of the CXCR4 promoter 
revealed the presence of a putative HIF-1 binding site at position -1725 (5'-GCGTG-3'). 
Our data are in line with P. Staller's paper where they have shown the presence of four 
potential hypoxia-response elements (HRE) at upstream of the transcriptional start of the 
CXCR4 promoter. In particular they have also demonstrated that mutation of sequence -1.3 
Kb upstream of the transcriptional start in the context of the full-length CXCR4 promoter 
rendered the promoter insensitive to hypoxia and HIF-la confirming that CXCR4 is a 
hypoxia dependent gene (Staller, Sulitkova et al. 2003). 
In addition to transcriptional activation, we found that Hyp further contributes to increased 
CXCR4 gene expression by stabilization of CXCR4 transcripts, suggesting that Hyp- 
regulated RNA binding factors may interact with and stabilize the CXCR4 mRNA at the 
posttranscriptional level. 
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The results of this chapter identify the Hyp-HIF-1-CXCR4 pathway as a relevant 
molecular circuit in the functional tuning of the chemokine system. The validity of this 
observation in different cell types (mononuclear phagocytes, HUVECs, fibroblasts, and 
cancer cells), consistent with the virtually universal expression of the Hyp-HIF-1 pathway 
in mammalian cells, argues in favour of its potential involvement in the pathophysiology of 
diverse conditions. In a multistep navigation process, the Hyp-HIF-Ia-CXCR4 pathway 
may regulate trafficking and localization in hypoxic tissues and represents a target for 
novel therapeutic strategies. 
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Chapter 5. Regulation of maturation of dendritic cells by 
hypoxia 
5.1. Introduction 
To anticipate and initiate immune responses, dendritic cells (DCs) follow a migratory route 
from their recruitment as sentinels into tissues, including solid tumours, to secondary 
lymphoid organs where they profile the immune response. Migratory capacities, and 
especially chemokine responsiveness, are therefore key elements in dendritic cell biology. 
DCs express receptors for and respond to both constitutive and inducible chemokines. 
Immature myeloid DC, generated in vitro from monocytes, express a unique repertoire of 
inflammatory chemokine receptors (CCR1, CCR5, CCR6). Purified circulating DCs were 
also found to express CCR1, CCR2, CCR3, CCR5 and CXCR4 (Ayehunie, Garcia-Zepeda 
et al. 1997; Sozzani, Allavena et al. 1999). 
A dramatic change in the repertoire of chemokine receptors is promoted by DC activation. 
This change is responsible for the migration of DC from periphery to the draining lymph 
nodes. The signals that promote this process include a variety of maturation factors, such 
as IL-I, TNF and LPS (Sozzani 2005). Many microbial products, such as the activators of 
Toll-like pattern recognition receptors (TLRs) and some endogenous molecules, like 
CD40L, expressed on the surface of activated T cells may also promote DC activation. DC 
activation is usually associated with the acquisition of a mature phenotype consisting in an 
up-regulation of co-stimulatory and MHC class II molecules. Activation of DC is also 
associated with down-regulation of chemokine inflammatory receptors and the de novo 
expression of CCR7, the receptor for CCL19 and CCL21, two chemokines that are 
expressed at the luminal side of high endothelial cells and in the T cell rich areas of 
secondary lymphoid organs, like tonsils, spleen and lymph nodes (Dieu, Vanbervliet et at. 
1998; Ngo, Tang et al. 1998; Willimann, Legler et al. 1998). Within the T cell area, CCL19 
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is expressed by mature interdigitating DC, whereas CCL21 is expressed 
by stromal cells, 
as indicated by the severe reduction of expression in the lymphotoxin-astromal cell 
deficient mice (Ngo, Korner et at. 1999). 
It was also shown by Sallusto et al. that when dendritic cells mature there is an 
upregulation of the CXCR4 chemokine receptor (Sallusto, Schaerli et al. 1998). 
DC maturation and function may be impaired by cytokines such as IL-6, IL-10, M-CSF 
and VEGF (Gabrilovich, Chen et al. 1996; Banchereau, Briere et al. 2000). This is of 
particular relevance in tumors, where Tumour-associated DC (TADC) generally show an 
immature phenotype with high CD1a and low costimulatory molecules CD80, CD86 and 
CD40 (Hillenbrand, Neville et at. 1999; Scarpino, Stoppacciaro et at. 2000). In agreement, 
while IL-10 has been shown to promote the differentiation of monocytes to mature 
macrophages and to block their differentiation to DC (Allavena, Sica et al. 2000) a gradient 
of tumour-derived IL-10 has been observed in various tumours, including papillary 
carcinoma of the thyroid. Strikingly, in this tumour tumour-associated macrophages 
(TAM) are evenly distributed throughout the tissue, in contrast to DC which are present in 
the periphery (Scarpino, Stoppacciaro et al. 2000). 
Furthermore, it was demonstrated in breast carcinoma tissue that immature dendritic cells 
reside within the tumour, whereas mature dendritic cells are located in peritumoral areas 
(Bell, Chomarat et al. 1999). 
These evidences emphasize the concept that tumour microenvironmental signals are 
determinant of DC differentiation and maturation and may contribute to impair effective 
antitumour immunity. 
5.2. Aim of this chapter 
This chapter was aimed to investigate whether tumour hypoxia could influence DC 
maturation and migration. In particular, the study was designed to provide insights into the 
expression profile of chemokine/chemokine receptors, cytokines and maturation markers 
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acquired by myeloid precursors exposed to DC-inducing maturation signals, under both 
normoxia and hypoxia conditions. Part of this work was performed in collaboration with 
Andrea Doni (purification of myeloid precursors and DC maturation), Silvano Sozzani 
(purification of plasmacitoid DC and phenotypic characterization) and Annunciata Vecchi 
(maturation of murine DC from myeloid precursors). 
5.3. Results 
5.3.1. Hypoxia induces CXCR4 mRNA expression in both immature and 
mature dendritic cells 
It was recently demostrated that DC maturation is paralleled by increased CXCR4 
expression (Sallusto, Schaerli et al. 1998). Monocyte-derived immature dendritic cells 
were cultured in the presence or absence of maturation stimuli (LPS at 100 ng/ml) either 
normoxia and hypoxia conditions. DFX was further used as hypoxia mimicking 
compound. After 24 hours RNA was isolated and analyzed for CXCR4 mRNA levels by 
real-time RT-PCR. 
As shown in Figure 5.1, in the presence of LPS dendritic cells expressed increased levels 
of CXCR4 mRNA (8.8 fold), as compared to untreated DC. A similar increase of the 
CXCR4 mRNA level was observed in immature DC cultured in hypoxia or DFX, in the 
absence of LPS, the LPS-dependent upregulation of CXCR4 was higher in the DFX- 
treated sample (37 fold) and in hypoxic conditions (23 fold). 
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Figure 5.1. Effects of hypoxia on C'X('R4 mRNA expression by dendritic cells 
Human Monocyte-derived dendritic cells were cultured for 24 Ii in normoxia, hypoxia or I)FX conditions 
with or w/o LPS (100nghnl). Total RNA was analyzed by Real Time PCR for ('XCR4 rnRNA expression 
(quantitative analysis, all the samples were normalized vs the ji-actin mRNA expression). Results are mein 
+SD of three experiments. *, P<0.03; **, P<0.005; ***, p-0.001 versus cells cultured in norinoxic conditions 
and untreated (Paired Student's i test). 
5.3.2. Modulation of chemokine receptors surface expression in DC by 
hypoxia 
To investigate whether the hypoxia-induced ('X('R4 mRNA expression was paralleled at 
protein Ievel. 
Ilulllllll Mo-DC's were cultured fier 24h with or without ITS at diI'lerent 
concentration (10 and 100 ng/mI) in normoxia, hypoxia or in the presence of I )I" X. 
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Figure 5.2. Ily poxia and I)FX induce CXCR4 surface expression in immature and manure Mo-D('s 
Cells were cultured for 24 Ii in the indicated conditions and analyzed for CXCR4 surface expression. Surface 
expression was determined by flow cytometry using a mouse monoclonal antibody anti human CXCR4. 
Results are mean -iSD of' three experiments. *, P<0.2; **, I1<0.3; ***, P- 0.03 versus cells cultured in 
nornioxic conditions and untreated (Paired Student's t test). 
As expected, CXCR4 surface expression was uhregulated 1O11Owing I)C maturation with 
LPS. In agreement with the RT-PCR results, its suu-face expression was higher when 
dendritic cells were matured in hypoxia or I)FX conditions (figure 5.2). Moreover, 
CXCR4 surface expression weis upº'egulated in immature 1)('s treated with hyhoxia or 
I)IX. 
As DC maturation is associated with the downregulation of in11ammatory chenºukine 
receptors (e. g. C'CR5) and the increased expression of ('CR7, we checked the surlier 
expression of these receptors in both nornxoxia and hypoxia conditions. 
Dendritic cells were tre ated for 24h in presence or absence of' I, l'S (1 0 ng/IuI), both in 
norn oxia and hypoxia conditions and surface expression of (VR5 and CCR7 was 
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evaluated by (ACS analysis. The results showed that ITS-mediated 
decrease of C'CR5 
expression was partially inhibited in hypoxia, as compared to normoxia (Figure 5.3). 
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Figure 5.3. Effects of hypoxia on the ('CRS chemokine receptor surface expression 
Cells were cultured for 24 Ii in the indicated conditions and analyzed for ('('RS surface expression. Surface 
expression was determined by flow cytomety using a mouse monoclonal antibody anti human ('CRS. 
Results are mean I SD of two different experiments. P- I versus cells cultured in normoxic 
conditions and untreated (Paired Student's test). 
In preliminary experiments. hypoxia partially prevented the I. PS-m ediated induction of 
CCR7 (Figure 5.4). These results will he confirmed in a larger number of dunurs. 
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Figure 5.4. Effects of hypoxia on the C'('R7 chemokine receptor surface expression 
Cells were cultured for 24 h in the indicated conditions and analyzed for C'CR7 surface expression. Surface 
expression was determined by flow cytometry using a mouse monoclonal antibody and human ('('K7. I he 
results are the average of three independent experiments and represent the °ý, of positive cells for ('CR7 
receptor. Results are mean i SD of two different experiments. *, P<0.3; **, P- 0.004; ***, P" 0.03 versus cells 
cultured in normoxic conditions and untreated (faired Student's I test). 
5.3.3. Expression of costimulatory molecules by DC, in normoxia and 
hypoxia 
The potent functional capacity of IBC to initiate the immune rCS Onsc IS related tu a higlh- 
Icvel expression of major histocompatibility complex (MII(') I/II molecules and 
constitutive expression of cost imulatoºy molecules (Celia. Salio ct al. 199t)). Classical 
cost imulatory molecules, expressed primarily On antigen-presenting cells that deliver the 
`signal 2' (an antigen non-specific signal) are, for example, 137-1 (('I)8O) and B7-2 
(CD86). U7-1 and 137-2 deliver a co-stimulatory signal through the C'I)28 receptor that is 
constitutively expressed on 'l' cells (Rieti. and ('hen 2004). During maturation dcndritic 
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cells change not only the chemokine receptor expression but also the level of expression of 
the costimulatoty molecules. In particular. C'1)80. CI)86 and the I)(' maturation marker 
C'[)83 (I, echmann. ßcrchtold et al. 2002) are known to he induced during M's maturation 
(Rietz and Chen 2004). 
As li)r the cheºnokine receptors, alter 24 h oltreatment ol'immature I)C with I, I'S (0.1 or 1 
rig, /ml), with or without hypoxia/DFX, we evaluated by F ACS analysis the expression of 
CD80 and CD83. 
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Figure 5.5. Effects of hypoxia on the ('U83 co-stimulatory molecules surface expression 
Cells were cultured for 24 It in the indicated conditions and analyzed t'ur ('I)83 surlace espne' ion. SL II e 
expression was determined by flow cytometry using a mouse monoclonal antibody anti human ('1)83. 
Results are mean ±SD of Four different experiments. *. P-0.03: ** I'- 0.0007; *** I, 0.3; **** I' 0.004 
versus cells cultured in normoxic conditions and untreated (Paired Student's / test).. 
As shown in Figure 5.5 hypoxia did not afTcct the Icvel of' ('1)83 induced) IW ITS 
treatment. 
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by hypoxia 
Regarding the expression of ('I)80, though still pI'eliminary, the results obtained 
Il-o111 IM11, 
experiments did not provide consistent and conclusive evidence. Additional experiments 
are required to fully clarify this aspect. 
Matiu"ation/inllanunatory stimuli lead to a burst of class II synthesis and translocation of 
the MI IC II-peptide complexes to the cell Surface (BanchereaLl. Briere et al. 2000). 
We treated immature DCs for 2411 with LPS (long/nil), either in nornloxia or hyhoxia, and 
then analized by FACS analysis the expression of'MI IC 11 molecules. 
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Figure 5.6. Fffects of hypoxia on the MIIIC II surface expression 
Cells were cultured for 24 h as indicated and analyzed for N111(' II surface expression. Surface expression 
was determined by flow cytomety using it mouse monoclonal antibody anti human Nil l(' 11. Results are 
mean . -LSD of 
lour different experiments. The differences between treated cells and cells cultured in nonnoxic 
conditions and untreated are not statistically significant. 
As showed in Figure 5.6 hypoxia did not affect the expression of' MI IC II in ii»nuaturc or 
mature DCs. 
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5.3.4. Analysis of cytokine expression by DC 
Upon activation DCs mature into potent immunostimulatory cells that can drive T-cell 
clonal expansion and through production of M1 and/or M2 immunomodulatory cytokines, 
such as IL 12 and IL IO respectively, promote the development of T helper I or Th 2 
effectors. 
To estimate the effects of hypoxia on cytokine production by DC, immature dendritic cells 
were treated with LPS at different concentrations (0.1 ng/ml, I ng/ml and 10 ng/ml) in 
normoxia, hypoxia and DFX conditions. After 24 hrs the supernatants were collected and 
cytokine expression analized by ELISA test. 
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Figure 5.7. ELSA for TNF-a in the supernatant of Mo-DCs treated as indicated 
Cells were incubated for 24h and supernatant were collected and assayed by ELISA to evaluate TNF-cx 
protein level. *, P<0.05 versus cells cultured in normoxic conditions and untreated (Paired Student's t test). 
As expected, LPS upregulated the production of TNF-a in a dose response manner. 
Strikingly, TNF-a production was further increased when LPS-treated DC were cultured in 
hypoxia or in the presence of DFX (Figure 5.7). 
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Figure 5.8. ELISA for IL-12 in the supernatant of Mo-DCs treated as indicated 
Cells were incubated for 24h and supernatant were collected and assayed by ELISA to evaluate IL-12 protein 
level. *, P<0.05 versus cells cultured in normoxic conditions and untreated (Paired Student's t test). 
We also tested the production of IL-12 (Figure 5.8). As shown, the LPS-induced 
production of IL-12 by dendritic cells matured in normoxia conditions was very low, while 
both hypoxia and DFX strongly increased its production in a dose response manner. 
5.3.5. Chemotaxis 
In addition to CXCR4, mature DCs upregulate the chemokine receptors CCR7 thus 
acquiring responsiveness to CCL 19 and CCL21. Consequently, mature DCs may leave the 
inflammed tissues and enter the lymph stream. As functional CCR7 expression by DC 
represents an essential event to promote an adaptive immune response, we analyzed the 
chemotactic responsiveness of LPS-activated DC (10 ng/ml) toward the CXCR4 
(CXCL12), CCR5 (CCL5) and CCR7 (CCL 19) specific ligands, either in normoxia, 
hypoxia or in the presence of DFX. 
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Figure 5.9. Effects os DX on the chemotactic response of immature and mature Mo-1)('s 
Cells were cultured for 24 li in the presence of 400 pM DIA. Migration of Mo-I)Cs was astiaycd by 
chemotaxis microchamher technique. Results are mean i SD of two different experiments. *, 1' 0. I; **, 
P 0.02; *** Vl; **** pß_0.2; ***** P<0.7 versus cells cultured in normoxic conditions and untreated 
(Paired Student's I test). 
As shown, the number of cells migrated in response to ('X('1.12 was higher when l)(' 
maturation and migration occurred in the presence of' I)lA. In contrast. no signiI cant 
changes were observed in resPOnsc to ('('I. l'), while DIA treatment partially prc, rntcd the 
ITS-mediated inhibition olthc chemotactic responsiveness in response to 
5.3.6. Analysis of CXCR4 surface expression in plasmacytoid dendritic cells 
It was recently demonstrated that p1)('s arc I)rese nt in tuniiuurs (Vicari, I reilleux rt at. 
2004) and that their ju liltratiuui in ovarian tumours correlates \\ith the level OI' ('X('I I2 
expression to which they respond (Lou. Maclhclun ct at. 200 I ). As tumours are caraclrrir. rd 
by hypoxic areas, we evaluated the influence of Ihypoxia on the expression of the ('y('R4 
chemokine receptor. pl)C pun lied from peripheral blood of' healthy donors v crc cultured 
for 24 h in normoxia or in the presence of I)I X. with or without the inactivated inllucnr, ai 
* 
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virus, typical inducers of p DC maturation (Vcrmi. Riboldi ct al. 2005). Next. C'X('R4 
expression was evaluated by FAGS analysis. 
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Figure 5.10. Effects of UFX on the ('X('R4 chemokine receptor surface expression in pDCs 
Cells were cultured for 24 h in the indicated conditions and analyzed for ('X('R4l surface expression. Surface 
expression was determined by flow eytometry using a mouse monoclonal antibody anti human ('X('R4. In 
the right corner percentage of positive cells for CXCR4 and mean of fluorescence are shown for normoxia 
condition (white box) and hypoxia conditions (grey box). (dotted line) Irrelevant antibody. (continuous line) 
Norm. (shaded region) I lyp. The results are representative of live experiments. 
As shown in Figure 5.10 the expression of the ('XLR4 eheinokine receptor was 
upregulated by DIA (grey pick), either in the absence or in the presence oI the inactivated 
influenza virus. 
5.4. Discussion 
Dendritic cells are the most efficient type of migrating AP(', playing an essential role in 
the initiation of immune responses. Accumulating data have slhow1,1n that I)(' migrmion is 
modulated in a conlplcx manner and requires m ullililr factors, illCIlüdIiig growth1 factors, 
hormones and inflammatory cytokincs such as "I'NF-cu and and chrmukiucs 
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(Cumberbatch, Dearman et al. 1997; Cumberbatch, Bhushan et al. 2003). Recently it was 
demonstrated that dendritic cell migration is also highly sensitive to microenvironmental 
changes (Turnbull and MacPherson 2001). Hypoxia, a local decrease in oxygen tension 
occuring in inflammatory and tumour lesions, is a common feature of many pathological 
processes: tumours, arthritis rheumatoid, and sepsis. There is much evidence that dendritic 
cells infiltrate tumours and their phenotype is affected by the tumour microenvironment. 
As solid tumours are partly hypoxic, infiltrating dendritic cells may be exposed to hypoxia. 
In this chapter of the thesis we tried to understand how hypoxia could affect the maturation 
process and migratory activity of DCs. Based on our results we propose that dendritic cells 
in hypoxic conditions do not develop a complete maturation program, as they still present 
high level CCR5, in contrast with low level of CCR7, as compared to normoxia conditions. 
On the other hand, hypoxia-derived DCs display a light upregulation of CD83, while other 
costimulatory molecules (e. g MHC II) are not affected. 
Recent publications have demonstrated that hypoxia inhibits the migratory capacity of 
human monocyte-derived dendritic cells by regulating the balance between MMP and 
TIMP gene expression (Qu, Yang et al. 2005; Zhao, Darmanin et al. 2005). These authors 
have also demonstrated that expression of some chemokine receptors is affected by 
hypoxia. Nevertheless, the results in these two papers are somewhat controversial. In 
agreement with our results, Qu X. et al. showed a downregulation of CCR7. In contrast, 
Zhao W et al. showed the opposite result. We have found that the migratory capacity of 
mature dendritic cells is affected by hypoxia reducing their capacity to migrate through 
CCL 19 but increasing their capacity to migrate in response to CXCL12 and CCL5. 
We also investigated the influence of hypoxia on cytokine production and we observed that 
LPS-treated DC produce higher amount of TNF-a and IL-12 in hypoxia condition, thus 
amplifying their inflammatory response. As the expression of both genes is controlled by 
the transcriptional complex NF-KB, overexpression of these genes is likely the result of a 
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synergism between NF-KB and the HIF-1 transcriptional factor, a mechanism previously 
suggested (Jung, Isaacs et al. 2003). 
It is demonstrated that plasmacytoid dendrictic cells (pDCs) are present in tumours (Vicari, 
Treilleux et al. 2004) and their infiltration in ovarian tumours is promoted by the 
expression of CXCL12, to which they respond (Zou, Machelon et al. 2001). Interestingly, 
we observed that pDC exposed to hypoxia upregulated the expression of CXCR4. 
Unfortunately, so far we could not confirm this observation in in vivo models, as we faced 
a lot of problems with the culture of murine dendritic cells. 
Recently, we discovered that 
the source of the problem was the new stock of FCS that we recently purchased. 
At the 
moment we are controlling the viability of these cells with different FCS (foetal calf 
serum). 
From these preliminary results we can deduce that hypoxia prevents full maturation of DC 
and amplifies inflammatory functions (increased level of CCR5, IL-12 and TNF-a) and 
suggest that hypoxia can promote DC functions associated with high local inflammation. 
Our data are also in agreement with previous observation on the inhibitory action that the 
hypoxia-inducible factor VEGF elicits on DC maturation (Gabrilovich, Chen et at. 1996), 
while it promotes macrophage differentiation. 
Studies on DC functions such as migratory activity in tumour tissue with low oxygen 
tension may contribute to a deeper understanding of the mechanisms by which tumour 
cells escape immune surveillance. 
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6.1. Summary 
Migration and motility are essential features of the behavioural repertoire of a cell. During 
embryogenesis, cells move in sheets or as loosely attached populations to create complex 
tissues. In the adult, cell motility is crucial to maintain immunity, or to repair damaged 
tissues. The recruitment of leukocytes in normal and pathological conditions is mainly 
regulated by chemokines and their receptors. The expression of these molecules is 
regulated by different stimuli such as LPS, IFNy and IL-10 (Sica, Saccani et al. 1997; 
Sozzani, Ghezzi et al. 1998). 
In this thesis we have demonstrated that hypoxia is a microvenvironmental condition 
influencing chemokine receptor expression and leukocyte migration. 
It was demonstrated that TAMs preferentially localize in hypoxic areas (Leek, Talks et al. 
1996) and that hypoxia represents a stop signal for macrophage migration (Turner, Scotton 
et al. 1999; Grimshaw and Balkwill 2001). 
In this thesis we have demonstrated that hypoxia induces the expression of CXCR4 in 
different cell types: monocytes, macrophages; endothelial cells with an amplification of 
angiogenesis and tumour cells. 
The induction of CXCR4 in monocytes and macrophages may increase their localization 
on hypoxic areas. Chemokines play a fundamental role in the recruitment of monocytes 
and macrophages and, along with other groups, our laboratory has demonstrated that CCL2 
is the most frequent CC chemokine found in tumours, whose level of expression correlates 
with increased infiltration of leukocytes. It was demonstrated that solid tumours (e. g. 
ovarian cancer) express the CXCL12 chemokine (Scotton, Wilson et al. 2001), thus 
supporting our hypothesis that the axis CXCR4/CXCL12 regulates the recruitment of 
leukocytes in tumours. Our results disclose a possible new mechanism by which the 
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chemokine system promotes recruitment and positioning of infiltrating macrophages into 
tumours. 
Angiogenesis is an important process for tumour growth and survival and is regulated by 
various molecules (e. g. VEGF). We have demonstrated that hypoxia induces CXCR4 
expression in endothelial cells, thus supposing a contribution to the angiogenic process in 
low oxygen condition. It was demonstrated that breast cancer cells are positive for CXCR4 
and that they migrate to organs such as bone, lung and liver, where high concentrations of 
CXCL12 have been found (Muller, Homey et al. 2001). We have shown that the 
expression of CXCR4 is induced by hypoxia, thus increasing the ability of these cells to 
migrate in response to CXCL12. The hypoxia-induced CXCR4 expression may contribute 
to increase the aggressiveness and capacity of tumour cells to form metastasis. 
The master regulator of the oxygen homeostasis is HIF-I. It regulates the expression of 
over 60 genes (Semenza 2003), involved in glycolysis to survival and apoptosis. Data 
obtained in this thesis show that HIF-1 activation mediates the Hyp-dependent 
upregulation of CXCR4 expression. 
It was very interesting to find that hypoxia further contributes to increase CXCR4 gene 
expression by stabilization of CXCR4 transcript, suggesting that Hyp-regulated RNA 
binding factors may interact with and stabilize CXCR4 mRNA. Noteworthy, a recent work 
has shown that HIF-1 activation may play a role in the induction of the CXCR4 ligand, 
CXCL12 (Ceradini, Kulkarni et al. 2004), further suggesting that 11117-la is a central 
determinant of the leukocyte trafficking in hypoxic environments. This is also supported 
by recent work by Cramer et al. (Cramer, Yamanishi et al. 2003), which showed that 
ablation of the hypoxia responsive transcription factor 11117-la resulted in impaired 
macrophage motility and cytotoxicity. These observations together with our results 
contribute to a better understanding of how cells are recruited into inflammatory sites. 
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As DC infiltrate solid tumours, which are often characterized by areas of low oxygen 
tension, we investigated the effects resulting from their metabolic adaptation to hypoxia on 
DC maturation. 
It is also known that in tumours, immature and mature dendritic cells localize in different 
areas: usually immature DCs migrate into the tumour while mature DC are confined to 
peritumoral areas (Banchereau, Briere et al. 2000). 
Our preliminary results suggest that hypoxia prevents full maturation of DC 
(CCR7'0W/CCR5h'gh) and amplifies inflammatory functions, thus being likely involved in 
the amplification of local inflammation. We have observed that hypoxia induces the 
upregulation of CXCR4 in immature and mature dendritic cells and hypothesize that this 
could be one factor that influences their localization in tumours. 
Recent publications by Zhao et al. and Qu X. et al. (Qu, Yang et al. 2005; Zhao, Darmanin 
et al. 2005) showed that hypoxia suppress the expression of MMP9 affecting dendritic cells 
migration, their most important function in response of infections or inflammation. In 
particular Qu X. et al. demonstrated that hypoxia downregulates the expression of CCR7 
affecting dendritic cells maturation. 
It is clear, from both our results and recent works by Zhao et al. and Qu X. et al. (Qu, Yang 
et al. 2005; Zhao, Darmanin et al. 2005) that hypoxia affects dendritic cells maturation and 
migration by affecting their function, the capability to migrate to the lymph nodes to active 
T cells. 
This work suggests that Hyp-HIF-la-CXCR4 pathway may represent a target for new 
anticancer therapies. At the moment there are many studies using antibody (Ottaviano et al. 
2005) or siRNA (Lapteva et al. 2005) against CXCR4 providing an inhibition of cancer 
metastasis and growth. Moreover the inhibition of HIF-la is considered a promising 
therapeuic approach against cancers (Semenza 2003) and in fact some antitumour agents 
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currently in clinical trials are specific HIF-1 inhibitors (e. g. farnesyl transferase inhibitors, 
P13K inhibitors) (Giaccia, Siim et al. 2003). 
Further work is required to validate the hypoxia-HIF-CXCR4 pathway as a therapeutic 
target in other diseases. 
6.2. Future plans 
There are a number of questions arising from this thesis that I hope will be answered by 
future works. The following sections outline ongoining experiments. 
6.2.1. Inhibition of the expression of PTEN and HIF-la by siRNA 
RNA interference is a mechanism of post transcriptional gene silencing using double 
strand RNA (dsRNA) (Elbashir, Harborth et al. 2001). RNA interference allows one to 
determine the function of selected genes by transfecting a target cell with small 
interference RNA (siRNA) able to promote degradation of specific mRNAs and to prevent 
their translation into protein. To accomplish this, we are using an expression vector 
(pSUPERIOR vector, by Oligoengine, Seattle) that expresses siRNA for the PTEN and 
HIF-la genes, under the control of tetracycline (Tet). As PTEN was found to be involved 
in the regulation of the PI3K-HIF-I activity it would be interesting to understand how this 
tumour-suppressor gene influences the expression of CXCR4 in hypoxia. 
pSUPERIOR vector is a tetracycline-regulated expression vector that utilizes regulatory 
elements from the E. Coli Tn10-encoded Tet resistance operon (Hillen and Berens 1994). 
Tetracycline (Tet) regulation in pSUPERIOR vector is based on the binding of Tet to the 
Tet repressor, which controls the expression of the gene of interest (Yao, Svensjo et al. 
1998). 
The siRNA sequence for PTEN (Czauderna, Fechtner et al. 2003) and HIF-la 
(Krishnamachary, Berg-Dixon et al. 2003) are known and we need to insert them in the 
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pSUPERIOR vector, before transfecting breast cancer (MDA-MB231) and ovarian cancer 
(TOV21G) cell lines with such constructs. 
Here below are listed the steps to obtain a cell line expressing our siRNA: 
1- to transfect cells with a plasmid expressing the Tet repressor 
protein. We'll use the pcDNA6/TR by Invitrogen (Milan); 
2- after blasticidin selection, clones will be screened for the j3- 
galatosidase production. Next, positive clones will be transiently 
transfected with the LacZ vector (where the gene lacZ is under the 
control of the tetracycline). Clones expressing high level of Tet 
repressor (corresponding of high level of n-gal) will be chosen; 
3- to transfect the selected clone with the pSUPERIOR vector 
containing the siRNA for HIF-la and PTEN; 
4- to select the clones with higher silencing activity for PTEN and 
HIF-la by Western Blot. 
We have just obtained some Tet repressor positive clones for breast cancer cell line. Next 
we need to transfect cells with the plasmid containing the PTEN and HIF-la si RNA and 
to select for positive clones. 
6.2.1.1. Functional and molecular characterization of these cell lines 
After clonal selection, we will check the expression of PTEN, 11117-la and CXCR4 in 
normoxia and hypoxia conditions, and in the absence and presence of tetracycline, by 
using real time RT-PCR and Western Blot. 
The second step will investigate the migratory capability of these cells after silencing of 
PTEN and HIF-la, controlling in particular their capability to migrate towards CXCL12. 
This will be done using the transwell system. 
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6.2.1. ii. Metastasis formation 
To evaluate the role of HIF-1a and PTEN in the formation of metastasis clones expressing 
inducible siRNA against PTEN or HIF-la will be injected in nude mice and, following a 
proper period, metastasis number will be determine. This part will be done in collaboration 
with Prof. Balkwill's laboratory (Queen's Mary Hospital, London). 
6.2.2. Hypoxia influences macrophage polarization 
In solid tumours TAMs represent a prominent component of the infiltrating mononuclear 
leukocyte population, which display an ambivalent relationship with tumours. It's known 
that macrophages localize preferentially to necrotic areas characterized by low oxygen 
tension. Recently in our lab we defined the phenotype of TAM by using the microarray 
technology (Biswas, Gangi et al. 2005). The results of this study showed that TAMs have a 
distinct and unique M2 phenotype. Based on this it could be interesting to study whether 
hypoxia could influence the M1-M2 polarization of monocytes and macrophages. 
To perform this, by using Real Time RT-PCR we started the study of the 
chemokine/chemokine receptors profile expressed by monocytes in normoxia versus 
hypoxia conditions, following activation with LPS or IL-4. 
Preliminary results have shown that hypoxia upregulates selected M1 genes (e. g. IL-12, 
CXCL10) in the presence of M1-polarizing signals, such as LPS. Compared with LPS, the 
M2-polarizing cytokine IL-4 didn't have any appreciable effect on the expression of these 
genes. 
Additional experiments are ongoing in the laboratory to further investigate the effects of 
hypoxia on the polarization of innate immune functions. 
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6.2.3. Regulation of maturation of DCs by hypoxia. 
A variety of experiments could be performed to further assess the influence of hypoxia on 
dendritic cells maturation after the confirmation of the preliminary data exposed in this 
thesis. As example we plan to evaluate the activation of T cells in a mixed leukocytes 
reaction (MLR). 
6.2.3. i. Knock down HIF-l a expression using siRNA. 
It will be interesting to study whether HIF-la silencing in dendritic cells results in the 
recovery of their capability to undergo to full maturation. To perform this study we would 
need to optimize methods to transfect dendritic cells with siRNA. 
6.2.3. ii. To characterize the phenotype of murine DCs under hypoxia conditions. 
Migration is essential function of dendritic cells as, following maturation, they move to the 
T cell zones of secondary lymphoid organs where they present Ag and costimulatory 
signals to recirculating lymphocytes. Our preliminary results suggest that hypoxia affects 
DC maturation in response to pro-inflammatory signals. In particular, as compared to 
normoxia-derived DC, DCs matured in hypoxia display higher expression of costimulatory 
molecules (CD83), lower CCR7, higher CCR5 and increased expression of pro- 
inflammatory cytokines (IL-12, TNF-a): a phenotype likely involved in amplification of 
local inflammation. Our aim is to provide in vivo evidence supporting this hypothesis. We 
performed in vitro experiments to investigate whether the functional responses of murine 
DC to hypoxia where similar to the human counterpart. By taking this approach we did not 
obtain conclusive results, as we faced several technical problems, relative to culture and 
differentiation conditions for murine DC. 
When the proper experimental conditions for murine dendritic cells will be optimized we 
will repeat the in vitro experimentation, before proceeding with the in vivo studies. 
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In particular, we will perform in vivo experiments with murine dendritic cells, treated in 
normoxia or hypoxia conditions, to evaluate their capacity to migrate to lymph nodes. We 
will label normoxic or hypoxic DCs with the vital dye 5-(and-6)-carboxyfluorescein 
diacetate succinimidyl estermixed isomer [5-(6)-CFDA, SE (CFSE)] and inject them 
subcutaneously into the hind leg footpad. At different time points popliteal lymph nodes 
will be recovered, disaggregated mechanically and treated with collagenase A (1mg/ml). 
The enzimatically treated cell suspension will be evaluated by FACS analysis (Del Prete, 
Vermi et al. 2004). 
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